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Abstract 
South Africa has had one of the fastest growing HIV epidemics in the world and almost 
30% of women attending public antenatal clinics (ANC) are currently infected with the 
virus. But as the epidemic is starting to level off and antiretroviral therapy (ART) is 
becoming increasingly available, few methods exist to determine the impact of ART or 
other interventions on the epidemic in South Africa. This thesis explores the epidemiology 
and dynamics of HIV infection and investigates the potential impact of ART. 
Methods 
Total and age-specific prevalence data are analysed in time and space and are used to 
investigate patterns of infection in men and women, urban and rural, and low and high risk 
populations. Dynamical models are developed to estimate incidence from age-specific 
prevalence and trends over time and are compared to laboratory-based estimates of recent 
HIV sero-conversion. Incidence is estimated in different populations in South Africa. A 
dynamical model is developed to estimate the impact of ART on the future course of the 
HIV epidemic. 
Results 
HIV prevalence varies geographically and by age, sex and race. The average female-to-
male HIV prevalence ratio is 1.7 and prevalence peaks at an older age among men than 
women. The age at which prevalence peaks among women has increased from 23.0 to 26.5 
years between 1995 and 2002. Four patterns of infection are identified: among pregnant 
women attending ANCs, among men and women in the general population, and among 
migrant workers. HIV incidence among ANC attendees peaked in the mid to late 1990s (at 
6.6% per year nationally) with variation between provinces. Current estimates of HIV 
prevalence and incidence among the general population in South Africa (aged 15-49 year) 
are 18.8% and 2.4% per year, respectively. Age-specific incidence estimates from 
dynamical models and laboratory methods are in good agreement provided the window 
period for the laboratory method is increased. Over the next ten years the provision of ART 
could avert 1 to 1.5 million deaths depending on whether it is provided when the CD4 cell 
count falls to 200 or 350 cells/ul. By 2015 about 1.1 million people will be receiving ART 
but this will have little impact on the incidence of HIV and scaling up of prevention efforts 
remains urgent. 
Conclusions 
The thesis explores some of the determinants and patterns of HIV prevalence and 
incidence in South Africa in order to find better ways to manage the epidemic of HIV, 
monitor changes and evaluate progress in control efforts. In order to fight the epidemic we 
need to mobilize the best possible science in support of those people and communities 
affected by the epidemic. 
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CHAPTER 1 Introduction 
"HIV/AIDS is the greatest threat to life, liberty, and pursuit of happiness and 
prosperity in many African countries" 
Kevin De Cock, 20021 
The global epidemic 
The acquired immunodeficiency syndrome (AIDS) was first identified in 1981 among 
homosexual men in the United States of America, and the human immunodeficiency virus 
(HIV) was identified as the cause of AIDS in 1984." The virus has since spread throughout 
the world and HIV/AIDS has grown into one of the greatest epidemics in human history, 
having killed more than 25 million people3 and threatening social and economic stability in 
the most affected regions. 
The Joint United Nations Programme on HIV and AIDS (UNAIDS) estimated that at the 
end of 2005, 40.3 million (range: 36.7-45.3 million) adults and children worldwide were 
living with HIV,3 while 3.1 million (2.8-3.6 million) died from AIDS in 2005. It is 
estimated that 4.9 million (4.3-6.6 million) new infections occurred in 2005, of which 
700,000 (640,000-820,000) were among children under 15 years of age. Currently, about 
half of all new infections are among children and young people up to the age of 25 years. 
The epidemic is increasingly affecting women and as of 2003 women accounted for about 
50% of all people living with HIV worldwide, and for 57% in sub-Saharan Africa.4 
The epidemic affects different parts of the world differently and even within regions it 
progresses at different rates and at different levels of intensity. Estimates of national adult 
prevalence have remained below 1 % in most countries in Asia, Oceania, West and Central 
Europe, North Africa, the Middle East, North America and Latin America, where 
transmission of the virus occurs mainly in concentrated groups of injecting drug users, men 
who have sex with men, and sex workers and their clients and partners.3 In contrast, almost 
8% of adults living in sub-Saharan Africa are infected with HIV, where the major route of 
HIV transmission is through heterosexual contact in the general population, with 
prevalence levels of around 20% or higher in most southern African countries. Despite 
increases in the number of people living with HIV in parts of East Asia, Eastern Europe 
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and Central Asia over the last three years, sub-Saharan Africa remains by far the most 
affected region in the world, accounting for 65% of all new infections and people living 
with HIV worldwide, and for 76% of all AIDS deaths.5 At the end of 2005, it was 
estimated that 25.8 million people (23.8-28.9 million) were living with HIV in this region.3 
In general, the HIV epidemic in sub-Saharan Africa appears to be levelling off.6 Although 
no country in this region has escaped the virus, some are more affected than others. 
Southern Africa is the most affected part of Africa and the southernmost nine countries, 
where only 2% of the global population live, accounted for 30% of the total number of 
people living with HIV in 2004.5 In contrast to the alarmingly high and sustained levels of 
HIV infection in Southern Africa, prevalence has stabilized in some countries in East 
Africa and has started to show a decline in some others. For example, the national 
prevalence in Uganda fell from 13% in the early 1990's to 4.1% at the end of 2003.7 In 
West and Central Africa prevalence levels have remained stable at lower levels than in the 
rest of sub-Saharan Africa. 
In developed countries HIV has been mainly concentrated in high risk groups, such as men 
who have sex with men and injecting drug users. In Western Europe, injecting drug users 
accounted for more than 10% of new infections in 2002. While harm-reduction initiatives 
have resulted in falling transmission rates in this risk group, recent data from Western 
Europe have shown an increase in the number of infections among women. In the United 
States of America, men who have sex with men accounted for 45% and injecting drug 
users for 24% of all cases in 2003.8 An increasing number of women and minorities are 
however becoming infected through heterosexual contact. 
Standards of treatment and care have improved considerably, primarily in high-income 
countries, since the virus was first identified. The first antiretroviral drug, AZT, became 
available in 1987 while many other drugs have been developed since then.9 Highly active 
triple combination therapies, available in high-income countries since 1996, have 
dramatically improved the quality of life and the life expectancy for many HIV infected 
people in these countries. Although antiretroviral drugs do not cure AIDS, they reduce 
viral replication and thereby the level of the virus in blood and, in most cases, improve the 
patient's clinical status and prognosis substantially. Until recently, antiretroviral therapy 
(ART) was accessible mainly to people living in developed countries with the exception of 
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Brazil and Thailand where triple combination ART has been provided in the public sector 
since 1996 and 2000, respectively.10'11 At the International AIDS conference in Durban, 
South Africa in 2000, there was a call for more serious efforts to provide HIV treatment to 
those in need in low-and middle income countries. Attention, resources and political 
commitment began to materialize after the United Nations General Assembly Special 
Session (UNGASS) in July 2001.10 Resources for HIV and AIDS programs in developing 
countries have since increased substantially, with new resources becoming available 
through the Global Fund to Fight AIDS, Tuberculosis and Malaria, the World Bank, and 
several bilateral initiatives, including the USA government's President's Emergency 
Program for AIDS Relief (PEPFAR) initiative.12 The World Health Organization (WHO) 
and UNAIDS launched the "3 by 5" strategy in 2003 which aimed to provide ART to 3 
million people in low and middle income countries by 2005.10 At the end of 2005, 
approximately 1.3 million people living in low and middle income countries had been 
receiving ART,13 and although the target of 3 million people was not reached, the efforts to 
expand access to ART have helped to encourage countries to set their own treatment 
targets and to mobilize support. The positive change and commitment from countries and 
donors have provided a basis for moving forward towards the goal of providing universal 
access to treatment and care by 2010 for all those who need it.14 
HIV/AIDS in South Africa 
The first two cases of AIDS in South Africa were diagnosed among homosexual men in 
Pretoria in 1982.15 During the next five years (1983-1988) this number had increased to 
over one hundred with high levels of mortality.16 In 1988, the pattern of AIDS in South 
Africa revealed that 81% of patients were homosexual or bisexual, and 96% were men. 
However, by the end of 1989, several surveillance studies had confirmed the entry of HIV 
infection into the heterosexual population and although the prevalence was still low, 
alarming increases were predicted.17"19 By January 1990 a total of 308 South African AIDS 
cases had been reported," among whom two thirds were male homosexuals, 21% were 
heterosexuals with a male:female ratio of 1:1.2, 9% were haemophiliacs or recipients of 
blood products, and 3% were children. 
Of great concern in the early 1990's was the extensive spread of HIV among attendees of 
public health sexually transmitted disease clinics and female family planning clinics, with 
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doubling times ranging from 6.5 to 10.7 months. While no paediatric cases had been seen 
before 1987, a total of 73 had been reported by the end of 1990. Predictions based on 
mathematical models in the early 1990s21'22 provided early warnings of the potential threat 
that HIV posed and suggested that infection levels could reach 20%-30% among the 
sexually active population in South Africa by 2000 to 2005. 
In 1990, the Department of National Health and Population Development instituted an HIV 
surveillance programme based on annual surveys of women attending antenatal clinics in 
South Africa.23 The data collected from these annual surveys have since been used to 
monitor the progress of the HIV epidemic in the heterosexually active population. In the 
past 15 years, the HIV sero-prevalence among antenatal clinic attendees increased 
dramatically from 0.8% in 1990 to 10.4% in 1995 and to 29.5% in 2004 (Figure 1.1). The 
total number of people infected with HP/ in South Africa at the end of 2003 was estimated 
to be about 5.3 million (4.5 - 6.2 million),4 the highest number of infections in any country 
in the world. With less than 1% of the world's population living in South Africa, the 
country currently accounts for about 14% of all people living with HIV. It is estimated 
that about 370,000 (270,000-520,000) people died from AIDS in South Africa in 20034 and 
that more than 1.2 million have died from AIDS since the start of the epidemic.24 While 
HIV prevalence is starting to level off (Figure l.l),25 the number of people dying from 
AIDS continues to increase. 
The HrV epidemic in South Africa is unevenly distributed. In KwaZulu-Natal, the province 
with the highest burden of infection, antenatal HIV prevalence increased from 1.6% in 
1990 to 40.7% in 2004. During the same period, HIV prevalence in the Western Cape, the 
province with the lowest prevalence, increased from 0.1% to 15.4%. Proportionally, more 
females are infected than males and younger people are more likely to be infected than 
older people. The peak prevalence among women occurs between ages 20 and 29 years 
while it is shifted to older age groups (30-39 years) among men.26 
HTV-1 is the dominant virus in South Africa while HTV-2 is rare. Phylogenetic studies on 
HTV-1 isolates from South Africa have shown that the subtype C virus is responsible for 
the majority of infections in South Africa," while early studies on HIV-1 (from hereon 
called HIV) isolates from Cape Town showed that subtypes B and D were also found 
among homosexual and bisexual men.28 
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Until 2003, provision of care and treatment for HIV infected individuals was generally not 
available through the public health sector, and expensive treatment with antiretroviral 
drugs was limited to those who could afford it through the private sector. In 2003, the 
Government of South Africa announced its operational plan for comprehensive treatment, 
care and support29 to those individuals with AIDS, through the public health sector, giving 
hope to many of those living with the virus. 
1988 1990 1992 1994 1996 1998 2000 2002 2004 2006 
Year 
Figure 1.1 Increase in national HIV antenatal clinic prevalence from 1990 to 
2004. {Sources: Department of Health, Annual Antenatal Clinic surveillance reports) 
Despite a substantial scientific response to the HIV epidemic in South Africa, our 
understanding of risk factors for acquiring infection, and our knowledge of which 
interventions work and which do not, the prevalence data collected from antenatal clinics 
in 2004 still showed an increase. Our understanding of the dynamics of the infection, 
however, is limited. There is limited information on incidence and mortality, both of which 
are essential for monitoring future trends of the epidemic and in particular, to monitor the 
impact of interventions. Interventions such as the provision of antiretroviral therapy to 
those in need of treatment will have an immediate impact on mortality, while prevalence 
levels will show an increase. On the other hand, control measures expected to have a 
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public health impact, such as the control of sexually transmitted infections (STIs) or male 
circumcision might show an impact on prevalence only over several years, while their 
impact on incidence will appear almost immediately. In this thesis, prevalence data are 
used to study the epidemiology and dynamics of HIV infection in South Africa, with a 
particular emphasis on patterns of infection, the estimation of incidence from prevalence 
data, and the impact of antiretroviral therapy on future epidemic trends. 
Objectives of the thesis 
The aim of this thesis is to study the epidemiology, population dynamics and impact of the 
HIV-1 epidemic in South Africa through the analysis and modelling of existing prevalence 
data. Specific objectives are: 
1. To study and analyse existing HIV prevalence levels and trends of infection among 
various population and risk groups in South Africa. 
2. To use age-specific prevalence data to identify and compare patterns of infections 
among various groups in South Africa, including women attending antenatal 
clinics, men and women in urban and rural communities, commercial sex workers 
and migrant workers. 
3. To compare estimates of prevalence among antenatal clinic attendees (who have 
been used as an indicator group for infection levels among the heterosexual 
population) with prevalence estimates among men and women from community 
studies. 
4. To develop methods for estimating HIV incidence using time trends in prevalence 
and age-specific prevalence data. 
5. To compare estimates of incidence using a mathematical model and a laboratory 
technique (the Standardized Testing Algorithm for Recent HIV Seroconverters). 
6. To use the mathematical models to estimate incidence among various groups in 
South Africa. 
7. To use existing prevalence data and assumptions about the provision of 
antiretroviral therapy to estimate the likely impact of antiretroviral therapy on 
future trends of the epidemic. 
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Description of the chapters 
HIV-l subtype B infection was introduced into the homosexual population in South Africa 
in the early 1980s while a second, independent, epidemic of HIV-l subtype C infection 
started to evolve among the heterosexual population in the late 1980s. Once introduced, 
the spread of HIV among the heterosexual population was very rapid with an initial 
i n 
doubling time of less than 12 months. In a 15 year period the HIV epidemic among 
public health antenatal clinic attendees grew from 0.73%23 in 1990 to 29.5% in 2004,31 and 
will have consequences far more serious than any other epidemic in the history of South 
Africa. The total number of people infected with HIV in South Africa in 2003 was 
estimated to be around 5.3 million, with estimated mortality rates of about 1000 people per 
day.4 Accordingly, the scientific and public health response to HIV and AIDS has been 
substantial, and the efforts and resources devoted to the epidemic have been greater than 
for any other disease or epidemic. In Chapter 2, the state of the scientific knowledge on 
HIV infection and AIDS in South Africa is assessed. A MEDLINE search was conducted 
and a description is given of the scientific literature in response to the epidemic and how it 
has changed over time. In addition, a detailed summary is provided on the number of 
studies in the literature reporting on HIV prevalence and incidence in different population 
groups. 
The epidemic of HIV infection threatens to overwhelm South Africa and if we are to deal 
with it effectively, we need to understand the underlying dynamics of HIV infection. 
Mathematical and statistical models are essential tools for understanding the population 
dynamics of an epidemic, and to study the factors that determine the course of infection in 
an individual, as well as those that determine the patterns of infection in a population. In 
Chapter 3, an introduction is given to mathematical models and its application in general to 
the HIV epidemic. The uses of models, types of models, and some basic concepts are 
discussed, and it is shown how simple models can be used to get a better understanding of 
the epidemic. 
Knowledge of the HIV epidemic in South Africa depends greatly on the annual, 
anonymous surveys conducted by the Department of Health among antenatal clinic 
attendees, supported by data obtained from studies among high risk groups including 
migrant workers (mine workers and truck drivers) and commercial sex workers, several 
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surveys among attendees of family planning and sexually transmitted disease clinics, 
workplace surveys, surveys among hospital patients, students and blood donors, 
community based surveys conducted in two areas of South Africa, a rural area in 
KwaZulu-Natal and an urban setting in Gauteng, and two large, national population-based 
surveys on behavioural and socio-cultural determinants of vulnerability to HIV/AIDS. In 
Chapter 4 the data sets that are used in this thesis are described and in Chapter 5 a detailed 
description is given of the epidemic in space and in time. Prevalence data are described, 
ranging from the rapid spread of the HIV epidemic over time, to differences in gender, age 
and geographical area, while risk factors associated with prevalence levels are also 
discussed. 
Age specific prevalence data obtained from various sources (antenatal clinics, community-
based surveys, and studies among commercial sex worker and migrant workers) are used in 
Chapter 6 to investigate patterns of infection. Differences between the patterns of infection 
in men and women, and in urban and rural communities are investigated. The female-to-
male prevalence ratio, estimated from community surveys, is shown to be around 1.7 while 
the prevalence peaks at an older age among men than among women. Differences in the 
patterns of infection between urban and rural populations are not significantly different. As 
the epidemic in South Africa is maturing, it is shown that the age of peak prevalence 
among women has shifted by 3.5 years from 23 in the mid-1990s to 26.5 years in 2002-
2004. Four patterns of infection are identified: among women attending antenatal clinics, 
among men and women in the general population, and among migrant workers. The 
implications of these different patterns of infection for the spread and management of the 
epidemic in South Africa are considered. 
Much of what we know about the HIV epidemic in South Africa is based on the analysis of 
data obtained from pregnant women attending antenatal clinics. It is therefore important to 
determine how accurately HIV prevalence among antenatal clinic attendees reflects 
prevalence in the community. In Chapter 7 this question is addressed by comparing HIV 
data collected from women aged 15 to 54 years as part of a community-based, cross-
sectional study in Hlabisa between 2000 and 2002 with data collected independently 
among women attending antenatal clinics in the same district during the same time. It is 
shown that antenatal clinic prevalence in Hlabisa overestimates the prevalence in the 
general female population. A limitation of this study however, is that only 34% of women 
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in the community consented to having blood taken for HIV testing. Although potential 
biases are investigated, the results of this study cannot be regarded as conclusive and more 
studies are needed in South Africa. 
The rate of increase in HIV prevalence among pregnant women attending antenatal clinics 
in South Africa has slowed over recent years. Good estimates of the incidence of infection 
will be of greater importance than prevalence for monitoring the epidemic over the next 
few years, for understanding the dynamics of the epidemic, and for estimating the number 
of new infections, all of which are essential for planning interventions. Direct estimates of 
incidence are difficult to obtain because of the cost, logistics and ethical problems of 
following people to HIV infection. However, incidence can be obtained indirectly from 
statistical and mathematical models. In Chapter 8, methods from which incidence estimates 
can be estimated are described. These include back-calculation methods, statistical 
methods, dynamical models, demographic models and laboratory techniques. 
Data on the incidence of HIV infection in South Africa are very limited. The first 
estimates of HIV incidence in South Africa were calculated in 1999 by the author of this 
thesis, using statistical methods to assess the feasibility of conducting vaccine trials in 
Hlabisa.32 This was followed in 2000 by a more sophisticated, dynamical model to obtain 
I T 
age-specific incidence from age-prevalence data. In Chapter 9, a detailed description is 
given of the dynamical model to estimate incidence from age-prevalence data for specific 
application to South African data. This model is applied to data collected from women 
attending antenatal clinics in Hlabisa and shows an extraordinarily high average incidence 
rate of about 10% per year among this population. A second model is also developed to 
estimate incidence in the absence of age-specific data, using time trends in prevalence data 
only. This model is particularly useful for estimating incidence in the various provinces of 
South Africa for which antenatal clinic prevalence is not reported by age. The model 
confirms the high incidence rates among women attending antenatal clinics in Hlabisa. 
In Chapter 10, the Standardized Testing Algorithm for Recent HIV Seroconversion 
(STARHS), a laboratory technique to estimate HIV incidence, is described. Estimates of 
HIV incidence using this method are then compared to the estimates obtained from the 
dynamical model described in Chapter 9. With some adjustment of the window period for 
the less-sensitive ELISA, good agreement is obtained in most of the age groups. 
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The methods described in Chapter 9 are applied to various HIV prevalence data sets in 
order to obtain estimates of HIV incidence for South Africa and these are reported by age, 
gender, geographical area and over time in Chapter 11. HIV incidence among national 
antenatal clinic attendees appears to have peaked in 1997 at 6.6% per year. Incidence 
estimates among antenatal clinic attendees in 2005 range from 2.5% per year in the 
Western Cape to 9.3% per year in KwaZulu-Natal (with a national average of 5.8% per 
year). The best estimate of HIV incidence for the general population in South Africa in 
2005, using the antenatal clinic data adjusted for potential biases, is 2.4% per year. 
Current mathematical models show that in 2003 alone, more than 350,000 deaths occurred 
in South Africa due to AIDS. In the absence of interventions, this is expected to continue 
to rise to about 500,000 deaths per year in the next 3-5 years, and to a cumulative number 
of more than 5 million deaths in the next ten years, with devastating consequences. In 
November 2003, the National Department of Health in South Africa announced an 
operational plan to provide comprehensive care, management and treatment for HIV/AIDS 
in the public health sector.34 The plan considers 3 scenarios (assuming 20% antiretroviral 
(ARV) coverage, assuming 50% ARV coverage, and assuming 100% ARV coverage) in 
which between 200,000 and 1.2 million people would be receiving treatment by the end of 
2008. To explore the impact of ARV on HIV incidence, prevalence and on AIDS deaths, a 
mathematical model is developed and described in Chapter 12. Through the use of the 
model, the consequences of providing ARV treatment at different levels of coverage and 
starting at different levels of CD4+ T-lymphocyte counts (CD4 cell counts) are explored. 
The results show that while the provision of antiretroviral therapy, if given according to 
present guidelines, could save the lives of about one million people in the next 10 years, it 
is unlikely to reduce HIV transmission significantly in the population as a whole, and the 
need to find ways to reduce transmission remains urgent. 
While much is known about the epidemic of HIV/AIDS in South Africa there is still much 
to learn. It is hoped that a better understanding of the dynamics of the epidemic based on 
the data presented and analyzed in this thesis will help us to find ways to deal with, 
manage and hopefully one day control, the epidemic of HIV that threatens to destroy so 
many lives in South Africa. 
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CHAPTER 2 HIV/AIDS in South Africa: A review of the 
scientific literature 
"The issues are so intense, the situation is so precarious for millions of people, the 
virus cuts such a swath of pain and desolation, that our voices, as well as your 
science, must be summoned and heard." 
Stephen Lewis, 200535 
Introduction 
In order to assess the state of scientific knowledge on HIV and AIDS in South Africa, a 
MEDLINE search was undertaken on HIV and AIDS related articles through the National 
Library of Medicine at the National Institute of Health (PUBMED). The key words used 
in the search included South Africa and (HIV or AIDS). Journal articles, letters and 
editorials (excluding news related articles) published only in peer reviewed scientific 
journals were assessed. As at the end of 2005, 1664 scientific articles, letters or editorials 
on issues related to HIV and/or AIDS in South Africa had been published in scientific 
journals. The first HIV/AIDS related scientific paper, a report of two AIDS cases in South 
Africa, appeared in 1983 in the South African Medical Journal.15 The total number of 
articles published each year increased slowly to a total of 31 in 1990, 76 in 1998, and 110 
in 1999 (Figure 2.1). In 2000, the year during which the International AIDS Conference 
was hosted in South Africa, the number of scientific publications reached 205. In 2001 the 
total number of publications dropped to 141 but increased again to a total of 207 in 2005. 
The increase in the number of scientific publications over time is almost proportional to the 
increase in HIV prevalence, as reflected in Figure 2.1. 
1983 to 1989 
The first scientific paper concerned with HIV/AIDS in South Africa appeared in 1983 and 
reported on the first two cases of the acquired immunodeficiency syndrome among male 
homosexuals in South Africa.15 During the next 6 years (1984-1989) 51 papers were 
published on HIV and AIDS in South Africa including several reports describing HTLV-
III, HIV, AIDS and AIDS related conditions in particular risk groups.17'36"38'39'40 One 
hundred and sixty-six cases of AIDS were seen in South Africa between 1982 and 1988, 
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with a mortality rate of 59%.19 Of interest was the absence of HIV infection in sex 
workers, women attending sexually transmitted disease clinics and drug abusers in 1987.41 
Several epidemiological studies on the status and future growth of the AIDS epidemic 
were published16 and in a three part series published in the South African Medical Journal 
in 1988, Ijsselmuiden and others emphasized the urgent need for, and proposed steps 
towards, a comprehensive strategy for the control of HIV infection.42"44 In 1988 and 1989 
the first papers appeared on medico-legal issues in caring for people with HIV infection,45 
the social impact of AIDS,46'47 and AIDS education.48"50 By the end of 1989, a number of 
surveillance studies had been presented and confirmed the entry of HIV infection into the 
heterosexual population in South Africa.16'39'51'52 While the number of visits by male 
homosexual patients to HIV clinics reached a plateau in 1989, the number of visits from 
heterosexual patients began to increase. Although the prevalence of HIV infection was still 
low in the general population (probably less than 0.5%), an alarming increase in the 
number of AIDS cases in particular risk groups was predicted.16'19 In the absence of a 
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Figure 2.1 The total number of scientific publications in peer reviewed 
scientific journals that are concerned primarily with HIV/AIDS in South 
Africa (blue bars), and the HIV prevalence among antenatal clinic attendees in 
South Africa (red curve: logistic function fitted to observed antenatal clinic 
data). 
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1990 to 1994 
Of great concern in the early 1990s was the extensive and continuing spread of HIV in 
urban heterosexual populations with the prevalence of HIV in some surveys doubling 
every 8.5 months.53 Data on the prevalence of HIV data suggested that the spread of 
infection was far more extensive than suggested by the still low numbers of reported AIDS 
cases.20 Of an estimated total of 122,951 HIV infected individuals in South Africa in 1991, 
69% were from urban populations, 20% from rural populations and 7% from homosexual 
men.54 Data from the National Department of Health's annual surveillance programme 
showed an increase in the point prevalence of HIV among first time antenatal clinic (ANC) 
attendees from 0.76% in 1990 to 7.6% in 1994, with wide geographical variation. 3'55 
Of 188 papers on HIV/AIDS published during this period, almost 20% were concerned 
with social and behavioural research. The majority of these dealt with knowledge, beliefs 
and practices among people in particular risk groups, such as youth, health care workers, 
STI and family planning clinic attendees, including reports on condom use and risk-taking 
behaviour.56"64 Several papers dealt with ethical issues, including informed consent and 
confidentiality57'65"68 and in four papers the question as to whether or not AIDS should be 
made a notifiable disease was discussed.69"72 Several papers were published on the 
statistical analysis and modelling of the epidemic during this period. Current, short-term 
and medium-term predictions of the prevalence of HIV infection were presented. Although 
the forecasts were tentative, they indicated the seriousness of the HIV epidemic. Using a 
macro-simulation model, Schall predicted in 1990 that the AIDS epidemic could reach 
prevalences of 30% in the sexually active population by the year 2000 to 2005, which is 
close to the current prevalence among women attending antenatal clinics.21'73 Similar 
predictions were made by Groeneveld and Padayachee using micro-simulation models." 
Other areas that were well researched during this time included: AIDS-related conditions, 
including Kaposi's sarcoma, Donovanosis and HIV related cancers;74"80 surveillance and 
epidemiological studies;""' " paediatric AIDS and HIV in children; transmission of 
HIV, mainly through blood transfusion84'88'89 and vertical transmission;90"92 sexually 
transmitted diseases and their association with HIV; 3'94 and HIV and dental/oral 
research. 5 '8 The relationship between tuberculosis (TB) and HIV was addressed in several 
papers99'100 while some others dealt with the diagnosis of HIV.101"104 
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Surprisingly few papers were published on prevention strategies, with the exception of an 
adaptation of the Health Belief Model,I05and the AIDS Educational and Training package, 
an education package designed to target low-literate groups in the workplace.106 The 
evaluation of a school based education programme in Cape Town showed that although the 
program greatly improved students' knowledge in relation to HIV transmission and 
prevention, it had little effect on behavioural.107 The evaluation of an education programme 
on HIV using puppetry and street theatre indicated that it could be more effective if 
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incorporated into existing community-based education programmes. " One further study 
identified the need for prevention programmes to address ADDS related issues in juvenile 
correctional centres.109 
There were several papers addressing factors associated with HIV including sexual 
behaviour,63 poverty110 and socio-economic determinants. l The first papers also 
appeared on migrant labour and HIV,112 traditional healers and ancient 
beliefs,113'114geographic progression of disease illustrated by mapping the AIDS 
pandemic,115 and the cost of adult AIDS inpatient care.116 With the exception of molecular 
analyses of HIV-1 infections in India which were shown to be closely related to a sequence 
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from a South African isolate, HIV-1NOF, few papers were published on molecular 
biological or immunological aspects of the disease during this period. There was also a 
lack of papers on disease management and care of HIV infected patients. 
1995 to 2000 
The rising trend in HIV prevalence rates during this period was matched by an increase in 
the number of scientific publications (Figure 2.1), reaching a maximum number of 205 in 
2000, coinciding with the International HIV/AIDS conference in Durban, South Africa. A 
total of 569 papers were published during this period. The prevalence of HIV infection 
among women attending antenatal clinics reached 23% in 1998, with the highest 
prevalence in KwaZulu-Natal (32%) and the lowest in the Western Cape (5.2%). Using 
data from antenatal clinic surveys, extrapolated to the general population, it was estimated 
that 3.6 million South Africans were infected with HIV in 1998, up from an estimated 1.7 
million in 1995. Of particular concern for public health professionals was the high 
prevalence among young women, aged 15 to 25 years. 
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South Africa joined the global effort to develop an effective ADDS vaccine and there was a 
substantial increase in the number of scientific papers on genetic, immunological and 
molecular biological aspects of the virus. Genetic analyses to determine HTV-1 subtypes in 
different risk groups in South Africa were reported in several publications.28'119"123 
Research suggested two different epidemics in South Africa: infection with HIV subtype 
B associated with homosexual transmission, and infection with subtype C associated with 
heterosexual transmission. Neutralization of HIV subtypes by antibodies and the 
implications for vaccine formulations were discussed.124 While one article summarized the 
development of HIV-1 subtype C vaccines for southern Africa," another reviewed an 
immunology-based approach to the design of an HIV-1 preventative vaccine, which will be 
I rye 
of great importance to reduce the high rates of HlV-transmission in South Africa. " In 
addition to the genetic and molecular components of vaccine development and new 
prospects in vaccine research, papers started to appear on issues related to the country's 
preparedness to participate in HIV-1 vaccine efficacy trials, " including discussions on 
ethical considerations and informed consent.127"129 
In countries with limited resources for diagnosis and management of the disease, absolute 
CD4+ T-lymphocyte counts (CD4 cell counts) are generally used to monitor disease 
1 ^0 
progression and to institute prophylaxis against opportunistic infections. Studies were 
done locally to assess the correlation between HIV RNA levels, CD4 cell counts and 
progression to AIDS or death.131"133 In addition, the role of surrogate markers (beta 2-
microglobulin and CD4/CD8 ratio) was discussed in relation to predicting maternal HIV 
transmissibility and disease progression in infants.134 
As in the previous period, a large number of papers were published on surveillance and 
estimating the size of the epidemic in different populations.55'135"144 Two peer reviewed 
scientific papers on the national antenatal clinic surveillance, providing HIV estimates by 
province between 1993 and 1996, appeared in the South African Medical Journal.55'141 
Almost one quarter of all scientific papers published during this period were concerned 
with tuberculosis145"151 and other HIV/AIDS-related illnesses, including Pneumocystis 
carinii pneumonia (PCP),152'153 HIV-related cancers,154'155 streptococcal diseases,156'157 and 
meningitis.158"161 Several papers were concerned with the association between sexually 
transmitted diseases and HIV,162"1 4 while disease management and assessment of care for 
patients infected with HIV were also addressed.165"170 Social aspects were still well 
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researched and included assessment of knowledge, attitudes and sexual behaviour,171"176 
children requiring social services,177 impact of HIV on quality of life178'179 and barriers to 
condom use.180"183 Many papers dealt with ethics, informed consent, confidentiality and 
voluntary testing and counselling,127'129'184"190 and whether AIDS should be made a 
notifiable disease.191'192 Most of the papers on transmission of infection were concerned 
with determinants of mother-to-child transmission such as breastfeeding, antibody levels 
of the mother and mode of delivery,193"198 while some were concerned with transmission of 
HIV through anal sex,199 blood transfusions200"202 and exposure of health care workers to 
blood and traumatized bodies.203'204 Diagnosis and testing received some attention, 
including an evaluation of several antibody assays and rapid tests, dried blood spots and 
polymerase chain reaction (PCR).121'205"208 Compared to the previous period, there was an 
increase in the number of papers dealing with prevention and public health interventions. 
Several papers were concerned with HIV in relation to sexual education and the evaluation 
of such programs.209"213 Of the other papers on prevention, there were first reports on 
microbicide research,214 papers on AIDS programmes at the workplace,215"217 on 
antiretrovirals for pregnant mothers218 and the cost-effectiveness of preventing mother-to-
child transmission,219'220 on child-feeding practices and a plea for dried milk formula,221 
and a call for universal precautions in health care settings.204 Only one study assessing 
community based interventions was reported on. A number of papers were concerned 
with paediatric HIV and AIDS, in particular with morbidity and mortality in children 
infected with HIV.223"227 Papers were published on adult mortality, including a study on the 
survival differences between the two independent epidemics of heterosexual and 
9 98 99Q 
homosexual infection in South Africa."" '"" First papers (although only a few) appeared 
930 939 
on the enormous potential problem of AIDS orphans. "" " Programs to provide 
antiretroviral treatment to individuals in need of treatment were not available in the public 
health sector in South Africa during this time and as a result, there were no papers on 
direct adult treatment of HIV in South Africa. However, treatment of sexually transmitted 
diseases, tuberculosis and HIV related cancer continued to receive attention. One 
paper, through modelling, investigated the extent to which low-level use of antiretroviral 
(ARV) treatment could curb the AIDS epidemic in southern Africa.236 Papers were also 
9-37 9'3Q 9"3Q 
published on nutrition," socio-demographic impact and demographic modelling," '" 
HIV and infertility,240 HIV among intravenous drug users,241 pharmacokinetics and 
antiretroviral activity of AIDS drugs,242geographical presentation of HIV heterogeneity 
and proximity to roads in a rural district in South Africa,243 and the origin of HIV.244 
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There were few papers on population dynamics and risk factors such as migrancy245'246 
and male circumcision247 which are now known to play an important role in transmission 
of HIV in South Africa. 
During 2000, a special edition on HIV/AIDS research in South Africa was published by 
the South African Journal of Science, presenting some of the varied contributions that 
science and South African scientists had made to our understanding of the HIV epidemic. 
The articles in the journal were grouped under the headings of origins, prevention, and 
treatment of HIV. 
2001 to 2005 
From 2001 to the end of 2005 a total of 855 papers were published in scientific journals. 
While prevalence data collected from the annual surveillance among antenatal clinic 
attendees between 2000 and 2002 indicated that the epidemic may stabilize at around 26%, 
the surveys in 2003 and 2004 showed an increase in prevalence to 27.9% and 29.5%, 
respectively. With morbidity and mortality increasing rapidly, the proportional number of 
articles that appeared in scientific journals on treatment, support and care for people with 
HIV/AIDS during this period increased significantly compared to previous years. While 
some papers described and evaluated the role of occupational health services and programs 
of care in the workplace,248"250 some others assessed the cost of HIV/AIDS to businesses 
in South Africa.251,252 The cost of a limited public sector antiretroviral programme was 
also assessed.253 Papers on access to HIV treatment and care as a human rights issue 
appeared in several (medical and law) journals." "" In anticipation of the South African 
government making ARV therapy available to those in need of treatment, papers started to 
appear on the first steps to providing ARV,25' ~261 while some studies showed that 
adherence might not be a barrier to providing ARV therapy in South Africa." "'" A few 
papers were published on voluntary counselling and testing (VCT) as well as on the 
barriers to VCT.264"267 In November 2003, the National Department of Health in South 
Africa announced an operational plan to provide comprehensive care, management and 
treatment for HIV/AIDS in the public health sector.268 A potential problem in rolling out 
ARV therapy in coming years is the lack of resources in the public health care sector. Few 
papers however, were published on strengthening health systems for implementation of 
ARV therapy and an increase in studies related to the challenges of providing ARV therapy 
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in the public sector, such as delivery mechanisms and the challenges of retaining patients 
in long-term primary care, are anticipated in the next few years. A first report appeared on 
side effects, cardiovascular consequences, related to provision of antiretroviral treatment, 
•}£Q 970 
and their was a call for earlier initiation of ARV treatment. 
As AIDS related mortality continues to rise in South Africa, more papers have started to 
appear on estimated mortality rates and cause of death profiles through modelling and the 
971 979 
analysis of vital registration data, and on maternal mortality." ' Only one paper 
considered the impact of the HIV epidemic on the number of AIDS orphans in South 
Africa.280 With the exception of the models described in this dissertation to estimate the 
incidence of HIV infection from prevalence data, very few papers reported estimates of 
HIV incidence. Two papers reported incidence estimates obtained directly from following 
a cohort of sex workers in KwaZulu-Natal,281'28' while one other study discussed the 
estimation of incidence among young mothers using a combination of HIV antibody and 
RNA tests on dried blood spots.283 In one further study the "detuned" ELISA technique 
was used to assess incidence of HIV among blood donors in South Africa.284 
Several scientific papers were published on studies investigating the relationship between 
9R1 9RS 9Rft 
HIV and genital ulcer disease, including HSV-2. '"" ' Several reports on tuberculosis 
and HIV were published,287"289 including the still growing burden of TB as a result of 
HIV,290 drug-resistant TB in areas with high HIV,291 maternal mortality associated with 
HIV-TB co-infection,271 the vicious cycle of poverty,292 and integrating TB and HIV care 
in primary care setting.29 295 Further studies were published on preventing mother-to-
child transmission,296"299 including the first district-wide program for prevention of mother-
to-child transmission (PMTCT),300 health systems constraints to optimal coverage of 
PMTCT programmes,301 and the benefits and risks of breastfeeding.302"305 A study was 
published on assessing the sensitivity of paediatric HIV diagnosis in a primary health care 
setting using a clinical algorithm (the Integrated Management of Childhood Illnesses).306 A 
few articles also appeared on rape and post-exposure prophylaxis,307"309 an area which had 
been neglected in previous years. 
Social and behavioural studies included factors associated with behaviour change and 
310 317 318 391 399 
condom use, " gender violence, " 'survival' sex among commercial sex workers, 
394. 391 39S 
" empowering women in the fight against HIV, ' and alarming reports appeared on 
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unsafe sexual behaviour among youth in South Africa. ' ' " The effect of migration on 
HIV was assessed in four papers related to studies from rural KwaZulu-Natal and the 
mining town of Carletonville,32'~330and one study on HIV prevalence among truck drivers 
in KwaZulu-Natal.331 
Molecular and genetic research included a report on novel evolutionary analysis of full-
length HIV type 1 subtype C molecular clones from Cape Town, ~~ host and viral factors 
that impact on HIV-1 transmission and disease progression, genotypic and phenotypic 
analysis of gag and env genes from subtype C and B isolates in South Africa,334,335 and 
molecular and genetic characterisation and selection of HIV-1 subtype C isolates for use in 
vaccine development,336'337'338'339'340 A review was also published on the development of 
HIV-1 subtype C vaccines for South Africa,341 on ethical issues related to vaccine 
trials,342'343 and on caring for HIV-1 vaccine trial participants.344 Additional papers 
appeared on viral dynamics and CD4 cell counts,345'346 and several were published on 
diagnostics, including the use of dried blood spots for surveillance purposes347 and the 
evaluation of commercially available assays to test for HIV.3 ~350 
In relation to research on prevention, the first results from a randomized controlled trial on 
male circumcision appeared from Orange Farm in the Gauteng province.351 The trial 
showed a 60% reduction in the risk of acquiring HIV among circumcised men compared to 
uncircumcised men, and if these results are confirmed in further trials currently being 
conducted in Kenya and Uganda, male circumcision could have significant implications for 
HIV control in sub-Saharan Africa. Further research showed high levels of acceptability of 
male circumcision as a tool for preventing HIV infection in South Africa.352 South Africa 
also contributed to research showing the beneficial effects of providing cotrimoxazole 
prophylactically to children infected with HIV in order to prevent opportunistic 
infections.353 
During this period, the first national population-based survey to assess HIV prevalence was 
conducted by the Human Sciences Research Council (HSRC),354"356 while the 
Reproductive Health Research Unit conducted another national survey among youth (aged 
15-24 years) to assess HIV prevalence and related sexual behaviour.357 Further research 
during this period included assessing the economic impact of HIV and AIDS,358 STI care 
in the private sector,359 care for health care workers with HIV,250'360 prevalence among 
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adult patients in a tertiary hospital in KwaZulu-Natal and among trauma patients in 
Johannesburg,362 oral manifestations of HIV,363'364 further reports on the effect of 
microbicides and the acceptability thereof," *" ' intra-vaginal practices and 
susceptibility to HIV, the impact of HIV infection on malaria, the role of nutrition and 
micronutrients in HIV infection369"371 including reports on the effects of herbal medicine in 
the treatment of HIV,372 and a first report appeared on HIV policies and practices in South 
African prisons.373 
Review of prevalence data 
A separate PUBMED search was done to review the scientific literature in relation to the 
prevalence of HIV infection in South Africa, using the key words {HIV or AIDS), 
prevalence and South Africa. Papers reporting on prevalence of HIV infections in various 
populations or risk group were included, but papers reporting on secondary analysis of 
prevalence or providing summaries of existing prevalence data were excluded. An 
extensive number of papers reporting estimates of HrV prevalence were published between 
1983 and December 2005, as summarized in Table 2.1. Where actual numbers or 
percentages were not provided in the papers, the figures in the table were derived using 
available data (e.g., calculating the total number of infected cases from the prevalence and 
the total sample size; or deriving the prevalence from the sample size and the number 
infected). Similarly, 95% confidence intervals were calculated, where not provided, 
assuming a binomial distribution in the case of small numbers or small prevalences, or 
assuming the normal approximation to the binomial in the case of large numbers. 
Between 1983 and 1988 papers reporting on HIV prevalence or the number of AIDS cases 
in South Africa appeared almost exclusively in the South African Medical Journal, with the 
exception of one paper published in the Transactions of the Royal Society of Tropical 
Medicine and Hygiene.41 HIV infection during this period was confined mainly to men 
who have sex with men, haemophiliacs and a high risk group of recurrent sexually 
transmitted infection (STI) clinic attendees. A study among sex workers in 1987 showed 
zero prevalence,41 while a prevalence of 2.86% was found among recurrent attendees of 
STI clinics in 1988.39 The introduction of the epidemic into the heterosexual population 
became apparent between 1988 and 1991 with several reports of HIV infection among 
attendees of STI or family planning clinics, mine workers and the general population 
20 
(urban and rural). In 1990 the then Department of Health and Population Development 
initiated annual anonymous HIV-prevalence surveys among antenatal clinic attendees, 
chosen as an indicator group for infection among the heterosexual population, to monitor 
the epidemic.23'141 Since then numerous articles have been published on the epidemic 
among the heterosexual population, showing the rapid increase in prevalence over time and 
reporting on extraordinarily high prevalences in some populations. As summarized in 
Table 2.1, prevalences have been reported for public sector antenatal, family planning and 
STI clinic attendees, TB patients, hospital patients from general, paediatric or gynaecology 
wards, cancer patients, sex workers and their clients, rape victims, mine workers and 
migrant women, blood donors, corpses for autopsy, general populations (urban and rural), 
the workforce, health care workers, young people and children. 
Review of incidence data 
In contrast to the large amount of prevalence data published in the literature, very few 
papers have reported on the incidence of HIV infection. Incidence is more difficult to 
measure directly than prevalence because it requires following a cohort over time which is 
logistically and ethically difficult. Incidence however, can be indirectly estimated through 
mathematical or statistical models or the use of laboratory techniques. With the exception 
of the incidence estimates described in this dissertation (and published as a result), only 
one cohort study in South Africa where incidence was directly estimated from following a 
cohort of sex workers in KwaZulu-Natal was reported on in two scientific papers.281'282 
One further study used the UNAIDS models and prevalence data obtained from the 
national population based survey in 2002 to estimate incidence in the general adult 
population indirectly,374 while one further study described the use of the "detuned" ELISA 
technique to estimate incidence among blood donors." The estimated incidences in these 
different risk groups were 18.2% among sex workers followed between 1996 and 1998, 
4.2% among the general adult population in 2002, 0.01% among low risk blood donors and 
0.5% among high risk blood donors in 1999. 
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Modelling the epidemic 
Despite the plethora of prevalence data in South Africa, few scientific papers have 
appeared in the public health literature using these data to model the dynamics of the 
epidemic. In the early years of the epidemic (1988-1992), two papers were published on 
91 7^ 
the future projection of the epidemic by Schall"' using a macro-simulation model, and 
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one by Groeneveld and Padayachee using a micro-simulation model."" During the period 
1993 to 2000, when the growth of the HIV epidemic in South Africa was very rapid, less 
than five scientific papers were found in the literature on modelling the epidemic. In 1990, 
Doyle and Millar gave a general description of an Actuarial Model with application to the 
HIV epidemic in South Africa in the Transactions of the Actuarial Society in South 
Africa*15, while two further publications appeared in journals on the application of the 
Doyle model.376'377 Further applications of this model were summarized in formal company 
or organizational reports. Williams and Campbell in 1998 analysed the South African 
antenatal clinic data, using maximum likelihood methods, to investigate the magnitude and 
time course of the epidemic in the different provinces.14 Since 2000, there has been an 
increase in the number of publications using mathematical models to understand the 
epidemic. Dorrington, Bradshaw and colleagues reported on the application of the 
Actuarial Society of South Africa (ASSA) model, specifically in relation to the current 
state and future projections of the epidemic, and on estimating the number of AIDS deaths 
in South Africa;378'379 Wilkinson and Floyd developed a model to estimate the cost and 
cost-effectiveness of interventions in Hlabisa; Rosen and colleagues applied models to 
estimate the cost of AIDS to companies;252Williams and Lurie developed a model to 
estimate the relative risk of infection for migrant and non-migrant men and women from 
their spouse and from partners outside the relationship;330 Rehle and Shisana applied the 
UNAIDS methodology, using the antenatal clinic data and data from the first national 
population-based HIV survey by the HSRC, to make epidemiological and demographic 
projections of the epidemic in South Africa;374 and Blower and co-workers from the 
University of California recently used uncertainty analysis to model the public health 
TOT 
impact of disease modifying HIV vaccines in South Africa. Further models are 
described in this dissertation to estimate the incidence of HIV infection from age 
prevalence data and to investigate the potential impact of antiretroviral therapy on future 
epidemic trends. 
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Table 2.1 Papers published in the peer reviewed literature on HIV prevalence in South Africa : 1983-2005. Unless provided in the paper, 
95% confidence intervals (CI) were calculated from available data 







































Ras et al.15 
Lyons et al.17 
Sher383 
Spracklen et al.37 
Sher384 
Sheretal.385 
De Miranda et al.386 
Schoub et al.41 
Botha et al.387 
Schoub et al.16 
O'Farrell & Windsor39 
Mertens et al.388 
Dusheiko et al.389 
Sher19 
Padayachee & Schall53 
Schoub et al.20 
Population 





Dental health care workers 
Drug abusers 
Sex workers in Johannesburg 
STI clinic attendees (women) 
Black South Africans 
White blood donors 
Black blood donors 
Recurrent attendees of STI clinics 
South African hospital 
Male mine workers 
General population - lab tests 
Blood donors 
South Africans 
Urban black men: STI clinic 






Urban black: women: STI clinic 
White men: STI clinic 
Urban black: female family planning 
Black men in general population 
Black women in general population 
New blood donors in South Africa (White men) 

























































































































1990 SAM J 
1990 SAM J 
1990 SAMJ 
1990 SAMJ 
1990 Trans R Soc Trap Med 
Hyg 










Ijsselmuiden et al.390 
Friedman & 
Robertson391 
Cohn et al.392 
Prior & Buckle88 
Martin et al.393 
Grobbelaar394 
Schoub54 
Friedman & Mclntyre91 
Friedman et al.85 
Schoub et al.395 
Abdool Karim et al.82 
Bhigjee et al.396 
Kustner et al.23 
Cronje et al.397 
New blood donors in SA (Black men) 
New blood donors in SA (Black women) 
Mine workers 
Children 
Haemophilia patients, JHB 
Blood donors, Natal 
Black female STI attendees 
Black male STI attendees 
White male STI attendees 
Black female family planning (FP) attendees 
White blood donors 
Black blood donors 
Urban black population in South Africa 
Rural black population in South Africa 
MSM 
Pregnant women, Baragwanath & Soweto clinics 
Pregnant women (ANC), Baragwanath hospital 
Black adults STI attendees in Johannesburg 
Black adult FP attendees in Johannesburg 
Black adults general population (JHB municipality) 
Black blood donors (new donors) in Johannesburg 
Rural black community, KZN 
Rural black women, KZN 
Rural black men, KZN 
General population, Ngwelezane, KZN 
National ANC attendees 
National ANC attendees 
National ANC attendees 
Rural women, OFS province 














































































































































1996 SAMJ Wilkinson & Moore398 
1996 Int J Gynaecol Obstet Hoosen et al.399 
1997 Br J Cancer 
1997 SAMJ 
1997 Int J Tuberc Lung Dis 
1997 J Acquir Immune Defic 
Syndr Hum Retroviral. 
1997 Genitourin Med 




1998 Int J Tuberc Lung Dis 
1998 AIDS 
1998 Int J STD AIDS 
TB patients, HIabisa hosp, KZN 
Female TB patients 
Male TB patients 
Women with granuloma inguinale, King Edward 
KZN 
Black cancer patients (HIV not origin), JHB 
TB patients, rural KZN 
TB patients in referral hosp, Durban 
Sitas et al.155 
Wilkinson & Davies148 
Anastasis et al.400 
Coleman & Wilkinson139 Rural ANC women, HIabisa 
Wilkinson et al.401 
Karstaedt et al.402 
Ramjee et al.403 
Kustner et al.55 
Swanevelder et al.141 
Connolly et al404 
Jones et al.405 
Wilkinson & 
Wilkinson406 
Rural ANC women, HIabisa 
Rural ANC women, HIabisa 
Women in rural KZN attending FP clinics 
TB (pulmonary) cases in urban hosp, Soweto 
Sexworkers at truck stops in KZN Midlands 
National ANC attendees 
National ANC attendees 
National ANC attendees 
National ANC attendees 
ANC women Western Cape 
ANC women Northern Cape 
ANC women Northern Province 
ANC women Eastern Cape 
ANC women Gauteng 
ANC women Mpumalanga 
ANC women Free State 
ANC women KZN 
ANC women North West 
TB patients HIabisa KZN 
TB patients HIabisa KZN 
Streptococcus pneumonia patients, Baragwanath 
hosp 





















































































































































1999 Ann Trap Paediatr 
1999 Int J Tuberc Lung Dis Churchyard et al.409 
1999 IntJSTDAIDS Wilkinson et al.410 
1999 Am J Forensic Med Pathol Du Plessis et al.203 
2000 SexTransmDis Chen et al.163 
2000 J Trop Pediatr 
2000 J AIDS 
2000 Int J Tuberc Lung Dis 
2000 Clin Infect Dis 
2000 J Trop Pediatr 
2000 Pediatr Infec Dis J 
2000 Int J Cancer 
2000 SA J Science 
2000 SA J Science 
2001 Int J Gynecol Cancer 
2001 AIDS 
ANC clinic attendees, HIabisa 
Colvin et al.162 Rural community, HIabisa, KZN 
Wilkinson et al.407 ANC clinic attendees, HIabisa 
Zwi et al.408 Children, paediatric wards Baragwanath hosp 
Children, paediatric wards Baragwanath hosp 
Mine workers with TB 
Mine workers with TB 
Gynaecological patients admitted to HIabisa hosp 
Autopsied bodies, Medicolegal lab, Pretoria 
Men with GUD attending STD clinics in Durban, CT 
and JHB 
Men with urethritis attending STD clinics in Durban, 
CT and JHB 
Children admitted to HIabisa hosp 
ANC clinic attendees, HIabisa 
Children admitted to Wits associated hospitals, 
JHB 
Urban Black children (2-60m) admitted to JHB hosp 
with LRTI 
Children under 5 years admitted to tertiary hosp in 
Soweto 
Children (3m-4y) with gastroenteritis admitted to 
Baragwanath hosp 
Cancer patients in 3 referral hops in JHB 
(excluding cancer with HIV as origin) 
Male patients 
Female patients 
Commercial sex worker in Johannesburg 
Commercial sex workers in Khutsong.Carletonville 
General female population in Khutsong, 
Carletonville 
General male population in Khutsong, Carletonville 
Migrant mine workers in Khutsong, Carletonville 
Moodley et al.416 Cervical cancer patients at KEVIN hosp, Durban 
Auvert et al286 Young men (14-24y) in Carletonville township 
Young women (14-24y) in Carletonville township 
Yeung224 
Wilkinson et al.32 
Madhietal.411 
Madhi et al.412 
Meyers et al.413 
Johnson et al.414 
Sitas et al.154 
Rees et al.415 
























































507 148 29.2 25.2-33.2 
176 31 17.6 11.9-23.2 




















































2001 Stat Med 
2001 Clin Infect Dis 
Colvin et al.361 
Williams et al.33 
Karstaedt et al.417 
2001 AIDS Patient Care STDs Morris & Cheevers418 




Ramjee & Gouws331 
Gouws et al.420 
McPhail et al.421 
2002 Int J Tuberc Lung Dis Jeena et al.422 












J Trap Pediatr 
J Clin Forensic Med. 
Vox Sang 
Pediatr Infec Dis J 




Sex Transm Dis 
Lagarde et al.352 
Zaretal.423 
Meel424 
Fang et al.284 
Grimwade et al.425 
Zuma et al.328 
Rosen et al.252 
Evian et al.426 
Grimwade et al.427 
Myeretal.428 
Adult medical inpatients, King Edward hosp, 
Durban 
Women attending ANC in Hlabisa, KZN 
Patients with pneumococcal bacteremia at 
Baragwanath hosp 
Men working in a sugar mill in KZN 
Children admitted to Paediatric ward in academic 
hospital (KEVIN) in Durban 
Truck driver clients of commercial sex workers in 
KZN 
Sex workers at truck stops in Midlands, KZN 
Women attending ANC in Hlabisa, KZN (age 14-
44y) 
Young men (14-24y) in Carletonville township 
Young women (14-24y) in Carletonville township 
Children (0-12 years) with proven TB from KE 
hosp, Durban 
Mothers attending rural immunization clinics in KZN 
Children (0-6weeks) born to HIV infected mothers 
Children (6 weeks to 6 months) born to HIV 
infected mothers 
Men aged 19-29y in Westonaria, Gauteng 
Women aged 14-25y in Westonaria, Gauteng 
Children in Cape Town hospitalized with 
community acquired pneumonia 
Rape victims attending Sinawe crisis centre in 
Transkei 
South African blood donors - low HIV prev 
South African blood donors - high HIV prev 
Febrile children in Hlabisa with malaria 
Migrant women in Carletonville 
Non-migrant women in Carletonville 
Workplaces in South Africa 
Formal sector workforces in South Africa 
Febrile adults at clinics and hospital inHlabisa 
Women participating in Gynae screening study in 
Cape Town 
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Shisana et al.355 
Shisana et al.429 
Connolly et al.356 
Auvert et al.430 
Grimwade et al.295 
Dunkle et al.431 
Mseleku et al.432 
Kagee et al.433 
Pettifor et al32e 
Married people, South Africa 
Unmarried people, South Africa 
Adults (>15 years) in South Africa 
South African health workers in four provinces, 
private and public sector 
General population in SA (HSRC study) 
Female general population (HSRC study) 
Male general population (HSRC study) 
Black general population (HSRC study) 
White general population (HSRC study) 
Coloured general population (HSRC study) 
Indian general population (HSRC study) 
Community men and women from township in JHB 
Adults treated for TB in rural KZN 
Female sex workers in JHB 
ANC attendees at Johannesburg hospital 
ANC attendees at JHB hosp who initially refused 
routine testing 
Muslims in the Cape Metropole 
Young women (aged 15-24 years) 

















































































'Indicate samples received and not tested 
Note: Where 95% confidence intervals were not provided in the paper, they were calculated here either assuming a normal approximation or 
the binomial distribution in the case of small numbers or prevalences. 
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Discussion 
The scientific review in this chapter shows that there is a substantial literature covering 
many aspects of HIV and AIDS in South Africa. These include social, behavioural, 
epidemiological, clinical, molecular and genetic research. During the first period covered 
in this review, 1983 to 1989, the focus of the scientific research was on men who have sex 
with men, the group most affected by the epidemic during this period. However, by 1989 it 
became clear that the virus had been introduced into the heterosexual population and 
several papers debated the likely impacts of the epidemic and warned of the potential threat 
posed by HIV/AIDS to the South African society. 
During the period 1990 to 1994 it became clear that the heterosexual epidemic was rapidly 
overtaking the homosexual epidemic in scale and importance and surveillance efforts to 
estimate the size of the epidemic in various populations and risk groups were described in 
several papers. The number of papers dealing with social and behavioural aspects of the 
epidemic increased steadily and important studies were published on the epidemiology and 
likely future growth of the epidemic. Predictions on the maximum size of the epidemic 
made by statisticians during this time have proved to be depressingly accurate. 
During the third period under consideration, 1995 to 2000, research increased on all fronts 
and the number of papers in scientific journals reached a maximum in 2000. In particular, 
there was a dramatic increase in the number of papers dealing with the genetic and 
molecular aspects of the virus as South Africa joined the international effort to develop an 
effective AIDS vaccine. There was also an increase in interest in AIDS related diseases 
with numerous papers on tuberculosis and its association with HIV. 
Trends during the third period continued after 2000, with an impressive number of 
publications in social, behavioural, epidemiological, clinical and molecular research areas. 
However, more emphasis was placed on issues related to providing treatment, care and 
support for patients with HIV or AIDS, an area of specific interest as the Government of 
South Africa announced its plan to provide antiretroviral treatment in the public health 
sector in 2003. South Africa also contributed significantly to international prevention 
efforts with research on the effect of cotrimoxazole in prevention of opportunistic 
infections in HIV infected children and the significant impact of male circumcision on 
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reducing the transmission of HIV from females to males. The first national population 
based surveys were also conducted in an attempt to estimate HIV prevalence in various 
population group (by region, men/women, children, young people) and to assess associated 
socio-economic and behavioural factors. 
Finally, while there is an impressive amount of data on HIV prevalence in various risk 
groups in South Africa, there is a clear lack of estimates on HIV incidence, which is crucial 
for understanding the dynamics of the epidemic and for planning interventions. At a time 
when prevalence is starting to level off and mortality is rising, it is of particular importance 
to monitor changes in the number of new infections in various populations. In this thesis, 
methods are developed and described to estimate HIV incidence in various populations in 
South Africa, and to estimate the impact of ARV on future epidemic trends. 
The scientific community has responded to the challenges of HIV/AIDS in South Africa 
with an impressive body of scientific literature, but more still needs to be done. Probably 
the greatest need however, is for social, epidemiological, clinical, biomedical and 
molecular scientists as well as policy makers and planners to work together to provide the 
intellectual support that will be needed if we are to deal with this devastating epidemic 
effectively. 
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CHAPTER 3 Mathematical modelling of HIV and AIDS 
"Understanding of the world in scientific terms is to build a model, to reduce 
apparent complexity to a set of simple rules. These rules constitute a theory. A 
theory may be verbal or in terms of mathematical equations, but a verbal theory is 
always incomplete. A mathematical theory provides a logical link between 
assumptions and conclusion. Thus, ultimately, the language of all natural sciences 
is mathematics. A verbal theory can be conveniently vague about its details and 
hide important assumptions. A mathematical theory is more transparent. It contains 
a clear list of assumptions, which are its ingredients generated by observation." 
Martin Novak and Robert May, 2000434 
Introduction 
Epidemiology is the study of diseases in populations rather than individuals. While 
clinicians are interested in disease in a particular person, epidemiologists are interested in 
knowing why some people get the disease while others do not. Epidemiologists are 
concerned with questions such as: If a vaccine is developed against HIV but it only gives 
50% protection, what effect would this have on the epidemic of HIV? How many people 
will have to be vaccinated in order to control HIV? If condoms are to be used to reduce 
the incidence of HIV, do we need to ensure that everyone uses condoms? Mathematical 
modelling is an essential part of epidemiology because it provides a tool to help understand 
the biology and the dynamics of disease. 
A central role of mathematical models in the study of epidemiology and control of HIV, as 
defined by Anderson and May, is to understand the interplay between the variables that 
determine the course of infection within an individual and those that determine the patterns 
of infection in communities of people.435 Mathematical models have become an integral 
part of research related to infectious diseases, partly because of the non-linear dynamics of 
most infectious disease epidemics, and the role of epidemic theory based on mathematical 
models has been of great importance in seeking explanations for patterns of diseases.436 
Brief history of mathematical modelling 
One of the earliest examples of mathematical biology in history was published in 1202 in a 
book by the Italian mathematician Leonardo of Pisa (known as Fibonacci) which 
introduced the Hindu-Arabic decimal system to Western Europe. One of his examples, 
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regarded as the very beginning of mathematical biology, was: "How many pairs of rabbits 
can be produced from one pair, if every month each pair bears a new pair which from the 
second month on becomes reproductive?" Assuming that 1 month elapses before the initial 
pair reproduces, that there are no deaths, and that each pair reproduces regularly, the 
number of adult rabbit pairs being present in consecutive months is then given by the 
Fibonacci sequence: 1, 1, 2, 3, 5, 8, 13, 21,.. . . 
The application of mathematical models to infectious diseases dates back to 1760 when 
Daniel Bernoulli developed a mathematical method to study the effect of variolation to 
protect against smallpox infection on life expectancy.437 In 1840, William Farr fitted 
curves to data of smallpox epidemics in England and Wales.4 5 At the beginning of the 20th 
century, Hamer and Ross developed mathematical equations to describe the spread of 
infectious agents within populations. Hamer first introduced the so-called "mass-action" 
principle for a deterministic epidemic model in discrete time in 1906,438'439 in which the net 
rate of transmission of infection is proportional to the product of the densities of infected 
and susceptible individuals. This principle, which incorporates the principle of 
homogeneous mixing, has been the basis of most subsequent development in epidemic 
theory.439 Ronald Ross, describing the spread of malaria in 1916, was the first to use the 
"mass-action" assumption in a continuous time model.439 In 1927, Kermack and 
McKendrick laid the foundations for a theoretical framework of epidemiology, describing 
the form of equations most commonly used to characterize the typical general epidemic 
with susceptibles, x(t), infecteds y(t) and immunes z(t).439 They assumed a fixed 
population size N= x(t) + y{t) + z(t) and used the homogeneous mixing principle for 
continuous time to derive the classical equations 
dxldt = b - Xxy, 
dy/dt = Axy - yy, 
dzldt - yy, 
where people enter the model at a rate b, become infected at per capita rate X which is 
determined by the contact rate times the prevalence of infection, and become immune at a 
rate y. Fisher, in 1930, first described the "net reproductive value" for the parasite, a 
concept which has become central in discussing the population biology of an organism.435 
The basic reproductive rate, Ro, is the average number of successful offspring that a 
parasite is capable of producing. A parasite species must have R0 > 1 in order to be able to 
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invade, and establish itself within a host population.435 The concept has been discussed 
and developed by, amongst others, Macdonald in 1952 in the context of malaria 
transmission,440 Dietz in the 1970's in studying the transmission and control of arbovirus 
disease and other infectious diseases,441'442 York and co-workers in studying sexually 
transmitted infections, and Anderson and May in studying the dynamics and control of 
infectious diseases in humans.435'443 
The literature concerned with mathematical epidemiology has grown rapidly over the last 
three decades, much of which has been concerned with probabilistic models, addressing 
the variation and elements of chance as important determinants of the spread of infection. 
In recent literature reviews it has been shown that the number of publications related to 
mathematical epidemiology increased from less than 10 in the period 1760-1855, to about 
100 between 1856 and 1957, and to about 500 between 1958 and 1978.435 Recent work has 
included studying control theory to epidemic models, the spatial spread of diseases, 
mechanisms underlying recurrent epidemic behaviour, heterogeneity in disease 
transmission, and extending threshold theory to more complex deterministic and stochastic 
models.435 
Mathematical models applied to sexually transmitted disease epidemiology 
Despite the early developments in mathematical models and epidemic theory, it is only 
during the last 30 years that mathematical models have been applied to sexually 
transmitted disease epidemiology. Following some early applications of mathematical 
models to describe the transmission dynamics of gonorrhoea in the 1970s444, two 
influential publications by Yorke and Hethcote, supported by data, attempted to address 
issues of interest to health workers and introduced a number of essential concepts in 
sexually transmitted disease epidemiology. ' These included the concept of the 
"reproductive number", already applied in other areas, as a measure of transmission 
success, the importance of asymptomatic infections in maintaining endemic infections, and 
the role of the "core group" of individuals with high rates of change in sexual partners to 
maintain transmission of disease in communities with both high and low rates of partner 
change.43 The development of the conceptual/theoretical model of the transmission 
dynamics of sexually transmitted infections (STIs) in the early 1990s had a major impact 
and made mathematical models more accessible to many scientists.447'448 Since then, the 
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conceptual model based on the basic reproductive number (7?o), has provided a framework 
for much of the research related to the dynamics of STI epidemiology. 
Mathematical models applied to HIV/AIDS 
A number of models have been developed globally to investigate the dynamics and impact 
of HIV and AIDS, ranging from relatively simple extrapolation models to large, complex, 
macro- or micro-simulation models. Among the simple models that have been applied to 
most of the countries and regions in the world are the Estimation and Projection Package 
(EPP) model developed by the UNAIDS Reference Group on Estimates, Modelling and 
Projections to fit epidemic curves to data collected over time,45 and the Spectrum (AIDS 
Impact Model) developed by Futures Group International, to estimate the demographic 
impact of HIV and AIDS.451 The UNAIDS EPP model replaced the earlier model 
developed by WHO (Epi-Model) which was used to produce estimates of HIV in sub-
Saharan Africa assuming that the HIV infection curve follows a gamma distribution.452 
Four major modelling efforts have been developed in relation to AIDS in developing 
countries, namely SimulAIDS, a Monte Carlo model of heterosexual transmission of 
AIDS, initially developed by Bertran Auvert and colleagues;453 iwgAIDS, a complex 
continuous simulation model of known modes of transmission, developed by Steve Seitz 
and others with funding from the USA government;454 a series of models to simulate the 
heterosexual spread of HIV, developed at Imperial College, London and Oxford University 
by Roy Anderson and colleagues;455"458 and STDSEVI, a micro-simulation model to 
describe the sexual transmission of HIV and STFs, developed at Erasmus University by 
Dik Habbema and colleagues with funding from the European Commission.459'460 
Modelling the HIV epidemic in South Africa 
In South Africa, models were developed in the early stages of the epidemic, and although 
the forecasts were tentative because of the lack of key data and the number of assumptions, 
they indicated the seriousness of the HIV epidemic. In the early 1990's, both Schall, using 
a macro-simulation model,21 and Groeneveld and Padayachee, using micro-simulation 
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models," predicted that the prevalence of HIV could reach 30% in the sexually active 
population by the year 2000 to 2005, which is close to the current prevalence among 
women attending antenatal clinics. The Doyle-Metropolitan model, first described by 
Doyle and Millar in 1990,375 was initially developed for use by Metropolitan Life to 
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investigate the demographic consequences of HIV in life insurance, health and pension 
applications. Application of the Doyle model in the early 1990s suggested that the number 
of AIDS cases could reach 800,000 in 2010.376 The component population projection 
model, subsequently developed by the Actuarial Society of South Africa (ASSA model), 
has its origins in the Doyle-Metropolitan model and has been widely used to project the 
demographic impact, including mortality, of the HIV epidemic in South Africa.461'462 The 
model is calibrated to the national antenatal clinic prevalence data and to estimates of 
mortality based on death data recorded by the Department of Home Affairs. The UN AIDS 
models have been used by some epidemiologists to estimate the current state of the 
epidemic (prevalence in adults and children, number of people living with HIV, number of 
AIDS deaths, and number of orphans)4 and to make future projections of the epidemic in 
South Africa.374 Models have also been used to estimate the cost and impact of HIV on 
businesses252 and the cost effectiveness of intervention programs;380 and a model has 
recently been described to predict the potential public health impact of disease-modifying 
HIV vaccines in South Africa.382 Further models to describe epidemic trends and the 
impact of the epidemic in South Africa are described in this thesis. 
Following an initiative by Brian Williams and colleagues to bring South African modellers 
together to investigate the dynamics of HrV/AIDS, TB and other diseases, the South 
African Centre for Epidemiological Modelling and Analysis (SACEMA) has been 
established with the support of the South African Department of Science and 
Technology.463 This Centre of Excellence is the first national research institution of its kind 
in Africa and is dedicated to modelling disease transmission and progression, with a focus 
on South Africa's major health challenges. 
The uses of mathematical models 
The main purpose of mathematical models is to understand the dynamics of a disease, in 
terms of the interplay between those variables that determine the course of infection within 
an individual, and those that determine the pattern of infection in a population.435 
Mathematical models can be used to study disease transmission, to identify patterns of 
infection, and to help define the most important factors associated with the observed 
disease patterns. Models can be further used to explore the potential impact of behaviour 
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changes and interventions on the spread of disease, and to assess cost effectiveness of 
interventions or the economic impact of HIV in a workplace or country. Knowledge of the 
factors determining the patterns of infection and the potential impact of interventions can 
be used to model the future course of the epidemic in a population. 
Mathematical models can help us to understand the demographic impact of HIV and AIDS 
in relation to mortality and morbidity, how HIV and AIDS will affect the demand for 
health services, or the productivity of labour, or how the dependency ratio will change and 
the impact this will have on social services. Finally, mathematical models can be used to 
inform policy and programmatic decisions related to the planning of adequate responses, 
targeting of medical and behavioural prevention strategies, and the provision of care and 
support in a community. 
Modelling can be done in different ways. When statistical models are applied to 
epidemiological data we often begin by looking for associations between variables and 
then proceed to use regression or analysis or variance models to see if the values of one 
variable can be accurately predicted using others. The significance levels of the variables 
in these models can help to identify and rank the most significant associations, while the 
strength of the association can be specified in terms of odds- or risk-ratios. While statistical 
models can take the features of data into account (e.g., categorical or continuous 
measurement, random or fixed effects, linear or non-linear effects), conventional 
approaches to statistical analyses often assume linearity in data, and transformations are 
often applied to data in such a way that the transformed variables are linearly related with 
each other. Such transformations tacitly assume a particular form of the relationship, and 
therefore of the underlying dynamics, which may or may not be appropriate. An important 
limitation of statistical modelling is that it generally presents a static analysis of the data: 
one might consider the prevalence of HIV at several points in time and show that the 
prevalence is significantly higher or lower at later than at earlier times, but this does not 
take into account the dynamics of the disease over time; to do this we need to develop 
dynamical models based on difference or differential equations. 
Dynamical models are designed to simulate an actual situation and are limited only by the 
imagination of the scientist building the model. They can be linear or non-linear, complex 
or simple, but they are usually designed to capture and describe the past (known) history of 
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the disease and to forecast the future (unknown) course of the disease. When developing 
models and interpreting model outcomes, it should be borne in mind that model estimates 
are always uncertain to some degree because they depend on the structure of the model, 
which is based on our assumed understanding of the epidemic, on the parameters included 
in the model, some of which are uncertain; and on the data sets used in the modelling 
exercise which contain further uncertainties. 
Basic concepts in mathematical models related to HIV/AIDS 
The simple epidemic 
Transmission of HIV depends upon direct contact between infected and susceptible 
individuals. The simplest model of the population dynamics of HIV is shown 
schematically in Figure 3.1. People are born or become susceptible at a rate /?, putting aside 
the issue of mother-to-child transmission, and the rate (A) at which infections are acquired 
is proportional to the number of encounters between susceptible (5) and infected (I) people. 
In the case of HIV, the rate at which infection spreads in a population depends on the 
number of infected people, the number of susceptible people who are available to be 
infected, the rate at which these two groups make contact, the probability of transmitting 
HIV per sexual contact, and the life expectancy of infected people. In the simple model 
infected people die at a per capita rate 8, while the per capita background mortality rate 
(in the absence of disease) is jU. 
Most mathematical modelling in biology consists in taking models conceptualised as in 
Figure 3.1, and formulating them in terms of differential equations which can be simulated 
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Figure 3.1 People are bom or become susceptible at a per capita rate /?, susceptible 
people become infected at a rate X times the current prevalence (JIN), and people die of 
AIDS at a rate 8. The population growth rate, in the absence of disease, is the birth rate 
minus the background death rate //. 
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Simulation models can be used to answer questions in relation to the HIV epidemic such 
as: How rapidly does the infection spread at the start of the epidemic when only a few 
people are infected and how does the spread of infection change later in the epidemic when 
many people are already infected? What happens later in the epidemic when infected 
people start dying? What happens if there are core groups of men or women who have 
many sexual encounters with other women or men? Once we know what has happened in 
the past, can we reliably forecast what we think will happen in the future? What percentage 
of the population need to use condoms with casual partners in order to significantly alter 
the course of the epidemic? If most sex workers use condoms will that have any impact on 
the spread of infection? What is the likely impact of providing anti-retroviral therapy to 
those in need on the future course of the epidemic? If we extend the life of people infected 
with HIV will that make the situation better (because they live for longer) or worse 
(because they infect more people)? If we had a vaccine, what sort of coverage would we 
need to bring down the overall rates of infection? 
The Basic Reproductive Number 
The rate and extent of spread of the epidemic can be derived from the basic reproductive 
rate of infection (Ro), defined as the average number of secondary cases of infection that 
arise from one infectious individual (primary case) in a susceptible population.435 
Essentially, it is a composite measure of transmission success in a particular community. 
The reproductive rate is influenced by three parameters: the transmission probability per 
partnership (ft), the mean rate of sexual partner change (c), and the mean duration of 
infectiousness (D), and can be formulated as follows: 
R0 = flxcxD 3.1 
Changes to any of the 3 variables, viz. /?, c or D, will determine whether or not the 
infection will persist and how quickly it will spread. For an epidemic to persist in a 
population, Ro must be greater than or equal to 1. The magnitude determines the likelihood, 
speed, and scale of the spread of infection. In order to eventually eliminate the infection Ro 
must be reduced to less than 1. In South Africa we estimate that R0 is approximately 7, as 
follows: From the analysis done in Chapter 5 of this thesis, the doubling time of HIV 
prevalence at the start of the epidemic is about 15 months. This means that each person 
with HIV infects one other person, on average, every 15 months (or 1.25 years). If the life 
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expectancy of an infected person is nine years then each person infected with HIV will 
infect 9/1.25 ~ 7 people before they die, i.e., RQ ~ 7. In order to eliminate the infection 
completely we need to reduce transmission by about seven times. Smaller reductions will, 
of course, lead to some decline in the prevalence. 
Co-factors that will have an impact on one or more of the variables in Equation 3.1 include 
demographic factors such as age and gender, social factors such as sexual networking 
patterns and sexual practices, biological variables such as the presence of other sexually 
transmitted infections and male circumcision, and medical factors including the provision 
of antiretro viral drugs and the treatment of AIDS related opportunistic infections. For 
example, transmission of HIV will be more efficient when the male has an STI because 
shedding of HIV into semen increases in the presence of an STI and hence the partner is 
exposed to greater concentration of the virus.464 A numerical example of how the epidemic 
growth could be reduced by managing STIs optimally is provided in Box 3.1. Using a 
condom reduces the transmission probability /?, because the semen (and hence HIV) is 
contained in the condom and does not infect the sexual partner. 
In order to reduce Ro to less than 1, so as to control the HIV epidemic in South Africa, 
prevention efforts need to be scaled up, including control of STIs, promotion of condom 
use, reduction of high-risk sex and number of sexual partners, development of vaccines 
and microbicides, provision of antiretroviral drugs to prevent mother-to-child-infection, 
while access to treatment of HIV and other opportunistic infections should be ensured so 
that the lives of those who are already infected can be extended. 
39 
Box 3.1 Numerical example to show how co-factors may influence Ro 
a. Reducing the rate of partner change 
If each HIV infected individual reduces the number of sexual partners that he/she has 
whilst living with HIV by half then c in Equation 3.1 would become c/2 and 
R0 = fix c/2 x D so that the reproductive number R0 would also be halved. If 
previously Ro was 7, reducing the number of partners by half would reduce Ro to 3.5. 
b. Managing sexually transmitted infections 
If we assume that about 20% of the adult population have at least one STI (p = 0.2) 
and that, on average, having an STI increases the chance of contracting HIV by a 
factor of 10, then the efficiency of transmission (/?) becomes: 
£ = (0.2 x 10) + (0.8 X 1) = 2.8 
If Ro = 7 then, with the eradication of STIs, Ro will become 7/2.8 = 2.5. 
Using models to understand trends in the epidemic of HIV in South 
Africa 
The epidemic of HIV infection in South Africa, predominantly of subtype C, has reached 
extraordinarily high proportions and threatens to overwhelm the country. However, if we 
are to deal with it effectively, it is essential to first understand the basic dynamics of the 
infection. The surveillance systems and data on HIV infection rates in South Africa are 
among the best in the developing world, largely as a result of the efforts of the Department 
of National Health and Population Development who in 1990 started an annual 
programme to collect data on HIV prevalence among pregnant women attending antenatal 
clinics throughout the country.23 Changes in the overall antenatal clinic prevalence of HIV 
over the last fourteen years (Figure 3.2) can be fitted to a logistic curve, described in Box 
3.2. 
The logistic curve gives a best estimate of the asymptotic prevalence (the value at which 
the epidemic is predicted to level off) of about 28% and an initial doubling time at the start 
of the epidemic of about 15 months (described in more detail in Chapter 5). Once the 
prevalence has levelled off, and depending on behaviour change and the impact of 
40 
prevention and interventions that reduce transmission of the virus, it is anticipated that the 
prevalence will eventually start to decline, as has been observed in countries such as 
Uganda (Figure 3.3, fitted to data obtained from UNAIDS, available at www.unaids.org). 
Once the prevalence of HIV begins to fall, a double logistic function can be used to 
describe the change over time, as explained in Box 3.2. 
2007 
Figure 3.2 Prevalence of HIV infection from national antenatal clinic 
surveillance between 1990 and 2004. The early stages of the epidemic showed 
an exponential increase in HIV infection with a doubling time of 15.6 months 
(95% CI: 15.2-16.1). Fitted to a logistic curve, the HIV epidemic reached half its 
peak value between 1996 and 1997 and has an expected maximum prevalence of 
28.3% (95%CI: 27.7-28.9). 
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Figure 3.3 Double logistic curve fitted to prevalence data from Uganda, 
showing a decrease in the epidemic over recent years (source: curve fitted 
to UNAIDS data, available at www.unaids.org (Epi Fact Sheets)) 
Understanding the geographical distribution of infection is equally important and the 
provincial prevalences are discussed in Chapter 5. The patterns of infection vary strongly 
between men and women and with age (described in more detail in Chapter 6), and basic 
dynamical models should therefore be age-structured to allow for diversity in the 
behaviour and risk of different populations. The age-prevalence of infection among men 
and women is essential for determining the age and gender specific mortality and hence the 
future age structure of the population. The pattern of HIV age-prevalence has shown to be 
close to zero in young adolescents before the age of onset of sexual activity, then increases 
rapidly as sexual activity increases to a peak in the late 20's for women and early 30's for 
men, followed by a more gradual decrease in prevalence among older people. The function 
that has been shown to best describe the age prevalence of infection is the log-normal 
function of the form 
R(a) 
N -(In((a-fl0)/m))2/2o-- 3.2 
(TyJ27r(a-a0) 
with age a, off-set of sexual activity at age aQ, mean m, standard deviation a and 
normalised to N, and is illustrated in Figure 3.4 using HIV prevalence data from antenatal 
clinics. 
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Box 3.2 Logistic or double logistic functions to model the change in the HIV epidemic 
over time. 
Wlien the prevalence is still increasing or showing signs of leveling off, 











Where a = asymptote (i.e., the level at which the epidemic is expected to level off) 
a = the rate of increase at the start of the epidemic 
to = the time at which the epidemic reaches half its asymptotic value 
The doubling time at the beginning of the epidemic can be determined from a, 
i.e., doubling time = ln(2) / a 
When the prevalence shows evidence of a decline, 
a double logistic curve of the following form can be fitted to the data: 
P(t) = 
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Where a = the rate of increase at the start of the epidemic 
a = determines the peak value 
/? = the rate of convergence 
b = final prevalence level 
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Figure 3.4 Age prevalence of HIV infection among women attending antenatal 
clinics in South Africa in 1999. Error bars are 95% confidence limits. The fitted curve 
is a log-normal function. 
Given our current knowledge of the HIV epidemic, one can make an immediate, but 
approximate, estimate of the number of people infected with HIV in South Africa. From 
the antenatal clinic surveillance in 200431 it is known that about 29.5% of pregnant women 
were infected with HIV (Figure 3.2) and that the rates among adult men are about 75% of 
the rates in women." Based on the United Nations Population Division population size 
estimates, it is assumed that the adult population (age 15-49 years) for South Africa was 
24,349,000 in 2005.465 If the antenatal clinic estimate is believed to give a reasonable 
estimate of the prevalence in adult women, then it is estimated that about 6.28 million 
adults are currently living with HIV. However, since the above data represent women 
attending public health clinics, it may exclude women from more affluent communities 
who are more likely to receive private health care, as well as women in deep rural areas 
who may visit traditional healers instead of public health facilities. In both these groups it 
is expected that HIV prevalence is lower than among those women attending public health 
clinics. If the antenatal prevalence estimate is adjusted down by 20%, the estimated 
number of adults (15-49 years) living with HIV is 5.03 million. This is within the range of 
the UN ADDS estimate of 5.1 million (range 4.3 to 5.9 million)4 adults infected with HIV 
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in 2003, using more sophisticated models that make assumptions about the age-
distributions, fertility reduction, the relative levels of HIV prevalence in women who use 
public antenatal clinics and those who do not, and survival rates. 
Using mathematical models one can estimate the age-specific incidence of new infections, 
the most sensitive marker of transmission, from the slope of the prevalence curve, allowing 
for natural deaths and AIDS deaths and assuming a life expectancy after infection of 9 
years, as will be described in Chapter 9. Similarly, the number of deaths can be estimated 
from models applied to HIV prevalence data, making assumptions about survival after 
infection with HIV. Future projections can be made about prevalence, incidence and 
deaths, as discussed in Chapter 12. Using vital registration data, the effect of HIV on adult 
death rates have become apparent over the last few years279'466 and the Medical Research 
Council's Burden of Disease Research Unit showed that AIDS was the leading cause of 
deaths in 2000 in all provinces in South Africa with the exception of the Western Cape.466 
Nationally, in 2000, AIDS accounted for 30% of all deaths in South Africa and the number 
of AIDS deaths, using the ASSA model, was estimated to be 165,792.466 It is further 
estimated that in 2010, AIDS will more than double the burden of premature mortality (as 
measured by years of life lost - YLL ) experienced in 2000. 
Many studies have speculated on the impact of HIV/AIDS on population growth. Most 
models suggest AIDS would only cause negative population growth in Africa if national 
HIV prevalence levels increased to 30-50% or if fertility rates decline sharply.467 It is 
therefore possible that in South Africa, with very high levels of prevalence and declining 
fertility, the population may well cease to grow over the next ten to twenty years. 
The importance of good demographic models cannot be over stated, for without such 
models it will be difficult to develop an effective response to the epidemic, to make 
sensible plans for the provision of health and welfare services, to manage the economic 
burden on the country's industries, or to assess the impact of interventions (including 
antiretroviral treatment, vaccines, increased condom use, management of sexually 
transmitted diseases, educational and behaviour change programmes, media campaigns, 
and so on). Fortunately, there is a considerable amount of data on HIV in South Africa 
(both from sentinel and site surveillance, and from community and national surveys), for 
without such data the best models in the world are no more than informed guesses. 
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Anderson and May pointed out in 1991 ' that despite the extent and sophistication of the 
mathematical literature, "the insights gained from theoretical work have, in general, had 
little impact on empirical approaches to epidemiological study and the design of public 
health policy", a consequence that they ascribe to the abstractly mathematical nature of the 
literature. They therefore stress that, "if theoretical work is to play a role in the solution of 
practical problems in disease control and in the interpretation of observed trends, a much 
greater emphasis must be placed on data-oriented studies." 
The models that have already been developed in South Africa have given us powerful 
advocacy tools. They have helped us to start develop an understanding of the dynamics of 
the epidemic, and to do demographic projections of the epidemic, while economists have 
started to look at the economic impact of HIV on the workplace and at national level. But 
more is needed to explore and evaluate the impact of the wide range of existing and 
potential interventions, from antiretroviral treatment, vaccines and the impact of male 
circumcision to persuading adolescents to use condoms, and to inform the policy makers 
how to best address the challenges that face us. 
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CHAPTER 4 Sources of data on HIV infection in South Africa 
"All scientific work is incomplete - whether it be observational or experimental. All 
scientific work is liable to be upset or modified by advancing knowledge. That does 
not confer upon us a freedom to ignore the knowledge we already have, or to 
postpone the action that it appears to demand at a given time". 
Sir Austin Bradford Hill, 1965468 
Introduction 
Many HIV sero-prevalence surveys have been undertaken in South Africa over the past 15 
years (Chapter 2, Table 2.1), providing important information on the course of the HIV 
epidemic and on factors that contribute to the spread of the epidemic. These sources 
include extensive and complete annual surveillance over time among pregnant women 
attending public health antenatal clinic surveys (national and provincial), surveillance 
among STI, family planning or TB clinics, some community based surveys such as those 
conducted in Hlabisa and Carletonville, and national population based surveys including 
those conducted by the HSRC (including all people older than 2 years)469'470 and the 
Lovelife survey among youth. These data sets can be used by epidemiologists and 
demographers to assess epidemic trends and to project the demographic impact of the 
epidemic, by health economists to study the economic impact of HIV on various aspects of 
society, by social scientists to investigate the impact of behaviour and behaviour change on 
the epidemic, and by statisticians and mathematical modellers to develop new analytical 
techniques and to try to understand the dynamics of the epidemic. In addition, these data 
can be used to evaluate the population level impact of interventions and to provide 
guidance to policy makers for prioritising and targeting interventions. 
Some of the existing, publicly available, prevalence datasets have been used as part of this 
thesis to perform secondary analysis and modelling to further our understanding of the 
epidemiology, dynamics and impact of HIV infection in South Africa. The data sources 
used in the thesis are described below. 
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Data sources 
Antenatal clinic surveys 
National, annual, anonymous, antenatal clinic surveys 
The rise in the number of HIV infections among heterosexual, voluntary blood donors 
during 1988 and 1989 prompted the Department of National Health and Population 
Development to initiate, in 1990, a national HIV surveillance programme based on 
anonymous, unlinked, cross-sectional surveys of pregnant women attending antenatal 
clinics in the public health sector throughout South Africa.23 Only women who were 
attending the antenatal clinic for the first time in their current pregnancy were included in 
order to minimize the chance of the same woman being included in the study more than 
once. 
Pregnant women were chosen as a proxy group for monitoring the spread of HIV in the 
heterosexual population because they represent a consistent subgroup that is easily 
accessible and it is assumed that they reflect the course of the HIV epidemic in the 
heterosexually active population.23'471 All pregnant women attending antenatal clinics in 
the public health services routinely provide blood samples to be tested for syphilis, rhesus 
factor (Rh) and ABO blood grouping in order to prevent haemolytic disease in the 
newborn. After removal of personal identifiers, these blood specimens are used for the 
annual HIV surveys. 
Notwithstanding several biases inherent in this population, the national, annual antenatal 
clinic HIV surveys conducted during October and November of each year provide the most 
reliable estimates of temporal trends of HIV infection in the general population, as well as 
the age-specific HIV prevalence and geographical distribution of HIV infection in South 
Africa. 
The ANC surveys have been designed to minimize bias by ensuring large sample sizes in 
all provinces, using a consistent methodology and ensuring that the surveys are done at the 
same time every year. The sampling strategy for these surveys is intended to provide a 
geographically representative sample which allows the estimation of provincial HIV 
prevalence. Prior to changes in the sampling methodology in 1998, samples of 
approximately 2000 specimens per province were collected annually.23'472 Because the 
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populations of the provinces vary across South Africa, the sample sizes also varied and the 
overall estimate was obtained by weighting the data accordingly. In 1998, the standard 
national protocol was modified by the Department of Health in collaboration with the 
Medical Research Council. The study methodology was strengthened, especially in regard 
to sampling and quality control, systematic cluster sampling was used with "probability 
proportional to size" techniques.118,473 Standard operating procedures were developed for 
provincial coordinators, clinic nursing staff and laboratories involved in the surveys. 
Annual reports have been published by the Department of Health since 1990, providing 
summaries of the national and provincial HIV prevalence, and producing HIV prevalence 
by five year age bands. The data from these surveys have been used to monitor the 
progress of the HIV epidemic in the heterosexually active population in South Africa. 
Antenatal clinic surveillance in rural KwaZulu-Natal 
The Hlabisa health district, situated in rural northern KwaZulu-Natal, covers an area of 
approximately 50km by 70km and is home to about 200,000 largely Zulu-speaking people. 
Hlabisa has a large male migrant population and a relatively stable female population 
(Figure 4.1). In addition to migrant labour, most people rely on subsistence farming and 
pension remittances. The district has a well developed clinical service, including fifteen 
fixed primary health care clinics, a mobile service, and the Hlabisa rural hospital.474 
Research has been conducted by the Medical Research Council in Hlabisa since the early 
1990s. From 1992 to 2002, repeat cross-sectional, anonymous, antenatal surveys were 
undertaken among antenatal clinic attendees in Hlabisa by the South African Medical 
Research Council, in the same months as the national ANC surveys.32'139 They provide 
comparative data from a rural area that are consistent with the temporal trends in HIV 
infection in KwaZulu-Natal as observed in the national survey. 
Specialized community-based surveys 
Hlabisa: a rural community-based study 
Between 1992 and 2002, most of the Medical Research Council's (MRC) HIV and STD 
research were conducted in the Hlabisa district, as described above. With a research 
structure already in place and HIV rates reflecting the rapid growth of the HIV epidemic in 
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the KwaZulu-Natal province, the province with the highest HIV prevalence, Hlabisa was 
identified by local and international organizations as a potential site for conducting future 
HIV vaccine trials. In 2000 and 2001, a large community-based study, the Vaccine 
Preparedness Study (with the author of this thesis as the Principal Investigator), was 
conducted to determine the preparedness of the community to participate in phase I, II and 
III vaccine trials. In addition, baseline demographic and health data were collected to 
assess the overall health profile of the community, and blood samples using dried blood 
spots were collected from consenting individuals to obtain community-based estimates of 
HIV prevalence. Data were collected from a total of 595 men and 1719 women aged 15 to 
54 years. 
The age distribution for men (n = 89,440) and women (n = 106,749) in the Hlabisa 
population, using census data from Hlabisa, is shown in Figure 4.1. Men and women, but 
especially men, often leave to seek work outside the district so that the curve for men falls 














0 10 20 30 40 50 60 
Age (years) 
70 80 90 
Figure 4.1 The age distribution of men (blue diamonds) and women 
(pink dots) in Hlabisa using census data 
Early community-based surveys in rural KwaZulu-Natal 
Three cross-sectional, anonymous, community based surveys were conducted in a rural 
area of northern KwaZulu-Natal in conjunction with the Malaria Control Programme 
between 1990-1992. ~ The puipose of these surveys was to determine the prevalence of 
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HIV infection and to monitor temporal trends of HIV in a predominantly rural population 
in the early stages of the epidemic. In addition, these surveys provide data on age and 
gender differences in HIV infection and are the only surveys in South Africa to provide 
population-based data for this early period of the HIV epidemic. The trends in HIV 
prevalence in these surveys are consistent with the provincial data from the national ANC 
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surveys. 
Carletonville: an urban community-based study 
The Carletonville Mothusimpilo ('Working-together-for-health') project was designed to 
demonstrate the feasibility of using sustainable interventions to reduce the transmission of 
HIV/AIDS in Carletonville, the largest gold-mining complex in the world.222'310'475 In 
addition to the approximately 56,000 people living in the township of Khutsong, there are 
70,000 migrant mineworkers living in single sex hostels without their wives or families 
who frequently visit sex workers operating in informal settlements in townships around the 
mines. The Mothusimpilo project was designed as a community based intervention with a 
strong biomedical and social evaluation component which would make it possible to 
identify and explore the contextual factors that influence the course of the epidemic and 
which can be used as markers of the effectiveness of the intervention. The intervention 
included community-based peer education, condom distribution, syndromic management 
of sexually transmitted infections and presumptive treatment for sex workers. A baseline 
survey was carried out in the general population in August 1998 while a follow-up survey 
was conducted in August 1999. The 1998 survey included a random sample of 1,185 men 
and women aged 13 to 59 years in the township of Khutsong, 899 mineworkers stratified 
by hostels, and 145 sex workers living in informal settlements or 'hotspots'. The 1999 
survey in the Khutsong sample was limited to those aged 15 to 25 years to obtain more 
detailed information about this important risk group.222 Information was collected on HIV 
and STI prevalence as well as on a range of social and behavioural determinants. 
In addition to the published data, individual level data on HIV prevalence from the 1998 
survey was made available by the Mothusimpilo project director, Prof B Williams, for 
inclusion in the analyses and modelling in this thesis. 
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National population based surveys to measure HIV prevalence 
HSRC/ Nelson Mandela Foundation population-based surveys 
In 2002, the Nelson Mandela Foundation in conjunction with the HSRC undertook the first 
national population-based survey on behavioural and socio-cultural determinants of 
vulnerability to HIV/AIDS and consenting people were tested for HIV infection.469 The 
study provides data on HIV prevalence by geographic area, race, gender, age and other 
demographic and socio-economic factors. 
The survey was repeated in 2005 and a total of 15,851 people older than 2 years of age 
were tested for HIV.470 While oral fluids were used to test for HIV in 2002, the 2005 
survey used dried blood spots for HIV testing. Bias is of particular concern in these 
surveys because of the very high level of household and individual non-response (about 
35% in both surveys). The 2005 survey included HIV incidence testing using the BED 
capture enzyme immunoassay (EIA) developed by Centres for Disease Control and 
Prevention (CDC). However, at the time of this survey the BED assay still required further 
validation and calibration and data from several countries in 2005 suggested that the BED 
assays over-estimated incidence by a factor of 2 to 3. (Statement on BED available on the 
UNAIDS website.476) 
Other studies 
Sex workers and clients at truck-stops in KwaZulu-Natal 
The MRC has undertaken research with sex workers operating at truck-stops in the 
KwaZulu-Natal Midlands since the early 1990s.477 Between 1996 and 1998, data were 
collected from commercial sex workers operating at truck-stops along the national road 
linking Durban to Johannesburg. At the time, there were an estimated 800 sex workers 
operating at the truck stops in the KwaZulu-Natal Midlands. Four hundred and seventy 
seven women were screened for HIV as a prerequisite for participation in a phase III multi-
centre microbicide trial.282'478 Of these, 198 HIV negative women were enrolled in the trial 
and followed up for an average of about three years to assess the effect of the microbicide 
(a nonoxynol-9 vaginal gel) on rates of HIV sero-incidence. To date, this has been the only 
cohort study in South Africa to obtain direct estimates of HIV incidence.282 Clinical 
investigations were performed to identify sexually transmitted diseases and HIV status. 
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In 1998 a cross-sectional HIV seroprevalence study was undertaken with truck driver 
clients of sex workers at these truck-stops in order to compare the prevalence of HIV in sex 
workers and their clients. Ten sex workers were trained as field workers to collect socio-
demographic data from their truck driver clients and to obtain a saliva sample to determine 
the HIV status of their clients.331 
Workplace survey 
Additional data on HIV infection in men and women by age, race and job category are 
available from an anonymous cross-sectional survey carried out among the workforce of a 
major South African parastatal company in 1999 in order to estimate the proportion of 
employees that were infected with HIV and to determine risk factors for HIV 
infection.479'480 Of all of the sites in the country with more than one hundred employees, 
fifty percent were chosen for inclusion in the study using probability-proportional-to-size 
sampling. A set number of employees was then recruited at each site. The results of this 
study were used to make projections on future HIV prevalence levels, to estimate the 
economic and other impacts of HIV on the company and to provide a baseline against 
which to evaluate the company's HIV/AIDS programme. This study provided information 
on overall HIV levels among men and women from all the provinces in South Africa. 
Discussion 
The data sets described above are used in several of the chapters in this thesis. The ANC 
surveillance provides samples that are consistent over time so that good estimates of trends 
can be obtained. They also provide good overall national coverage, and provide estimates 
by age and geographical region. However, the use of these data sets is limited because the 
clinic and individual level data are not made publicly available. Only certain, limited 
analyses are published in official reports of the Department of Health. For example, the age 
distribution is given in bands of 5 years for the national sample but not by province, while 
infection rates by race group are generally not made available. The geographical 
distribution of HIV consists of a breakdown by province and no finer detail is provided on 
the spatial distribution of HIV within provinces (for example at district or clinic level), nor 
between urban and rural areas. 
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The specialized community-based surveys provide good coverage of the general 
population, including men, and provide detailed information on demographic factors (e.g., 
HIV prevalence can be obtained by one-year age categories for both genders), on social 
and economic factors, sexual behaviour and biomedical factors associated with HIV. The 
community-based studies described here covered a rural area in KwaZulu-Natal and an 
urban area in Gauteng. 
Data sets on high risk groups, including sex workers in KwaZulu-Natal and in 
Carletonville, truck drivers operating between Durban and Johannesburg, and mine 
workers in Carletonville, are studied in this thesis to determine if the patterns of infection 
are different to those of men and women in the general adult population. 
Together, these data sets can provide a clear picture of overall trends, and are used here to 
study the dynamics and the impact of the HIV epidemic in South Africa. Using the 
prevalence data collected over time and the age-specific distribution of infection, models 
are developed to estimate the incidence, to make projections about AIDS deaths and to 
assess the potential impact of antiretroviral treatment on the future course of the epidemic. 
54 
CHAPTER 5 Trends in the prevalence of HIV infection in 
South Africa 
"What is not surrounded by uncertainty cannot be the truth." 
Richard Feynman, 1976481 
Introduction 
This chapter explores the burden of HIV infection in particular populations at specific 
points in time as well as trends of infection over time. Using the data sources described in 
Chapter 4, the HIV epidemic in South Africa is analysed and described in relation to key 
events in the spread of HIV in South Africa from the first reported cases of HIV subtype B 
infections among men having sex with men in the early 1980s, haemophiliacs, and 
recipients of unscreened blood products to the current generalized, subtype C epidemic 
among the heterosexual population where the prevalence of HIV infection is starting to 
level off although morbidity and mortality are still increasing. Distinctive characteristics 
of the South African HIV epidemic are described ranging from the rapid spread of HIV 
infection, to differences in gender, age and geographic area. Risk factors contributing to 
the spread of the epidemic are discussed and the chapter concludes by describing the effect 
of HIV on morbidity and patterns of mortality. 
Fundamental measures of the HIV epidemic 
As the epidemic of HIV infection continues to grow in South Africa, it is important to 
understand the basic dynamics of the epidemic in order to deal with it effectively. It is 
necessary to know not only how much disease there is in a population at any time but also 
how the burden of infection and disease is changing with time. The two most fundamental 
measures of disease, in this regard, are prevalence and incidence. 
Prevalence of HIV infection is defined as the proportion of individuals in the population 
who are infected with the virus at a given point in time (hence provides a measure of the 
cumulative risk of infection up to a cerain point in time), while the incidence of infection 
gives the rate at which new cases of infection are acquired during a given period of time. 
Definitions are provided in Figure 5.1. 
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Prevalence provides a snapshot view of the number of people currently infected with HIV 
and this is essential for understanding the health impact of a disease within a community, 
for assessing the demand for medical care, and for targeting and evaluating interventions, 
mainly for care and treatment. In contrast, incidence data provide information on current 
rates of new infections among individuals who were previously uninfected. Incidence data 
are therefore more sensitive than prevalence data to the current dynamics of disease 
transmission and are important for exploring causal theories concerning the course of the 
disease as well as for measuring the immediate or short-term impact of interventions. 
In this and the following chapters, measures of both prevalence and incidence will be used 
to describe trends and characteristics of the HIV epidemic in South Africa. Where possible, 
95% confidence intervals are calculated to indicate the range of values within which the 
population values are likely to fall. For prevalence estimates, these are based either on the 
binomial distribution or, in the case of large enough prevalence and sample size, the 
normal approximation to the binomial distribution.3 In this chapter however, the focus is on 
HIV prevalence. 
Number of individuals who are infected with HIV at a specific time 
Prevalence = ; ; ; 
Number of individuals in the population at that point in time 
Number of new cases of HTV infection during a certain time period 
Incidence rate = 
Number of uninfected individuals in the population x time period of observation 
Figure 5.1 Definition of prevalence and incidence rate 
The binomial theorem gives the probability of getting k successes out of n trials if the expected value is u as 
P(k,n\u)= "l -uk(l-u)n-k 
v ' ; k\(n-k)\ v ' 
For given values of k and n the upper confidence bound on u is estimated as the value for which one would 
observe k or fewer success with probability 0.025 and use a similar argument to obtain the lower bound. If 
k and n are both sufficiently large, the 95% confidence interval can be estimated from the normal 
approximation to the binomial distribution as 
, „ \pi\-p) 
p±\.96. 
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The HIV epidemic in time and space 
The first cases of AIDS in South Africa were diagnosed in 1982.15 Up to 1987, the spread 
of HIV in South Africa occurred mainly among men who have sex with men and 
haemophiliacs receiving blood products (i.e., before the introduction of universal HIV-
screening of blood products in 1985). Several surveys conducted between 1985 and 1987 
in a diverse range of populations demonstrated that until 1987 HIV infection in the 
heterosexual population was rare19,20 and zero prevalence was found in a rural community 
in 1985, among sex workers in the Transvaal in 1986 and among antenatal clinic attendees 
in KwaZulu-Natal in 1987. In a study conducted among 29,312 mine workers in South 
Africa in 1986, only 3 men tested positive for HIV infection.389 
By 1989 however, several surveys had confirmed the entry of HIV infection in the general 
population,16,39'51'52 and despite this relatively late introduction of the virus into the 
heterosexual population, South Africa experienced one of the fastest growing HIV 
epidemics in the world. Over a 14-year period from 1990 to 2004, HIV sero-prevalence 
(predominantly of subtype C) among antenatal clinic attendees in South Africa increased 
dramatically from 0.8% to 29.5%, as illustrated in Figure 3.2 (Chapter 3). The high 
infection rates in pregnant women also gave rise to a concomitant epidemic in the children 
born to HIV infected mothers. 
In the early stages of the generalized heterosexual, subtype C epidemic, the prevalence 
rose exponentially with a doubling time of a little over one year and by 1994 had reached 
10% among women attending ANCs.141 Between 1994 and 1997 the prevalence of 
infection continued to rise rapidly,118 with young women being at greatest risk of infection. 
Because of the long survival time for people infected with HIV (estimated median survival 
time of about 9 years)450 and because the prevalence had increased so dramatically in only 
four or five years, morbidity and mortality remained low during this time. 
Since the late 1990's, the rate of increase has slowed substantially and the overall HIV 
prevalence in the country as well as the age-specific and provincial data (Table 5.1) 
suggest that the prevalence is starting to level off. It is important to note, however, that the 
estimate based on the 2004 antenatal clinic surveillance was significantly above the fitted 
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logistic curve, suggesting that prevalence might still be increasing. More importantly is 
that while the prevalence may be increasing less rapidly, new infections are still arising but 
are more or less balanced by the increased mortality. 




















































































































































































There is considerable geographical variation in the distribution of HIV infection in South 
Africa with highest infection rates in KwaZulu-Natal on the east coast and the lowest in the 
Western and Northern Cape (Table 5.1 and Figure 5.2a). Between 1990 and 2004 the 
antenatal HIV prevalence increased from 1.6% to 41% in KwaZulu-Natal and 0.06% to 
15.4% in the Western Cape. 
One explanation for the wide variation in the geographical distribution of HIV infection is 
the uneven population distribution.482 The distribution of people infected with HIV 
obtained by combining the provincial prevalence data with the population density is 
illustrated in Figure 5.2b. Although the Western Cape has low rates of infection, Cape 
Town has a large population and thus a high density of people infected with HIV. In 
contrast, while the overall infection rates in KwaZulu-Natal are high, the population is 
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patchily distributed and infections do not occur evenly through the province. In the former 
Transkei, to the north-east of East London, infected people are more evenly spread over a 
large area. The mining centres at Carletonville, Klerksdorp and Welkom show high 
densities of infected people as do the port cities of Port Elizabeth, Cape Town, East 
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Figure 5.2 (a) Prevalence (%) of HIV infection among women attending 
antenatal clinics in the provinces of South Africa in 2004 (b) The number of 
people living with HIV infection per square kilometre 
To estimate the asymptotic value (i.e., the value at which the epidemic is expected to level 
off) and the initial growth rate of the epidemic, logistic functions of the form described in 
Box 3.2 were fitted to the prevalence data from all provinces and the estimates obtained in 
this way are shown in Figure 5.3. Assuming exponential growth rate at the start of the 
epidemic, the initial doubling time was estimated nationally and for each of the provinces 
from the estimates of the initial growth rate, using 
Doubling time (months) = x 12 
initial annual growth rate 
While the overall doubling time at the start of the epidemic in South Africa was estimated 
to be around 15.6 months (95% CI 15.2 -16.1 months), the doubling time at provincial 
level varied from 10.5 months in the Limpopo province to 15.2 months in KwaZulu-Natal 
(Table 5.2). 
Table 5.2 shows that the observed prevalence of HIV in 2004 in most provinces is close to 
the estimated asymptote and the observed prevalence in 2004 falls within the 95% 
confidence intervals of the asymptotic value for seven of the nine provinces, but with much 
higher rates in KwaZulu-Natal than elsewhere. The prevalence in the Western Cape is 
therefore likely to remain significantly below the current levels in the Eastern Cape and the 
levels there below that in KwaZulu-Natal. The asymptote for two of the nine provinces 
(Limpopo, and KwaZulu-Natal) were significantly higher than the estimated asymptotic 
value, indicating that the growth in 2004 was significantly greater than the expected 
estimate derived from the trend data. 
Plotting the intrinsic doubling time against the asymptotic prevalence for the nine 
provinces in Table 5.2 shows that there was no significant correlation (r = 0.43, p = 0.213) 
so that asymptotic prevalence in a province cannot easily be predicted from the epidemic 
growth rate (Figure 5.4). 
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Table 5.2 The 2004 HIV prevalence, the expected maximum (asymptotic) HIV 
prevalence estimated from logistic regression, and doubling times at the start of the 
epidemic (with 95% confidence interval) for data collected from antenatal clinic 
attendees by province. 
Province 
Prevalence (%) (95% CI) 
Prevalence (2004) Asymptote* 
Doubling Time 
(months) 
Western Cape (WC) 
Eastern Cape (EC) 
Northern Cape (NC) 





































* The expected maximum prevalence (asymptote) is the prevalence at which the HIV epidemic is 
expected to level off in each province and is estimated by fitting a logistic curve to trend data with a 
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Figure 5.4 The asymptotic prevalence of the epidemic plotted against 
the initial doubling time (in months) by province 
69 
Age differences in HIV prevalence 
Estimates of the prevalence of HIV by age in 1998 for national antenatal clinic attendees, 
two sentinel sites and selected risk groups in South Africa are summarized in Table 5.3. 
The age specific prevalence of HIV infection generally follows a log-normal distribution, 
as described in Chapter 3 and illustrated in Figure 5.5 using the data from antenatal clinic 
attendees in Hlabisa. The prevalence is close to zero among girls younger than 15 years 
and as people become sexually active, increases rapidly with age to a peak among 20-24 
year old women, after which it declines slowly with age among older women. 
In 1998, the national antenatal clinic surveillance data showed that 26.1% of women in the 
age group 20 to 24 years were infected with HIV, compared to a prevalence of 10.5% 
among women 40 years and older. In Hlabisa and Carletonville, 39.3% and 53.8% of 20-24 
year old women, respectively, were infected in 1998, compared to 12.3% and 23.5%, of 
40-44 year old women, respectively (Table 5.3). 
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Figure 5.5 Age prevalence of HIV infection among women attending 
antenatal clinics in Hlabisa in 1998. Error bars are 95% confidence limits. 
The fitted curve is a log-normal function. 
CI 
Table 5.3 Age-specific prevalence of HIV in various groups surveyed in South Africa in 1998. Numbers and percentages are shown in five 
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The age-specific HIV prevalence data nationally (Table 5.4) and from Hlabisa (Table 5.5) 
show the rapid increase in infection over time from 1992 - 2001 among all age groups and 
highlight the alarmingly high rate of increase among women under the age of 30 years. 
In Hlabisa, the prevalence of HIV among 20-24 year old women increased from 6.9% in 
1992, to 21.1% in 1995, 39.3% in 1998 and 50.8% in 2001 (Table 5.5). The rapid increase 
in prevalence in young women has been a major cause for concern. 
Figure 5.6 shows that although prevalence increased dramatically over time the shape of 
the antenatal HIV age prevalence curves, fitted to a log-normal function, has remained 
much the same over a period of nine years, with peak prevalences among pregnant women 
occurring at around 24 years. In 1992, prevalence among pregnant women peaked at 3.7% 
at age 24.4 years, in 1995 it peaked at 14.2% among women aged 23.7 years, in 1998 it 
peaked at 27.7% among women aged 23.4 years, and in 2001 it peaked at 30.5% among 
women aged 24.3 years old. 
Table 5.4 Temporal trends in the age-specific HIV prevalence (%) among women 
attending antenatal clinics in the annual national survey. Prevalence is presented as a 
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Table 5.5 Temporal trends in the age-specific HIV prevalence (%) among 
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Figure 5.6 Age-prevalence curves showing temporal trends of the HIV epidemic among 
women attending national antenatal clinics. 
Age and gender differences 
Population-based surveys undertaken in rural KwaZulu-Natal during 1990-1992 showed 
that in addition to the rapid rise in HIV infection, there was a striking difference in the age 
distribution of HIV infection among men and women. Figure 5.7a illustrates the early rise 
of infection in young women between the ages of 15-19 years compared to the later rise of 
infection in men to a peak in the age group 25-29 years. 
In Carletonville in 1998, the prevalence of infection was close to zero for both sexes before 
the age of 15 years but increased rapidly thereafter reaching 39.3% in 20-year old women 
but only 8.3% in 20-year old men (Figure 5.7b). The peak prevalence among women was 
57.9% at 25 years of age and among men it peaked at 44.5% at 32 years of age. The 
median age at first sex was about 16 years for both men and women in Carletonville and 
the prevalence of infection increases rapidly thereafter. 
The difference between the age-specific prevalence of infection in men and women is in 
part related to the age difference of sexual partners. Young women in South Africa often 
have male partners who are older than they are, which explains the shift to older ages of 
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infection in men compared to women (women have sex with men who are on average five 
years older than themselves). In addition, it has been shown in a systematic review of HIV -
1 transmission probabilities that male-to-female transmission is on average higher (median 
0.1% per sexual contact) than female-to-male transmission (median 0.07% per contact). 
Factors that have explained the higher risk of infection among women compared to men in 
other African settings include the increased vulnerability of women around the age of 
puberty, rape and coercive sex, and dry sex. 
The age-specific prevalence of infection for rural men and women in KwaZulu-Natal in 
1991 and for urban men and women in Carletonville in 1998, as illustrated in Figure 5.7, 
show that while there are important gender differences between men and women the 
shapes of the age-prevalence curves, reflecting the age-specific risk of infection, have not 
changed over time and are similar in urban and rural settings. Although the overall 
prevalence in the later urban survey is approximately ten times higher than in the earlier 
rural survey the shape of the age-prevalence curves for men and women are statistically the 
same. The national population-based survey carried out by the HSRC in 2005 show data 
that are consistent with the earlier observations on gender and age differences in HIV 
infection (Figure 5.8).470 
The patterns of infection are investigated in more detail in Chapter 6, including an analysis 
of data on the age-specific prevalence of infection among men and women in urban and 
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Figure 5.7 Age prevalence of HIV infection among men and women in a) Rural 
KwaZulu-Natal (KZN) in 1991 and b) Carletonville (CLV) in 1998. 
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Figure 5.8 National prevalence of HIV by sex and age in 2005. Log-normal curves were 
fitted to data from the 2005 HSRC national population based survey.470 
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Racial differences 
As in most countries, collection of data by race is politically sensitive, and few estimates 
are available on the racial distribution of HIV in South Africa. The majority of users of 
public sector health facilities in South Africa are Black Africans except in the Western 
Cape where the number of Black and Coloured women attending antenatal clinics are 
about equal. Most of the data collected from public sector facilities (including antenatal 
clinics) are therefore from Black women or, in the Western Cape, Black and Coloured 
women. Some data on the prevalence of HIV infection by race are available from early 
antenatal clinic surveillance (1991-1992), from the recent national population-based 
surveys conducted by the HSRC (2002 and 2005),469'470 and from the Lovelife survey of 
sexual behaviour and HIV among a national sample of almost 12,000 young people, aged 
15 to 24 years in 2003.485 In addition, HIV data are available from a large workplace 
survey in which specimens were collected in 1999 for HIV testing from more than 5000 
workers in 175 sites across the nine provinces in South Africa.480 These data are 
summarized in Table 5.6 and show that while HIV infection is prevalent in all race groups, 
the prevalence is significantly higher in the Black African population. 
Table 5.6 HIV prevalence by race in South Africa, 1991-2005 
HIV prevalence (%) at national level with 95% confidence intervals 
ANC ANC Workplace Lovelife survey HSRC Survey 
(1991) (1992) (1999) (2003) (2005) 
Race Pregnant Pregnant women Men and women Men and women Adult men and 
group women aged 15-24 years women (15-49) 
African 1.84(1.49-2.18) 3.22(2.74-3.70) 13.9(12.6-17.2) 11.8(10.7-13.1) 19.9(18.2-21.7) 
White 0(0-0.22) 0.09(0-0.22) 2.1(1.4-6.7) 2.0(0.09-4.3) 0.5(0.1-1.7) 
Coloured 0.14(0.02-0.26) 0.33(0.12-0.54) 2.3(0.8-12.2) 3.8(2.7-5.5) 3.2(2.1-4.5) 
Indian 0.11(0-0.31) 0.33(0-0.7) 3.6(0.9-17.3) 0.9(0.2-3.6) 1.0(0.2-2.3) 
Using antenatal clinic data to obtain estimates of HIV in the general 
adult population 
In addition to using the ANC data to determine epidemic trends over time and to analyse 
the geographic and age-specific distribution of the epidemic, this data can be used to obtain 
estimates of HIV prevalence among the general adult population in South Africa. 
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However, ANC data are biased estimators of the general adult population prevalence 
because the samples include only a select group of people (pregnant women attending 
public health services). HIV prevalence among women who attend public health services is 
generally estimated to be higher than prevalence among those who attend private health 
services. Furthermore, the distribution of HIV prevalence among pregnant women is likely 
to be different than the distribution among the general adult population. In order to correct 
for these biases the ANC prevalence estimates need to be adjusted. One way to do that is to 
firstly adjust for relative attendance rates at antenatal clinics and secondly to adjust for the 
difference in prevalence between pregnant women and the general adult population. Using 
this approach, the estimated adjustment factor is 0.64, as described in Appendix 5.1. The 
HIV prevalence among the general adult population can then be estimated by applying the 
correction factor to the ANC prevalence estimate, for example, for 2004 the estimated 
adult prevalence in South Africa is 29.5% x0.64 = 18.9%. 
Risk factors 
Migration 
One of the most important driving forces of the HIV epidemic in Southern Africa is the 
system of oscillating migration which increases people's risk of infection and when they 
become infected facilitates the rapid spread of the epidemic. "Influx control" laws during 
the apartheid era only allowed single, able-bodied people (mainly men) to migrate to the 
urban areas to sell their labour. Male migrants from other southern African countries also 
came to work in South Africa and in 1990 it was estimated that 2.5 million official - and 
many more unofficial - migrants were working in South Africa's mines, factories and on 
farms.486 The migrant labour system has survived despite the change in Government in 
South Africa and as late as 1997 a study in rural KwaZulu-Natal found that 60% of adult 
men and 28% of women were away from their homes for most of the time.246 
Migrant workers in southern Africa typically travel great distances to their places of work 
and return home infrequently, sometimes as seldom as once or twice a year. While away 
from home, these workers often live in single sex hostels. In a survey conducted in the 
early 1970s, Francis Wilson summarized the migrant/hostel system as leading to: "family 
break-ups, bigamy, prostitution, homosexuality, alcoholism, violence, corruption, venereal 
disease, tuberculosis and malnutrition". This lifestyle results in men having more casual 
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partners and more frequently visiting prostitutes. Several studies have reported on the 
sexual practices of migrants and demonstrated that they are at significantly higher risk than 
non-migrants of having more sexual partners490 and having an increased risk of acquiring 
sexually transmitted infections and/or HIV.8 '491'4 While many migrant workers visit sex 
workers in urban areas, they also maintain conjugal relationships in their rural home areas 
and can thereby contribute to the rapid geographical spread of the HIV epidemic. 
A study in rural KwaZulu-Natal however,330 highlighted the fact that it is not only the 
migrant men who are at risk of HIV but also the women that are left behind This study 
found that in 40% of discordant couples it was the wifes of migrant men who were HIV 
infected which indicates that these women must be having sex with men other than their 
husbands. 
A risk factor analysis among women in Carletonville showed that migration, in addition to 
age, marital status, alcohol use, syphilis and gonorrhoea, were independently associated 
with HIV infection.328 HIV prevalence was significantly higher among migrant women 
(46%) than non-migrant women (35%) (Odds ratio 1.61, 95% confidence intervals (CI): 
1.1-2.3). 
Often in disadvantaged areas women are pushed towards selling or exchanging sex for 
food and support as this is the only commodity that they have to sell in order to survive.493 
The practice of 'survival sex' increases the total number of partners that a women has as 
well as the probability of having concurrent partners, i.e., having more than one partner at 
the same time. 
Migrancy almost certainly contributes to the spread of HIV prevalence by the nature of the 
sexual networking that it promotes. Although men in Africa may not have more total 
lifetime partners than men from other parts of the world, the impacts of a migrant lifestyle 
result in the tendency to have more concurrent partners. Concurrency, which increases the 
number of individuals linked to the sexual network at any one time, has been shown to 
potentially increase the size of the epidemic by a factor of 10 over a five year period if 
50% of individuals have concurrent relationships as opposed to sequential but 
monogamous relationships.494 Also, HIV infected people may be more infectious in the 
very early stages of their infection and in the terminal stages. Therefore, an individual who 
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becomes infected from a sexual contact and who has a concurrent partner is more likely to 
infect that concurrent partner (because the newly infected person is highly infectious) than 
a subsequent sequential partner (because the newly infected person is likely to be less 
infectious after a period of a few months). 
Sexually transmitted infections 
Sexually transmitted infections are an important co-factor in facilitating the spread of HIV. 
Evidence for the synergistic interaction between HIV and STI's came from epidemiologic 
studies that showed a higher prevalence of HIV among individuals who had a history of an 
STI that could not be explained by behavioural factors only.495'496 Subsequent biological 
studies have shown that the shedding of HIV into genital fluids is increased both from 
genital ulcers497 and from the inflammatory process associated with non-ulcerative STIs.498 
People who are HW positive and have a sexually transmitted co-infection are therefore 
more likely to transmit HrV to their sexual partners than in the absence of STIs. Futher 
studies have shown that an STI not only makes people more infective but women with 
chlamydial infection or gonorrhoea may also be more susceptible to acquiring HIV 
because they have a disproportionate increase in CD4 cells in the endocervix and it is this 
cell line that is the target for HIV infection.499 
A positive association between ulcerative disease, in particular Herpes Simplex virus-2 
(HSV-2) and HIV has been found in several studies.495'500 In a recent study, the impact of 
incident HSV-2 on the incidence of HIV-1 infection was investigated among commercial 
sex workers in KwaZulu-Natal.281 This remains the only study in which follow up was 
done at sufficiently small intervals to clearly separate out the effect of incident and 
prevalent HSV-2 on the incidence of HIV-1. The results showed that the hazard ratio for 
incident HIV-1 seroconversion was 6.0 (95% CI: 2.6-14.0) times greater among women 
with incident than among women with prevalent HSV-2 infections. Immediately after 
HSV-2 sero-conversion women experienced a significantly increased risk of acquiring 
HIV, but the effect wanes with time since infection. Figure 5.9 (a) shows Kaplan-Meier 
survival curves for time to HIV seroconversion for women who were HSV-2 positive 
throughout the study (PP) (i.e., they were HSV-2 positive on entry), HSV-2 negative 
throughout the study (NN), and those who were HSV-2 negative on entry and positive on 
exit (NP). When treating HSV-2 as a time-dependent co-variate, all women who were 
HSV-2 negative up to the time when they seroconverted to HSV-2, or left the study, were 
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combined in a group called NT. All those who seroconverted to HSV-2 during the study 
were then considered in a second group (called PT) for whom incidence of HIV was 
measured from the time of HSV-2 seroconversion. The Kaplan-Meier curves for time to 
HIV infection for these groups are shown in Figure 5.9(b). 
The presence of other sexually transmitted infections has been studied in detail and has 
shown to increase the probability of transmitting HIV. The presence of an ulcerative STI 
(GUD), however, has been shown to be a more important co-factor of HIV infectivity than 
other STIs and in a prospective study of men visiting sex workers in Kenya, none of the 
men without GUD seroconverted to HIV compared to 16.2% of those with GUD, after 
only one contact-exposure to HIV.501 Although effective management of STIs should have 
an impact on the transmission of HIV, it is still not understood how the control of STI's as 
a public health intervention will contribute to HIV prevention. Observational studies have 
not yet provided convincing evidence and results from two STI treatment trials in the 
1990's gave conflicting results. In a community-based, randomized trial in Mwanza, 
Tanzania, syndromic management for patients with STI symptoms who were seeking 
treatment in clinics were offered to patients in the intervention arm. The intervention lead 
to a 38% reduction in the incidence of HIV (95% CI: 15%-55%).502 However, a trial 
conducted in Rakai, Uganda, in which the entire adult population were given mass 
treatment with a broad spectrum antibiotic, showed no significant reduction in the 
incidence of HIV (incidence ratio 0.97, 95% CI: 0.81-1.16).503 The reasons for the different 
impact in these two trials has been the subject of extensive debate.504"507 The consensus 
seems to be that in the early stages of an epidemic of HIV the infections are concentrated 
in people with high-risk behaviour who are likely to have other STIs. STI treatment 
therefore has a significant impact on HIV. In the later stages of the epidemic, HIV 
infection is more wide-spread among people who are less likely to have other STIs and STI 
treatment therefore has less impact on the HIV epidemic. 
The intervention project in the mining town of Carletonville included syndromic 
management of sexually transmitted infections and presumptive treatment for sex workers 
as part of the intervention, together with community-based peer education and condom 
distribution. Cross-sectional studies carried out in 1998 and 2000 indicated that the 
















Figure 5.9 Kaplan-Meier curves for HIV-1 free survival: a) among those who were 
HSV-2 positive on enrolment (PP); HSV-2 negative throughout (NN); sero-converted 
to HSV-2 during the course of the trial (NP) and b) among those who were negative 
until they left the trial or seroconverted to HSV-2 (NT); and from the time at which 
they seroconverted to HSV-2 (PT). Dots indicate times at which women sero-
converted, squares indicate times at which they were lost to follow up. 
Male circumcision 
Several observation studies have suggested that male circumcision might provide 
protection against HTV infection.508 In a meta-analysis of 21 observational studies, most of 
which were cross-sectional studies, Weiss et al.509 found that male circumcision reduced 
the risk of HP/ acquisition in men by almost 50% (Relative risk 0.52, 95% CI: 0.40 -
0.68). A further review by the Cochran collaboration also showed strong epidemiological 
associations between male circumcision and prevention of HIV, in particular for high risk 
groups.508 Observational studies however, may be limited by confounding and important 
factors such as religion and sexual practices are often not adequately adjusted for in these 
studies. In the absence of experimental studies, a causal relationship between male 
circumcision and protection against HIV infection could therefore not be established. 
Results from the first randomized control trial on male circumcision were released in 
2005. In the study carried out in Orange Farm, South Africa, Auvert and collegues 
showed that circumcision reduced the incidence of HIV-infection by 60% (95% CI: 32%-
76%).351 When controlling for behavioural factors, including sexual behaviour that 
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increased slightly in the intervention group, condom use, and health-seeking behaviour, the 
protection was 61% (95% CI: 34%-77%). Further trials are being conducted in Kenya and 
Uganda, with implications for policy and planning of prevention strategies. Implications of 
this finding for the promotion of male circumcision as a public health intervention to 
control HIV in sub-Saharan Africa have subsequently been explored using dynamical 
simulation models.510 Assuming that full coverage of male circumcision is achieved over 
the next ten years, the results indicate that circumcision could avert 2.0 million (95% CI: 
1.1-3.8 million) new HIV infections and 0.3 million (95% CI: 0.2-0.5 million) deaths over 
the next ten years in sub-Saharan Africa. In the ten years after that it could avert a further 
3.7 million (95% CI: 1.9-7.5 million) new HIV infections and 2.7 million (95% CI: 
1.5-5.3 million) deaths. In South Africa alone increasing male circumcision coverage has 
the potential to avert up to 144 thousand new infections each year. 
The association between the prevalence of HIV and male circumcision is shown for 
countries in sub-Saharan Africa in Figure 5.10. Estimates of male circumcision rates510 are 
plotted against the UNAIDS estimates of HIV prevalence for those countries,4 showing 
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Figure 5.10 The relationship between the prevalence of HIV and male 
circumcision in sub-Saharan Africa. The percent prevalence of HIV4 is plotted on 
a logarithmic scale against the estimated proportion of adult men who are 
circumcised.510 Green, southern Africa; red, East Africa; orange, Central Africa; 
blue, West Africa. 
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Morbidity and Mortality 
Morbidity 
Given the long lag period between infection with HIV and progression to illness and death, 
it is only in the past few years that the disease burden has begun to have a serious impact 
on health facilities in South Africa. 
As in other African countries, tuberculosis (TB) is the most common opportunistic 
infection associated with advancing HIV disease. It has been shown that HIV infection 
greatly increases a person's risk of infection with TB.290 The risk of developing active TB 
infection among HIV positive patients is about five times higher than among HIV negative 
people, indicating the importance of HIV surveillance among TB patients. South Africa 
has one of the highest reported rates of TB in the world, estimated at close to 400 per 
100,000 population511 and the increasing burden of TB in South Africa has been attributed 
in part to the impact of HIV infection. In KwaZulu-Natal, the estimated number of TB 
cases in the year 2000 was 65,695, of whom 64.6% were HIV positive. Figure 5.11 
illustrates how the TB burden in the rural community of Hlabisa has increased as the HIV 
prevalence has increased despite major advances and successes in TB control attained in 
this community in the early 1990s.512 HIV prevalence among TB patients in the gold mines 
in Welkom rose from 15% in 1993 to 45% in 1996 (p < 0.001).513 At the same time, the 
incidence of TB among goldminers in Welkom increased from 1174/100,000 in 1990 to 
2476/100,000 in 1996. The increase occurred in the presence of a comprehensive TB 



















1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 
Year 
Figure 5.11 Tuberculosis caseload (from hospital records) and antenatal 




The increase in adult mortality in the late 1990s, as estimated by the South African 
Medical Research Council (MRC), provides evidence of the impact of the HIV epidemic 
on the number of deaths in the country.277 Analysis of South Africa's death registration 
data showed an increase in the total number of reported adult deaths of more than 65% 
between 1998 and 2003 (Figure 5.12), and in the case of women aged 20^-9 years, an 
increase of more than 150% after adjustment of population growth and possible 
improvement in death registrations. 379 
500 456.7 
Figure 5.12 Number of registered adult deaths in South Africa, 1998 -
2003 {Source: Bradshaw et. al. South African Medical Journal, 2004.37 ) 
Given the limitations of the death registration data (including incomplete registrations, 
misclassification of cause of death, and delays in the production of mortality statistics),27' 
the MRC undertook a national burden of disease study based on an analysis of all 
available data in an attempt to derive estimates of the underlying causes of death in South 
Africa.466 The ASSA model was used to estimate overall mortality, population size and the 
number of deaths due to HIV/AIDS in each province. Estimates of the total burden of 
disease show that in 2000 HIV accounted for 30% of all deaths in South Africa, and 
HIV/AIDS was the leading cause of death in all provinces with the exception of the 
Western Cape.466 In 2004, it was estimated that HIV was responsible for 44% of the total 




Statistics from the South African Government confirmed the large increase in mortality; 
57% in the total number of deaths between 1997 and 2002 and an increase of 62% among 
people over the age of 15 years during the same period.515 Although some of the increase 
can be explained by population growth and more complete reporting of deaths over time, 
this does not explain the substantial rise in the proportion of deaths among persons aged 25 
to 49 years (Figure 5.13 - extracted from Statistics SA report5'5). In 1997, people in this 
age group accounted for 23% of all deaths, while in 2003 they accounted for 34%. 
Although death certificates often do not state HIV/AIDS as a direct cause of death, but 
rather record deaths related to HIV/AIDS as being due to associated opportunistic 
infections and diseases such as TB and pneumonia, the age and disease patterns provide 
strong evidence of the growing impact of AIDS. The report from Statistics SA shows that 
recorded TB deaths increased by 131% and influenza and pneumonia deaths by almost 
200%. The MRC analysis showed that of 22 potential causes of death investigated, there 
were nine that increased in the same distinct age pattern and could be considered AEDS-
related conditions, including TB, pneumonia, diarrhoea, meningitis, other respiratory 
diseases, non-infective gastroenteritis, other infectious and parasitic diseases, anaemia, and 
protein energy malnutrition.279 The increase in these conditions accounted for 61% of total 
deaths related to HIV. 
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Figure 5.13 Distribution of deaths by age and year of deaths (1997-2002). 
(Source: Statistics South Africa. Mortality and causes of death in South Africa, 
1997-2003: Findings from death notification 2005) 
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Further evidence of steep increases in AIDS related mortality is also provided from 
demographic surveillance and community/hospital surveys. Demographic surveillance 
conducted in Hlabisa, rural KwaZulu-Natal, confirmed a significant rise in adult mortality 
starting in the late 1990s, while in 2000 AIDS was the leading cause of adult death, being 
associated with 48% of all adult deaths. The risk of dying from AIDS was highest in 
women aged 25-39 years and men aged 30-44 years.516 A study to investigate causes of 
child under-5 deaths in the North-West province showed that 31.4% of all deaths were 
caused by lower respiratory tract infections, 21% by AIDS, and 13.4% by sepsis. The 
percentage of those who died from AIDS and AIDS related conditions was 62%.517 
Discussion 
Cross-sectional data on HIV prevalence in South Africa are widely available, the most 
extensive being based on the annual surveillance system that was set up by the National 
Department of Heath and Population Development in 1990 to monitor the prevalence of 
HIV infection in pregnant women attending public health antenatal clinics. Many 
additional surveys have been conducted in South Africa over the last 15 years to provide 
essential information on epidemic trends, patterns of infection, and on factors that 
contribute to the spread of the epidemic. 
South Africa has experienced one of the fastest growing HIV epidemics in the world and 
currently bears about 14% of the global burden of HIV infection. Estimates of prevalence 
have reached high levels and vary by age, gender and geographical area. Data collected in 
recent years show that the epidemic is starting to level off, an effect that more likely 
reflects the natural saturation of the epidemic than the impact of interventions. While the 
HIV prevalence is no longer increasing rapidly, the incidence of new infections is balanced 
by rising mortality rates. 
The HIV epidemic in South Africa can be considered in different stages: before 1987 the 
epidemic was concentrated among men who have sex with men and recipients of blood 
products and was predominantly of subtype B. Once introduced into the heterosexual 
population, the prevalence of HIV subtype C started to rise exponentially reaching 4% in 
1993. During the period 1994-1998 the prevalence of infection continued to increase 
rapidly among antenatal clinic attendees from 7.6% to 22.8%. Mathematical models show 
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that the peak incidence of infection occurred during this period, although AIDS-related 
mortality was still relatively low. Since 1998 the rate of increase in the epidemic has 
slowed substantially and prevalence data suggest that the epidemic is reaching a plateau. 
Mortality rates however, are still rising and the incidence of new infections are balanced by 
deaths. 
In the current stage of the HIV epidemic, South Africa has had to deal with continued large 
numbers of new HIV infections, ongoing high mother-to-child transmission rates, rising 
morbidity, rapidly rising deaths, and an increasing number of orphans. Each of these 
factors demands effective and rapid interventions if the epidemic is to be brought under 
control. Finally, the high rates of new infections in young women highlight the importance 
of targeting interventions at youth, addressing gender inequalities, and the need for greater 
involvement of men. The increased risk of infection among migrant men, especially among 
older men, also needs to be addressed when designing interventions to manage the 
epidemic. 
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Appendix 5.1 Estimating HIV prevalence in the general adult population 
in South Africa by adjusting antenatal clinic HIV prevalence 
Our knowledge of the HIV epidemic in South Africa is based primarily on the prevalence 
data that have been collected annually from pregnant women attending public antenatal 
clinics since 1990. This data can be used to obtain national estimates of HIV prevalence 
among the adult population in South Africa. However, ANC data are biased estimators of 
general population HIV prevalence because only pregnant women attending public health 
services are included in the sample. In order to correct for these biases it is firstly 
necessary to adjust for relative attendance rates at antenatal clinics (because HIV 
prevalence among women attending public health services is expected to be higher than 
among women attending private health services) and secondly to adjust for the difference 
in prevalence between pregnant women and the general adult population. Ideally, national 
population-based HIV prevalence surveys would be an unbiased sample of the general 
adult population but the response rate in the population based survey conducted by the 
HSRC in 2005 was low (combined household and individual response rate was 55%) and 
might therefore be biased.470 If non-responders are more likely to be HIV positive than 
responders, then the HSRC survey is likely to underestimate the true population 
prevalence. One approach is therefore to start from the ANC estimates of prevalence, and 
to use the HSRC data to calculate correction factors. The two corrections factors needed to 
adjust the ANC data when estimating the national adult prevalence can be calculated as 
follows: 
1. Adjusting for relative attendance rates at antenatal clinics 
This adjustment requires that the ANC data are standardized for race because the race 
distribution of ANC attendees is different from the race distribution in the general 
population. Because the prevalence by race among ANC attendees is not available, the 
prevalence by race can be obtained from the 2005 HSRC survey, as shown in Table A5.1. 
The race distribution for the South African adult population (age 15-49 years), also shown 
in Table A5.1, can be obtained from the latest available Census data.518 The correction 
factor is then estimated as the ratio of the unadjusted prevalence to the race-standardized 
prevalence (Table 5A.1). 
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Total 100 16.2 17.6 0.92 
2. Adjusting for prevalence in pregnant women versus prevalence among adults 
To adjust for the difference between HIV prevalence in pregnant women and prevalence 
among adults in the general population, a correction factor based on the ratio of prevalence 
in these two population groups can be calculated using data from the 2005 HSRC survey, 
as 16.2/23.2= 0.7 
Combined adjustment 
The combined correction factor can then be estimated as the product of the two correction 
factors described above, i.e. 0.92x0.7 = 0.64. 
Adjusted adult HIV prevalence in South Africa is therefore estimated to be 29.5% x 0.64 
= 18.9% 
The calculation of the correction factor as described above was endorsed by the 
Department of Health and UNAIDS at a meeting in the Department of Health in Pretoria in 
2006. 
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CHAPTER 6 Analysing age prevalence data to understand the 
patterns of HIV infection in South Africa 
"For me, a hypothesis is a statement whose truth is temporarily assumed, 
but whose meaning must be beyond all doubt." 
Albert Einstein, 1918519 
Introduction 
Understanding the spread of the HIV epidemic in time and space is an essential step in 
trying to understand the dynamics of the epidemic, to make projections of the likely future 
course of the epidemic, to evaluate the impact of interventions and to find ways to deal 
with the epidemic effectively. In this chapter data are used on the age-specific risk of 
infection among various groups of men and women in an attempt to understand how 
patterns of infection vary with age, gender, geographic location, and migrancy status. The 
HIV prevalence data sets used in this analysis include data from women attending 
antenatal clinics in South Africa and in rural KwaZulu-Natal (Hlabisa), data on men and 
women from urban and rural community settings (rural KwaZulu-Natal in 1991, Hlabisa in 
2000 and Carletonville in 1998), sex workers operating along the trucking route in 
KwaZulu-Natal and near the gold mines in Carletonville, mine workers from Carletonville, 
truck drivers visiting sex workers in KwaZulu-natal, and data from male and female 
employees of a large South African company in 1999. Different patterns of infection are 
identified among different risk groups and the implications for the spread and management 
of the epidemic in South Africa are considered. 
Methods 
In order to compare the different data sets it was first necessary to parameterize the data by 
fitting the age-prevalence data to suitable functions. In some cases the age-prevalence 
curve was statistically either constant or varied linearly with age. However, in most cases, 
including all the data collected from antenatal clinics and the general population, the age-
specific prevalence increases rapidly between the ages of 15 and 30 and then declines more 
slowly with increasing age. A log-normal function with an age off-set, as described in 
Chapter 3, Equation 3.2, provides a suitable analytical function for fitting these data and 
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provided a good fit to all the data sets for which the age-prevalence of infection deviated 
from a straight line. 
The shape of the age-prevalence curve is usually consistent with an onset of sexual activity 
in the early teenage years and a peak of sexual activity between the ages of about 20 and 
30 years, and is supported by data on the age-incidence of pregnancy in Hlabisa, shown in 
Figure 6.1. These data were collected as part of an HIV seroprevalence survey of 3,163 
women, age 15 to 49 years, attending antenatal clinics in Hlabisa between January and July 
1998. Data from the 1996 census were used as the denominator and a log-normal function 
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Figure 6.1 Fitted and observed annual fertility (for ages up to 50 years) estimated 
from the number of women attending antenatal clinics in Hlabisa. The curve is log-
normal (Equation 3.1) with m = 14.9 years, aO = 10 years, a = 0.629 and N = 2.156. 
The incidence of pregnancy is shifted down by 0.75 years to allow for the 9 months 
gestation. 
The log-normal curves were fitted to the data using a maximum likelihood procedure520 
with binomial errors. For the interpretation of the data the mode was more useful than the 
mean and the fits were done using the mode as one of the parameters. For a log-normal 
function the relationship between the mode and the mean is given by 
mean = {mode — offset) x ec 
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The p-values for goodness of fit, calculated using a x~ test of deviance, were used to assess 
the significance level of the model fit, and if greater than 0.05 it indicates that the fitted 
line does not differ significantly from the data. 
The maximum likelihood procedure was also used to obtain the covariance matrices for the 
fitted parameters,520 from which 95% confidence ellipses for the shape parameter and the 
mode were constructed and used in the comparison of the different fits. The mode gives the 
age at which the peak prevalence occurs, while the shape parameter, a, is the standard 
deviation of the frequency distribution of the log-transformed data and determines the 
shape of the frequency distribution of the untransformed data. Only these two parameters 
were considered, and not the normalization parameter, since the prevalence of infection is 
expected to increase with time, while the only interest here was in the shape of the age-
prevalence curves. 
Data sources 
The data used in this analysis came from a variety of sources, all of which are described in 
detail in Chapter 4. These included age-specific HIV prevalence data for: 
. Pregnant women attending national antenatal clinics between 1995 and 
2QQ4.25,31,118,472,473 
. Pregnant women attending antenatal clinics in Hlabisa in 1997, 1998, 1999, and 
2001;32 
• Men and women participating in a cross-sectional, anonymous, community based 
survey in rural KwaZulu-Natal in 1991; 
• Men and women taking part in the Vaccine Preparedness Study in the Hlabisa district 
in 2000; 
• Men and women participating in a community based survey in an urban setting 
(Carletonville) in Gauteng in 1998;222'310 
• Sex workers operating at truck stops along the national road between Durban and 
Johannesburg, in the KwaZulu-Natal Midlands, between 1996 and 1998;331 
• Sex workers operating near the gold mines in Carletonville in 1998; ' 
. Truck drivers visiting sex workers along the trucking route in the KwaZulu-Natal 
Midlands in 1998;331 
• Migrant mine workers working on the gold mines in Carletonville in 1998™1 U and 
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• Men and women participating in a large cross-sectional survey carried out among the 
workforce of a major South African company in 1999;479'480 
Results 
National ANC data 
ANC data collected from national surveys between 1995 and 2004 are plotted by age in 
Figure 6.2, showing the dramatic increase in HIV prevalence in all age groups over time. 
The log-normal function provided a good fit to the age-prevalence data for each of the 
antenatal clinic surveys carried out between 1995 and 2004. The data and the fitted curves 
are shown graphically in Figure 6.3, and are provided in Table 6.1 together with the 
parameter values for the log-normal fits and the peak prevalence. The mode indicates the 
age at which the peak prevalence occured. The peak prevalence of HIV increased 
dramatically in all age groups, from an average of 14.2% in 1995 to 37.1% in 2004 (Figure 
6.2). The prevalence in all ten surveys peaked among young women but shifted from age 
22.4 years in 1995 to 26.7 years in 2004 (Table 6.1). 
In order to compare trends over time in the location and shape of the age-distributions, 
Figure 6.4 shows 95% confidence ellipses for the two parameters of the log-normal 
distributions fitted to the data. The shapes of the curves for 1995, 1997 and 1998 were not 
significantly different but the ellipse for 1996 was quite different from all the other data 
sets with a much broader curve (a = 0.825) and was therefore excluded from further 
consideration. It is clear from Figure 6.4 that the shapes of the age prevalence curves for 
HIV infection among antenatal clinic attendees have remained much the same over a 
period of ten years (excluding the data for 1996) as indicated by the parameter a. 
However, the data show that the age at which the peak prevalence occurs has shifted over 
the period under consideration. Between 1995 and 1998, the peak prevalence occurred 
among young women aged around 23 years. By 1999-2000, the average age of the peak 
prevalence had shifted by about 1.5 years to 24.5 years, and by 2002-2004 it had shifted to 
an average of 26.5 years. The shapes of the curves for 2002, 2003 and 2004 were not 
significantly different. The observed changes are most likely the result of a maturing 
epidemic, reflecting possible saturation of the epidemic, although differences in the 
sampling procedure and other biases in the data may also have affected the shapes of the 
86 
curves. Over time the size of the confidence ellipses also became smaller because of 
smaller standard deviations related to higher prevalences and more precise data. 
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Figure 6.2 National antenatal clinic HIV prevalence data plotted by age for 
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Figure 6.3 Age-prevalence of infection for women attending national antenatal 
clinics from 1995 to 2004 fitted to log-normal functions. The data, the parameters of 
the fits and the goodness of fit are given in Table 6.1. Error bars are 95% binomial 
confidence limits. 
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Table 6.1 Age-prevalence of infection among women attending national antenatal 
clinics. Parameter values of the log-normal fits, the observed and fitted prevalences 
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Figure 6.4 95% Confidence ellipses for the fits to the national antenatal clinic 
data between 1995 and 2004. The mode indicates the age at which peak 
prevalence occurred and the standard deviation indicates the width of the 
distribution of the log-normal curve. 
Figure 6.5 shows the peaks in the age-prevalence curves for each ANC survey between 
1995 and 2004 and the age at which these peaks occurred. While the peak prevalence 
increased from 14.2% in 1995 to 37.1% in 2004, the ages at which this occurred increased 
from 22.4 years to 26.7 years over the same period. 
The increase in prevalence over time in each of the age groups (where age was grouped in 
categories of five years) was analysed and is shown for each age group in Figures 6.6 and 
6.7. Logistic curves were fitted to the data. While the epidemic among the younger age 
groups (15-19 and 20-24 years) appears to have levelled off after 2000, the prevalence in 
the older age groups is still increasing. The data for the 15 to 19 year old age group 
suggests that the incidence is now fairly constant but at a high level. If very few women are 
infected before the age of 15 years and the prevalence in those aged 15 to 19 is about 15%, 
then this suggests an annual incidence of about 5-7% per year. 
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I Age of peak 
prevalence 
• Peak Prevalence 
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Year 
Figure 6.5 Age of peak prevalence (indicated by the mode in the log-normal 
fits) and the peak prevalence among national antenatal clinic attendees between 
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Figure 6.6 HIV prevalence plotted over time within age groups. Logistic curves 













1994 1996 1998 2000 
Time (year) 
2002 2004 
Figure 6.7 Comparison of change in HIV prevalence by age group among ANC 
attendees over time 
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Hlabisa ANC data 
The shapes of the age-prevalence curves from antenatal clinic attendees in Hlabisa in rural 
KwaZulu-Natal between 1997 and 2001 (Figure 6.8) were similar to those for the national 
antenatal clinic surveys with the age of the peak prevalence shifting from 22.7 years in 
1997 to 25.5 years in 2001 (Table 6.2). Log-normal distributions provided good fits to all 
four sets of data. HIV prevalence in Hlabisa in general reflects the high prevalences in the 
KwaZulu-Natal province. The peak prevalence among ANC attendees in this district 
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Figure 6.8 Age-prevalence data for women attending antenatal clinics in Hlabisa 
between 1997 and 2001, fitted to log-normal functions. Error bars are 95% binomial 
confidence limits. 
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Table 6.2 Age-prevalence of infection among women attending antenatal clinics in 




















































































































































































































Three sets of data from community based surveys were available for analysis; one from a 
rural population in northern KwaZulu-Natal, carried out between 1990 and 1992;82 the 
second from the Hlabisa community (Vaccine Preparedness Study), also in rural KwaZulu-
Natal, carried out in 2000; and the third from the urban population of Carletonville carried 
out in 1998. The age-specific prevalence curves for these populations are shown in 
Figure 6.9 using the data shown in Table 6.3. The infection rates in the later urban and 
rural surveys were approximately ten times higher than the rates measured in the earlier 
rural survey, and the fractional errors correspondingly smaller. Standard errors for the 
infection rates among rural men in 2000 were very large because of the small sample sizes 
in the various age groups. The patterns of infection are similar between the three sets of 
data with infection rates increasing more slowly among young men than among young 
women (Figure 6.9). Table 6.3 and Figure 6.10 show that the peak prevalence occurred at 
older ages among men than among women (about 7.5 years older among men in rural 
KwaZulu-Natal and about 5 years older among men in urban Gauteng). For rural women, 
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the age at peak prevalence shifted from 21.9 years in 1991 to 26.0 years in 2000; while it 
shifted from 29.8 to 33.3 years for men. Prevalence peaked among urban women in 1998 
at age 26.1 years and among men at age 31.6 years. The ellipses indicate a narrower 
distribution (i.e., smaller standard deviation) for men than for women. 
Data from the three community surveys were used to calculate the ratio of HIV prevalence 
among females to the prevalence among males. Figure 6.11 shows that the female to male 
prevalence ratio for all ages combined was about 1.7 in all three surveys. The female to 
male ratio among young people aged 15-19 years was much higher (20.5, 7.2, and 10.4, 
respectively, for rural KwaZulu-Natal 1991, rural KwaZulu-Natal 2000, and urban 
Gauteng 1998) than among older ages because of the much higher prevalence and 
vulnerability among young women compared to young men. At ages 25 to 49 the female 
to male prevalence ratio was about 1, while all three surveys indicate that prevalence was 







Rural women 1991 Rural men 1991 
Rural women 2000 
20 30 40 
Rural men 2000 
Urban women 1998 Urban men 1998 
Age 
Figure 6.9 Age-prevalence curves for men and women in rural areas of northern KwaZulu-
Natal in 1991 and 2000, and in the urban area of Carletonville in 1998. The data, 
parameters of the fits and the goodness of fit statistics are given in Table 6.3. Error bars 
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Urban Women 1998 
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Figure 6.10 95% Confidence ellipses for the fits to the men and women from 
the community surveys conducted in 1991, 1998 and 2000. 
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Table 6.3 Age-prevalence of infection among men and women from three community 
surveys (rural KwaZulu-Natal in 1991 and 2000, and urban Carletonville in 1998). 
Parameter values of the log-normal fits, the observed and fitted prevalences, and peak 
prevalences are provided. 
Parameter values 
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Figure 6.11 Ratio of female to male prevalence by age (and combined) for 
the three community surveys. 
Migrant men 
Two sets of data were available for migrant men: one for mineworkers from the 
Carletonville study222 and the other for truck driver clients of sex workers in KwaZulu-
Natal and these are shown in Figure 6.12 and Table 6.4. For neither group did the age-
prevalence deviate significantly from a constant, in contrast to all the other data sets, 
although the prevalence among the truck drivers (56.3%) was approximately twice the 
prevalence among the mine workers (28.6%). 
Commercial sex workers 
The age-prevalence of infection among commercial sex workers operating at truck stops in 
the KwaZulu-Natal Midlands and near the gold mines in Carletonville is shown in Figure 
6.13 and Table 6.5. For the women operating out of truck stops the data differed 
significantly from a straight line ix~ test of deviance, p = 0.0013) and the log-normal 
function gave a statistically good fit, even though the number of sex workers in older age 
groups was small. However, for the women operating near gold mines in Carletonville the 
data did not differ significantly from a straight line but the sample size was small and the 
power to demonstrate differences correspondingly weak. The prevalence of infection 
among women operating near the mines in Carletonville was significantly higher (68.7%) 
than among the women operating along the trucking route in KwaZulu-Natal (50.0%). 
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Figure 6.12 Age-prevalence data for mine workers in Carletonville and truck 
drivers in KwaZulu-Natal in 1998. The data and the parameters of the linear fits are 
given in Table 6.4. Error bars are 95% binomial confidence limits. 
Table 6.4 Age-prevalence of infection among mine workers in Carletonville and 
truck drivers in KwaZulu-Natal. The parameter values of the linear fits and the 
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Figure 6.13 Age-prevalence for sex workers operating at truck-stops in KwaZulu-
Natal and at a gold mine in Carletonville. The data, the parameters of the fits and the 
goodness of fit are given in Table 6.5. Error bars are 95% binomial confidence limits. 
Table 6.5 Age-prevalence of infection among commercial sex workers operating at 
truck-stops in KwaZulu-Natal, and at a gold mine in Carletonville. Parameters values of 
the log-normal fit and linear fit, and the observed and fitted prevalences are provided. 
Parameter values 
























































































Figure 6.14 and Table 6.6 show the age-prevalence of infection from a national work-place 
survey carried out in a large parastatal company across the country. There were few 
women in the survey and the data for men were separated into those who live in hostels or 
camps and those who live in their own homes. For the men who live in hostels and camps 
the prevalence peaked at the age of 35.9 years, fairly similar to that among men in the 
community based surveys. For men living in hostels and camps the sample sizes were 
small so that the error bars were relatively large. The prevalences for men living in their 
own homes, however, were low and did not deviate significantly from a straight line. The 
average HIV prevalence among men living in their own homes was about one third (6.2%) 
of that among the men living in hostels or camps (18.1%). 
Workplace men 1999 - Hostels & camps Workplace men 1999 - own home 
, 111 i I \ l" 
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Figure 6.14 Age-prevalence for men working in a large parastatal industry in 1999, 
separated according to those who live in a hostel or a camp, or those men who live in 
their own home. The data, the parameters of the fits and the goodness of fit are given 
in Table 6.6. Error bars are 95% binomial confidence limits. 
101 
Table 6.6 Age-prevalence of infection among men working for a large parastatal, for those 
who own their own homes and those who live in hostels or camps. Parameter values of the 
log-normal fit and the linear fit, and the observed and fitted prevalences are provided. 
Parameter value 


























































Workplace men living in 

















































Comparisons between data sets 
In order to compare the shapes of the age-prevalence distributions between various groups 
of data, 95% confidence ellipses for the fitted parameters were constructed; first for all 
women (Figure 6.15), then for all men (Figure 6.16), and finally for men and women in 
KwaZulu-Natal (Figure 6.17). 
Figure 6.15 shows that data for women attending antenatal clinics are clustered, although 
there was a shift in the mode (age of peak prevalence) over time as the epidemic started to 
show signs of levelling off. The shapes of the curves for the ANC women were similar 
with similar distributions and the value of standard deviations did not vary much between 
antenatal clinic attendees, nationally as well as in Hlabisa. The data for women in the 
community survey in 1991 showed a wider distribution than for those in the community in 
2000. The distribution for women in urban (1998) and rural (2000) communities did not 
differ significantly. 
Data for men in South Africa (Figure 6.16) showed wider distributions for migrant mine 
workers than for men in the community. There were no significant differences between the 
distributions for men in the three community surveys although the mode shifted to older 
ages by about three years. 
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Figure 6.17 shows that data for women attending antenatal clinics in KwaZulu-Natal were 
clustered and that the shapes of the curves for women were similar not only for antenatal 
clinic attendees over different years, but also for women from community surveys and for 
female sexworkers. The mode for women in the community surveys shifted by about 4 
years from 1991 to 2000; for men it shifted by about 3 years over the same period. The 
distributions for the men in the two community surveys were similar, while the 
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Figure 6.17 95% Confidence ellipses for the fits to data sets available for men and women 
in KwaZulu-Natal. 
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To illustrate the above observations in more detail Figure 6.18 shows a series of 
comparisons in which the curves are all scaled so that the area under each curve is one. 
This is done to facilitate the comparisons of the shapes of the curves since the average 
prevalence varies widely among the different data sets. Figure 6.18a shows first a 
comparison of the age-specific incidence of pregnancy (using fertility data from KwaZulu-
Natal) and the average fit to the age-specific prevalence of HIV among women attending 
antenatal clinics in the years 1995, 1997 and 1998. Since the age-specific incidence of 
pregnancy gives a measure of sexual activity it also gives a measure of risk of infection 
although this will be confounded by the use of non-barrier methods of contraception. 
Nevertheless the curves are surprisingly similar. In Figure 6.18b the HIV prevalence data 
for women attending antenatal clinics are compared to the data for urban community 
women. Compared to the urban community survey data, antenatal clinic data appear to 
overestimate infection rates in younger women and underestimate infection rates in older 
women. The best comparison between men and women is based on the urban community 
survey carried out in Carletonville in 1998 and these data are shown in Figure 6.18c from 
which it is seen that the curve for men is shifted to older age-groups, as compared to 
women in the same community, by about five years. Finally Figure 6.18d shows a 
comparison of the fits to the data for urban men and migrant workers with the latter being 
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Figure 6.18 Age-specific incidence of fertility and age-specific prevalence of HIV 
infection, a) Left: fertility; right: women attending antenatal clinics, b) Left: women 
attending antenatal clinics; right: urban women, c) Left: urban women; right urban men. 
d) Curve: Urban men; straight line: migrant men. All the curves are scaled so that the 
area under the curve is one. The line for the migrant men is scaled by the same factor as 
the curve for the urban men. 
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Discussion 
This chapter investigates patterns of HIV infection, reflecting the age-specific risk of 
infection, and how these patterns vary with age, gender, migrancy status and between 
urban and rural settings. 
National antenatal clinic surveys provide data by age for women (at a national level) over 
time and show the rapid increase in HIV prevalence in all age groups over a ten year 
period (Figure 6.2). Although the shapes of the prevalence distributions by age remained 
fairly similar over time, the age at which the prevalence peaked shifted significantly to 
older age groups by about 3.5 years, from an average of about 23 years in 1995-1998 to an 
average of 26.5 years in 2002-2004 (Figure 6.4). As the epidemic is starting to level off, 
this is most probably a reflection of the ageing epidemic in South Africa. While the 
change in prevalence over time seems to be stabilizing among young women between the 
ages of 15 to 24 years, the prevalence in the older ages was still showing an increase in 
2004 (Figure 6.6). In addition to the epidemic showing signs of leveling off, this could 
also be due to behavioural changes that are more likely to occur among younger women 
before it occurs among older women. 
Data from three community surveys allowed comparisons between men and women and 
between urban and rural settings. Comparison between female and male prevalence show 
higher rates among females than males in all three surveys with an average female to male 
ratio of about 1.7 (Figure 6.11). This is very close to the ratio of 1.73 (prevalence of 
20.2% among females and 11.7% among males, aged 15 to 49 years) obtained from the 
national population based survey conducted by the HSRC in 2005.47 The three community 
surveys analysed here showed much higher prevalences among young women (15-24 
years) than among young men (with an average female to male ratio for the three surveys 
of 12.7), while the female to male ratio in the age groups 25 to 49 years was about 1. 
Analysis of the various data sources in this chapter revealed four main patterns of 
infection: among women attending antenatal clinics, among women in population surveys, 
among men in population surveys, and finally among migrant men. The pattern of 
infection does not appear to be changing substantially with time, although the peak 
prevalence is shifting to older age groups as the epidemic is maturing. Differences 
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between urban and rural populations were not significant. Data for men generally show 
narrower distributions (smaller values for the standard deviations in the log-normal fits) 
than for women, while the maximum prevalence for men occurs 5 to 7 years later than for 
women. 
A number of important conclusions follow from this analysis. First of all, when the 
epidemic growth rate is very high, in particular in the early stages of the epidemic, the age-
specific prevalence of infection gives an approximate measure of the age-specific 
incidence of infection and this is supported by the finding that the shape of these curves for 
particular populations between 1995 and 2004 does not vary greatly over time. Reliable 
estimates of the age-specific incidence of infection are essential for developing reliable 
demographic models to forecast the course of the epidemic and against which to assess the 
impact of interventions, and will be discussed in detail in further chapters in this thesis. 
Comparing the age-specific prevalence of infection among women attending antenatal 
clinics with that of urban community women shows that the antenatal clinic data tend to 
overestimate the prevalence of infection among younger women and underestimate it 
among older women. The age-specific prevalence of infection among men is shifted up by 
about five to seven years as compared to that for women probably because males are 
usually older than their female sexual partners. The two data sets for migrant workers show 
a completely different pattern of infection with no significant variation with age. There are 
no very young migrant workers in the sample but these data suggests that among older 
migrant workers the risk of infection does not fall off in the way it does among all of the 
other groups for which data have been presented. It seems reasonable to suppose that 
migrant men, through the nature of their work, remain at high risk of infection as they get 
older since they do not have the social support provided in even the poorest of stable 
communities. 
Finally, there were no significant differences between the data sets for people living in 
urban and rural areas as indicated by the results shown in Figure 6.10 so that the age-risk 
of infection does not appear to depend on whether or not people live in urban or rural 
areas. This, in turn, is probably a reflection of the high rate of circular migration between 
urban and rural areas in South Africa.521 
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The data presented here show alarmingly high prevalence rates among young women aged 
15 to 24 years and prevalence rates of close to 60% in some groups of 25-29 year old 
women who are not commercial sex workers. Although the prevalence among women 
aged 15 to 24 years seems to be levelling off in most groups, much more work is needed to 
understand the reasons for these very high infection rates and to find ways to protect young 
women from becoming infected. It is of interest to note that in most of the data sets for 
women (antenatal clinic as well as community women), the prevalence tends to rise again 
among women aged 45 years and older, after having come down from its peak value in 
younger age groups. Although the sample sizes for women in this age group are generally 
small, this increase is observed almost consistently and needs to be further investigated. 
The data also highlight the increased risk of infection among migrant men, especially 
among older men, and this too must be taken into account when designing interventions to 
manage the epidemic. Finally, while the analysis in this chapter highlights the urgency of 
the HIV situation and the need to deal with the spread of infection effectively, it can also 
be used as a basis for predicting the future course of the epidemic, for planning effective 
responses and for evaluating the impact of interventions. 
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CHAPTER 7 Comparison between antenatal clinic and 
community based estimates of prevalence 
"At the time I read the report with great interest, but I never imagined I was 
looking at the first sign of an epidemic, that in just 20 years would have infected 60 
million people, killed 22 million and achieved the status of the most devastating 
epidemic in human history" 
Peter Piot, 2001522 
Introduction 
Much of our understanding of the HIV epidemic in South Africa is based on prevalence 
data collected from surveillance among pregnant women attending public sector antenatal 
clinics. Antenatal clinic surveillance has been used to determine the overall HIV 
prevalence, age-specific prevalence, geographical variation and trends over time of HIV 
among women of reproductive age and hence to derive estimates of the overall burden of 
disease in the country. 
In the mid 1980s, facility-based sentinel surveillance of HIV was recommended by the 
World Health Organization for monitoring the HIV epidemic, mainly because of easy 
access to people attending public health facilities.471 In most countries in sub-Saharan 
Africa in which the HIV epidemic has spread into the general population, surveillance 
among pregnant women attending public sector antenatal clinics has since become the 
primary source of data on the spread of HIV.523 In South Africa, antenatal clinic 
surveillance was initiated in 1990" and has since been conducted annually. Pregnant 
women are used as an indicator group for infection in the heterosexual population because 
they represent a readily accessible subgroup of sexually active adults from whom blood is 
routinely collected to test for syphilis or haemolytic diseases and among whom the trend 
of HIV infection is believed to mirror that in the overall adult population.23 
In order to assess whether antenatal clinic prevalence accurately reflects community based 
prevalence in rural KwaZulu-Natal we compared data collected from a community based 
survey (the Vaccine Preparedness Study) in the rural community of Hlabisa between 2000 
and 2002 to data collected independently from antenatal clinics in the same area from 




HIV prevalence was measured as part of a community-based survey (the Vaccine 
Preparedness Study) conducted in Hlabisa, a rural district in KwaZulu-Natal, between 
February 2000 and March 2002. The purpose of the study was to determine the 
preparedness of the community for participation in future HIV vaccine and prevention 
trials, to collect key baseline demographic and health variables and to obtain community-
based estimates of HIV prevalence. Interviews were conducted among 2314 adult 
participants, of whom 1719 (74%) were female. Hlabisa has a large migrant population 
and many men work and live away from home (e.g., working in factories in Empangeni or 
on the mines in Carletonville). The number of men who participated in the survey was 
therefore small (n =595). 
Data on key demographic and health variables were collected by trained research assistants 
using standard questionnaires developed for men, women and households. Dried blood 
spots (DBSs) from a finger prick were collected on high-grade filter paper from each study 
participant who gave written, informed consent to having a blood sample taken. Pre-and 
post-test counseling were provided to those participants who wanted to know their results. 
Confidentiality was maintained by identifying blood specimens by bar code numbers only, 
while only two of the study investigators had access to the full data base. Samples were 
tested for HIV by the Virology Laboratory at the University of Natal in Durban using 
commercial third and fourth generation HIV ELISAs. Ethical approval for the study was 
obtained from the University of Natal Ethics Committee. 
Antenatal clinic survey 
Between November 2001 and February 2002 a survey was conducted, independently of the 
community-based survey, among women attending antenatal clinics (including fixed 
primary health care clinics, mobile clinics and the Hlabisa hospital) in the Hlabisa district. 
Blood samples that were routinely collected from pregnant women attending antenatal 
clinics for syphilis serology during this four-month period were used for anonymous HIV 
antibody testing. Only the age of the participant and the clinic numbers were recorded. 
Blood samples were analyzed at the University of Natal Department of Virology using a 
Uniform 11 (Vironostika) test for first line HIV and Abbott M X as a confirmatory test. 
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Results 
Response rates for HIV testing in the community-based survey were low and of the 1719 
women (aged 15 to 54 years) who participated in the study, 34% consented to having a 
blood sample taken. Only 26% of the men (aged 15 years and above) consented to having a 
blood sample taken. Age-specific HIV prevalence data were therefore collected from 581 
women and 154 men in the community. HIV prevalence is reported in Table 7.1 by age 
group for women and men in the Hlabisa community (2000-2002), and for women 
attending antenatal clinics (2001-2002). 
Table 7.1 HIV prevalence by age for adult men and women in the community, and for 













total PrfT 95% CI 
50 2.0 0.1-10.6 
25 4.0 0.1 -20.4 
17 41.2 18.5-67.1 
8 25.0 3.2-65.1 
9 11.1 0.3-48.2 
11 36.4 11.0-69.2 
7 14.3 0.4 -57.9 
8 12.5 0.3 -52.8 
17 6.0 0.3 -28.8 
152 12.5 7.7-18.8 
Community women 
Total P r ^ 95% CI 
4 0.0 0.0 -52.7 
180 14.4 9.6-20.4 
114 31.6 23.2-41.0 
65 41.5 29.4-54.4 
46 39.1 25.1 -54.6 
53 16.9 8.0-29.7 
48 8.5 2.5-20.1 
39 10.3 2.9 -24.3 
31 16.1 5.4-33.7 
580 22.2 18.8 -25.6 
ANC women 
total P / ^ 95% CI 
(%) 
3 0 0 -52.7 
179 22.9 17.0-29.8 
185 50.8 43.4-58.2 
89 47.2 36.5-58.1 
73 38.4 27.3-50.5 
44 36.4 22.4-52.3 
15 26.7 7.8-55.1 
3 33.3 0.8-90.5 
591 38.2 33.4-43.6 
HIV prevalence among women 
HIV prevalence data from 581 consenting women in the community were compared to 
data from 591 women attending antenatal clinics during the same time period for which 
HIV and age data were available (Table 7.1). In all but one age-group, HIV prevalence 
among women attending antenatal clinics was higher than among women in the general 
population. The overall HIV prevalence among women attending antenatal clinics (38.2%, 
95% CI: 33.4-43.6%) was significantly higher than among women in the general 
population (22.2%; 95% CI: 18.8-25.6%, p = 0.0001). The overall prevalence of HIV in 
the two groups remained significantly different after standardizing the data to the age 
distribution of women aged 15 to 54 years in the general population in Hlabisa (31.3% 
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among antenatal clinic attendees versus 24.3% among women in the general population, p 
= 0.0004) 
The prevalence data for the two groups were fitted to log-normal distributions using a 
maximum likelihood procedure and are presented in Figures 7.1 and 7.2. Although the data 
were collected over a short period of time it is important to determine the presence or 
otherwise of an overall time trend in the data because the ANC data were collected 
between November 2001 and February 2002 while the community data were collected 
between February 2000 and February 2002. The log-normal age-prevalence model for the 
community survey was therefore extended to include a linear time trend. The reduction in 
the deviance for the extended model was tested using a chi-square test and the trend was 
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Figure 7.1 Log-normal curves fitted to the HIV prevalence data for women who attended 
antenatal clinics and women from the general population in Hlabisa between 2000 and 
2002. Observed data points are plotted with 95% binomial confidence intervals. 
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Figure 7.2 Log-normal curves fitted to the HIV prevalence data for women who 
attended antenatal clinics and women from the general population in Hlabisa. 
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Comparison of risk factors for HIV among women who did or did not consent to provide 
blood samples for HIV testing 
Of concern in this study was the fact that only 34% of women in the community-based 
survey consented to having an HIV test done and it is therefore important to consider 
differences between those who consented and those who did not that might bias the data. 
Of those who refused having a blood sample taken, 61% gave the fear of knowing their 
status as the reason for refusal. A number of variables were compared between those who 
consented to having a blood sample taken and those who did not, including the proportion 
of women who had been diagnosed with a sexually transmitted infection in the last twelve 
months, the number who thought their husbands had had other sexual partners, age, marital 
status, age at first sex, the number of sexual partners they had had, the likelihood that 
women had changed their behaviour because of AIDS, and their perception of their risk of 
infection. The results, summarized in Table 7.2, indicate that the difference in HIV 
prevalence between women in the community and women attending antenatal clinics is 
unlikely to be explained by the effect of non-response in the community survey. Those 
who consented had their first sexual experience at a slightly younger age (17.0 years) and 
had more sexual partners (6.7% reported having more than 1 partner in the last 12 months) 
than those who refused to provide a blood sample (age at first sex 17.4 years; 3.5% had 
more than 1 partner in the past 12 months) so that, if anything, the prevalence of infection 
is likely to be lower among women who refused to participate leading to an even greater 
difference between the ANC and community based estimated than reported here. 
HIV prevalence among men in the community 
Of the 152 men who consented to having a blood sample taken, 12.5% (95% CI: 7.7-
18.8%) were HIV positive. Fifty percent of the men who consented were younger than 25 
years so that the samples of the men in the older age categories were small, and hence 
standard errors for estimates of HIV prevalence were large and confidence intervals were 
very wide. Figure 7.3 shows the HIV prevalence, with 95% confidence intervals, by age 
for men in the community, fitted to a log-normal distribution. 
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Table 7.2 Comparison of potential risk factors for HIV between those women who consented 
and those who did not consent to having blood taken for HIV in the Hlabisa community-
based survey 
Risk factor 
Percent ever tested for HIV 
Mean age in years (SE) 
Percent currently married or in a 
stable relationship 
Diagnosed with an STI in the last 
12 months 
Mean age at first sex in years (SE) 
% Having more than 1 sexual 
partners in last 12 months 
Thought husband had other sexual 
partners 
% Never using condoms 
Perception of risk 
No risk of HIV 
Small risk 
Big risk 
Women who gave 
consent to have 
blood taken 












Women who did 























Comparison between men and women in the community 
Figure 7.4 shows the comparison of age-specific prevalence between men and women in 
the Hlabisa community. HIV prevalence among young women (age 15 to 24 years) were 
significantly higher than among men of the same age (2.7% vs 21.1%, respectively; %2 = 
14.2, p<0.001). Differences in prevalence between men and women in older age groups 
were not statistically significant, mainly because of the small sample sizes and large 
standard errors (in particular for men). Log-normal curves fitted to the data show that for 
women in the community prevalence peaked at 35.4% at age 27 years and for men 
prevalence peaked 6 years later (at age 33 years) at 32.0%. In contrast, HIV prevalence 
among female antenatal clinic attendees peaked at 51.5% at age 26 years. 
When combined, the overall adult HrV prevalence in the general population in Hlabisa was 













Figure 7.3 HIV prevalence among men in the Hlabisa community. Large 
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Figure 7.4 Comparison of age-specific prevalence between men and 
women in the Hlabisa Community 
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Discussion 
Several studies conducted in sub-Saharan Africa have shown that HIV prevalence among 
antenatal clinic attendees is generally similar to adult female prevalence in the same 
communitjr J in both high " and low ~ fertility populations. However, in a comparison 
of HIV prevalence in community-based and antenatal clinic surveys in Mwanza, 
Tanzania,529 the prevalence among women attending antenatal clinics (3.6%) was lower 
than among women in the general population (4.7%, p - 0.025), but there was no 
difference between the two groups after adjustment for parity (4.6 versus 4.7%, p = 0.95). 
A comparison between HIV prevalence measured among adults in the community and 
HIV prevalence measured by sentinel surveillance in antenatal clinics in Yaounde, Kisumu 
and Ndola530 showed that antenatal clinics underestimated HIV prevalence in the general 
female population (aged 15-49 years) in Yaounde (5.5% and 7.8%, respectively) and 
Ndola (27.3% and 31.9%, respectively), while prevalence among antenatal clinic attendees 
in Kisumu was similar to that of women in the general population (30.6% versus 30.1%, 
respectively). Factors identified to influence the difference in HIV prevalence between 
antenatal clinic attendees and the population included age, marital status, parity, schooling 
and contraceptive use.530 
In contrast to these findings, the study in Hlabisa shows that antenatal clinic HIV 
prevalence over-estimates prevalence in the general female population (as well as in the 
general adult population). A major limitation of this study, however, is that two-thirds of 
the women in the community survey refused to give a blood sample to be tested for HIV. 
Differences in potential risk factors for HIV between those who consented to having blood 
taken and those who did not were considered (Table 7.2) but it was not possible to identify 
any potential confounding factors that might significantly bias the ANC estimate of 
prevalence upwards relative to the community estimate of prevalence. 
In countries with generalized epidemics, the HIV prevalence among ANC attendees has 
been used as a proxy for prevalence in the general heterosexual population. When 
compared to the general adult population (men and women aged 15 to 49 years), a review 
of studies conducted in sub-Saharan Africa showed that prevalence among pregnant 
women is a good approximation to prevalence among the sexually active adult population 
(Appendix 7.1). In all these studies, estimates of adult HIV prevalence (men and 
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women aged 15-49 years) from the community were compared to prevalence estimates 
C O 1 
from ANC attendees in the same locality over the same time period. Of 14 comparisons 
in seven countries, only two showed a significant difference between ANC and community 
prevalence. Prevalence from the ANC sample overestimated community prevalence in 
1997 in Kisumu, Kenya,530 and underestimated community prevalence in 1999 in 
Zambia.532 
In contrast to the above observations, however, population based surveys (including 
Demographic and Health surveys) conducted at a national level in several countries in sub-
Saharan Africa over the last few years, have shown that national estimates of adult HIV 
prevalence are generally lower than those obtained from national antenatal clinic surveys 
(Table 7A, Appendix 7.1). In South Africa, for example, the population-based survey 
conducted by the HSRC in 2002469 reported a national adult (aged 15-49 year) prevalence 
of 15.6%,(95% CI: 13.9-17.5%) compared to the national ANC estimate for the same year 
of 26.5% (95% CI: 25.5 - 27.6%). The prevalence among women from the population 
based survey of the same age group (15-49 years) was also significantly lower (17.7% 
among all women and 20.7% among Black African women) than the national ANC 
estimate. Similarly, HIV prevalence among adult women aged 15-49 years from the 2005 
HSRC population-based survey470 was significantly lower (20.2% among all women and 
24.4% among Black African women) than the national HIV prevalence from antenatal 
clinics for 2004 (29.5%; 95% CI: 28.5-30.5). Both estimates may reflect sampling biases. 
For example, national population based surveys, by nature of their design, are more likely 
to exclude groups at higher risk of infection such as mobile populations living in hostels, 
sex workers and army recruits, and estimates from these surveys may underestimate the 
true prevalence in a population. In addition, non-response or absence from a household at 
the time of the survey may bias population based estimates. At the same time, antenatal 
clinic estimates may be biased upward because it represents pregnant women who attend 
public health services and exclude those who are not sexually active and those seeking 
private care, among whom the prevalence of infection might be lower. It is recognized that 
both antenatal clinics and national population based surveys have strengths and 
weaknesses and these are described in more detail in Appendix 7.2. Taken together, 
however, antenatal surveillance and population based surveys can provide complementary 
information and should both be considered when obtaining a national estimate of HIV 
prevalence.533 
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The prevalence measured among antenatal clinic attendees in the Hlabisa study is close to 
the reported value for the province of KwaZulu-Natal. However, the results reported here 
suggest that the ANC data might overestimate the actual prevalence among women by as 
much as 29% (95% CI: 5%-53%) which would have important implications for estimates 
of the total number of people infected with HIV in the country as a whole. Further studies 
are needed to investigate the relationship between the prevalence of HIV infection among 
women attending ANC clinics and among women and men in the general population and to 
understand the biases that operate in both and that might affect the estimates of HIV 
prevalence. 
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Appendix 7.1 Comparison between antenatal clinic prevalence and 
population-based prevalence of HIV 
Table 7A Antenatal clinic prevalence and adult (men and women) community based 
prevalence. In part (a) HIV prevalence from community-based studies are compared with 
HIV prevalence from ANC women at the same locality over the same time period (adapted 
from Grassly et a/.531). In part (b) national adult (aged 15-49 year for women and 15-54 years 
for men) HIV prevalence from population based demographic and health surveys (DHS) are 
compared with HIV prevalence estimates from national ANC surveys. 
Location/community 
a. Community specific 
Fort Portal Uganda 
Chelston Zambia 
Chelston Zambia 
Kapiri Mposhi Zambia 









































































































































































































Appendix 7.2 Strengths and limitations of antenatal clinic surveillance 
and population-based surveys 
Concerns about the representativeness and accuracy of national HIV estimates derived 
from antenatal clinic surveillance have led to an increased demand for more surveys and 
more data on the prevalence and distribution of HIV in the population. In recent years, 
several countries have included HIV testing in national population-based surveys. 
Technological developments, such as the use of dried blood spots for HIV sample 
collection and rapid HIV testing, have greatly facilitated the collection of biological data in 
population based surveys. 
The strengths and limitations of antenatal surveillance and national population based 
surveys in countries with a generalized epidemic are discussed below. 
Antenatal clinic surveillance 
Although the main purpose of surveillance based on antenatal clinic attendees is to assess 
trends in HIV prevalence over time, antenatal clinic surveillance has also been used to 
estimate population levels of HIV because of the lack of data from other sources. 
HIV surveillance in antenatal clinics has been implemented in more than 115 countries 
worldwide.523 As in South Africa, these are usually based on anonymous, unlinked, cross-
sectional surveys of pregnant women attending antenatal clinics in the public health sector. 
Only first time attendees are included in order to minimize the chance of any woman being 
included more than once. Blood is taken routinely from pregnant women for diagnostic 
purposes (e.g., to test for syphilis or rhesus factor). After removal of personal identifiers 
(with the exception of a few key characteristics such as age, parity, marital status, clinic 
location, or urban/rural residence) the blood is tested for HIV. Antenatal clinic surveys are 
usually done annually at the same time of the year to obtain an estimate of the point 
prevalence for that year but also to assess trends over time. 
Strengths 
• Antenatal clinics provide ready and easy access to a cross-section of sexually active 
women from the general population who are not using contraception. Blood is 
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drawn for routine testing for syphilis and a portion can be used for anonymous 
testing of HIV. 
• In generalized epidemics, HIV testing among pregnant women is considered a good 
proxy for prevalence in the general population. 
• Annual antenatal clinic survey data can be used to assess trends of the HIV 
epidemic over time. 
• Data for pregnant women will reflect the prevalence in groups that may be of 
higher risk of infection because of their living arrangements (e.g. workers who live 
in hostels or army barracks) if there is regular unprotected sexual contact with 
women in the general population. 
• Limitations of antenatal surveillance are recognized and acknowledged, and where 
possible, correction factors can be developed to overcome some of the limitations, 
(e.g., prevalence can be age-standardized using the age distribution of the general 
population). 
• Geographical coverage ( number and sample sizes of sites) of sentinel surveillance 
can be expanded, particularly in rural areas, to improve the representativeness of 
the samples 
Weaknesses 
• Most sentinel surveillance systems have limited geographical coverage, especially 
in smaller and more remote rural areas. 
• Women attending antenatal clinics may not be representative of all pregnant 
women because many women may not attend antenatal clinics or may attend 
private clinics. 
• The rate of contraceptive use in a country may affect the number of pregnant 
women 
• Implementation of antenatal clinic based surveillance varies considerably between 
countries.548 The quality of the surveys may vary over time depending on available 
resources. 
• Antenatal clinic surveillance does not provide information about HIV prevalence in 
men. Because these surveys are conducted among pregnant women, estimates for 
men are based on assumptions about the ratio of male-to-female prevalence that are 
derived from community-based studies in the region. However, this ratio will vary 
between countries and over time. 
no 
Population based surveys including HIV testing 
The demand by decision makers for better data on the burden of HIV/AIDS in countries 
and the limitations of antenatal surveillance systems with respect to geographical coverage, 
under-representation of rural areas and the absence of data for men, have led to an interest 
in including HIV testing in national population-based surveys. Population-based surveys 
can provide reasonable estimates of HIV prevalence for generalized epidemics, where HIV 
has spread throughout the general population in a country. However, for low-level and 
concentrated epidemics, these surveys will underestimate HIV prevalence, because HIV is 
concentrated in high risk groups and these groups are often not adequately sampled in 
household based surveys. 
In recent years, the number of national population-based surveys that included collection 
of biological specimens for HIV testing has increased. Many of these surveys covered 
women and men of reproductive ages (15-49 year old women and 15-59 year old men) and 
used dried blood spots for specimen collection. Some of the early surveys were designed 
for unlinked anonymous testing, where the HIV test results could not be linked to 
individuals, while more recent surveys have incorporated linked anonymous testing, where 
HIV test results can be linked to behavioral data without revealing the identity of any 
individual who has been tested. 
Strengths 
• In generalized epidemics, population based surveys can provide representative 
estimates of HIV prevalence for the general population, as well as for different 
subgroups, e.g., urban and rural areas, men and women, age groups and region or 
province. 
• Results from population based surveys can be used as a means to adjust estimates 
obtained from sentinel surveillance systems. 
• Population based surveys provide an opportunity to link HIV status with social, 
behavioral, and other biomedical information, thus enabling researchers to analyze 
in more detail the dynamics of the epidemic. Information from this analysis could 
lead to better program design and planning. 
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Weaknesses 
• In population based surveys sampling from households may not adequately 
represent high risk and mobile populations. In low-level epidemics or epidemics 
where HIV is concentrated among high risk groups (e.g., sex workers, men who 
have sex with men, or intravenous drug users), population-based surveys will 
underestimate HIV prevalence. 
• Non-response (either through refusal to participate or absence from the household 
at the time of the survey) can bias population based estimates of HIV. Collecting 
information on non-response can help in the process of making adjustments for 
non-response. 
• Population based surveys are expensive and logistically difficult to carry out and 
cannot be conducted frequently. Typically, these surveys are conducted every five 
to ten years. 
Combining data from sentinel and population based surveys 
Sentinel surveillance and population-based surveys each have strengths and weaknesses 
but together provide complementary information. Sentinel surveillance provides samples 
that are consistent over time so that good estimates of HIV trends can be obtained. They 
can also provide good overall national coverage, and allow estimates to be generated by 
age and geographical location. Population-based surveys, on the other hand, provide much 
better coverage of the general population, including men, and can provide much more 
detailed information on social, economic, sexual behaviour and biomedical factors 
associated with HIV infection. Because of the cost, they can usually not be conducted 
regularly and therefore provide limited temporal coverage. However, in countries where 
both surveys have been conducted, analysis of combined data from sentinel surveillance 
and population-based surveys can provide a clear picture of both overall trends and 
geographical distribution of HIV as well as detailed information on potential risk factors 
and groups. 
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CHAPTER 8 Methods for estimating HIV incidence 
"The purpose of models is not to fit the data but to sharpen the questions" 
Samuel Karlin, 1983549 
Introduction 
In order to understand the dynamics of an epidemic we need to know not only how much 
disease there is in a population but also how it is changing with time. The two most 
fundamental measures of disease, in this regard, are prevalence and incidence, as defined 
in Chapter 5. While prevalence provides a measure of the cumulative risk of infection, the 
incidence of infection gives the rate at which new infections are acquired over a certain 
time period and is therefore a more sensitive measure of the current state of the epidemic. 
Prevalence data provide valuable information on the burden of disease and are essential for 
understanding the health impact of a disease within a community and for assessing the 
need for medical care. Incidence data, on the other hand, give a more immediate measure 
of the current infection rates and are therefore more sensitive to the changing dynamics of 
disease transmission, for making reliable projections into the future and for measuring the 
immediate impact of interventions on infection levels. Incidence data are also more useful 
than prevalence data for exploring causal theories, where the interest is focused on the rate 
of change of cases from the normal (disease-free) state to the diseased state. Furthermore, 
estimates of the risk of acquiring HIV infection are needed in order to establish a research 
infrastructure for designing clinical and vaccine trials. They are required for determining 
sample size and resource requirements, to evaluate the effect of interventions, and to 
identify populations with high transmission rates which could be targeted for future 
intervention trials. 
While many estimates of the prevalence of HIV in South Africa are available in different 
risk groups from annual national antenatal clinic and other sentinel surveillance, 
community surveys, and studies among specific risk groups (Chapter 2, Table 2.1), few 
estimates have been made of incidence. In part this is because prevalence data are easier 
and less costly to collect than incidence data. Whereas prevalence data can be obtained 
from cross-sectional studies, it is more difficult to measure incidence. Ideally, one would 
follow a cohort of people for a year or more to determine the number who became newly 
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infected with HIV during the course of the study. However, very few cohort studies to 
obtain estimates of HIV incidence have been performed in South Africa because of the 
cost, logistics and the ethical considerations of following people to HIV infection. 
Several indirect ways, including mathematical and statistical models, have been developed 
globally to obtain estimates of the incidence of HIV infection, many of which utilize cross-
sectional prevalence data, without having to resort to cohort studies. In this chapter, a 
number of existing methods for estimating incidence are reviewed, and in the following 
chapter two new dynamical mathematical models are described to measure incidence from 
prevalence data, relying on both age-specific prevalence and on trends in prevalence over 
time. The models are used to derive estimates of incidence directly from cross-sectional 
HIV prevalence data in South Africa and are illustrated using data from Hlabisa in 
KwaZulu-Natal. In the chapters that follow a laboratory based method (the Standardized 
Algorithm for Recent HIV Sero-conversion) is also used to estimate incidence and results 
are compared to that of the mathematical models. Finally, the models are applied to other 
data sets from South Africa to further examine HIV incidence rates in the country. 
Review of existing methods to estimate HIV incidence 
Back-calculation methods 
Back-calculation is a method for estimating past infections rates from AIDS incidence data 
and is useful for obtaining short-term projections of HIV incidence and estimating HIV 
prevalence. The methods assume that trends in new AIDS cases reflect existing and past 
trends in HIV incidence. They require reliable estimates of the number of AIDS cases in 
the population over a period of time and a precise knowledge of the distribution of the 
incubation period, from which the incidence rate of HIV infection for some years earlier 
can then be estimated. Because of the need to have reliable estimates of AIDS incidence, 
back-calculation has been used mainly in developed countries. Methods of back-
calculation have not been applied in South Africa because reporting of AIDS cases is 
voluntary and data are too incomplete to be of much use. The methods will therefore not be 
discussed in great detail in this chapter. 
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Statistical models using HIV prevalence data to estimate HIV incidence 
Several statistical models have been developed to estimate incidence from cross-sectional 
age-prevalence data which are widely available in many countries from sentinel 
surveillance designed to monitor the progression of the HIV epidemic among particular 
risk groups such as pregnant women attending antenatal clinics, commercial sex workers, 
injecting drug users, sexually transmitted disease clinic attendees and blood donors. 
Birth cohort methods 
The simplest of these methods is based on the assumption that HIV incidence rates in the 
population are stable over time and that the prevalence in young people increases linearly 
with age. It further assumes that they have not been infected for long enough for significant 
numbers to have died, so that the slopes of the regression lines from repeated samples of 
birth cohorts provide crude estimates of HIV incidence.551"553 
"Podgor and Leske " method 
Various statistical models have been developed in order to estimate incidence after 
adjusting for mortality or cohort effects. For example, Podgor and Leske554 developed a 
method for estimating incidence from age-specific disease prevalence, assuming a steady 
state, but allowing for differential mortality between people with and without disease. The 
method assumes that the overall prevalence, more specifically the force of infection, is 
constant and allows the incidence to be estimated over age bands. 
The model used by Podgor and Leske is based on the functional relation between the 
cumulative incidence or risk (CInc) over a time At and the incidence per unit time (ID), 
CInc = 1 - e "(ID x At) 
where At is the elapsed time between the beginning and end of an age interval. Letting X\ 
be the mortality rate among people without disease, A.j the incidence of disease, and A3 
the mortality rate among people with disease, they show that 
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where PQ is the prevalence at the beginning of the interval and P, is the prevalence at the 
end of the interval.554 The model makes the assumption that the disease/infection is 
irreversible, that individuals with and without disease may have differential mortality rates 
that are assumed to be constant throughout the interval under consideration, and that the 
disease incidence and population composition remain constant during the time period 
being analysed. The main difficulty in applying this method to data from South Africa is 
that the prevalence has increased dramatically over time and is only now starting to 
approach a steady state. 
Saidel and co-workers studied a cohort of initially sero-negative male volunteers in 
Burundi between 1990 and 1993.555 They were able to measure the incidence of HIV 
directly and to validate the method developed by Podgor and Leske. The authors concluded 
that the method provided useful approximations of HIV incidence, particularly in 
countries where HIV prevalence has stabilized. 
Dynamical models 
Dynamical models simulate change over time in the incidence, prevalence and deaths due 
to a particular disease, in this instance HIV and AIDS. The simplest dynamical model 
which captures the essential aspects of these processes for HIV is described in Chapter 3, 
Figure 3.1, in which people enter the model at a rate ft, susceptible people (S) become 
infected (V) at a rate A. times the current prevalence (I/N), and people die of AIDS at a per 
capita rate 8, while the per capita background mortality rate (in the absence of disease) is 
jU. The population growth rate, in the absence of disease, is the birth rate minus the 
background death rate //. For other diseases it may be necessary to include latent class, 
recovery from infection, and so on. The rate at which HIV infection spreads at a population 
level depends on the number of infected people, the number of people who are susceptible 
to infection, the rate at which these two groups make contact, the probability that HIV is 
transmitted per sexual contact, and the life expectancy of infected people. Dynamical 
models can be formulated in terms of differential equations which can be simulated on a 
computer. 
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Many of the dynamical models related to HIV transmission that are described in the 
literature use data on age-specific prevalence of infection and data on the time trends in the 
average prevalence of infection together with assumptions about the form, age dependence 
and survivorship function for people infected with HIV. An example is described below. 
Gregson et al. methods 
Gregson and co-workers described two methods for estimating HIV incidence from age-
specific prevalence data under stable endemic conditions (i.e. constant age-specific HIV 
incidence and HIV related mortality over time).55 In their "cumulative incidence and 
survival" method they calculate the HIV prevalence at any given age as the cumulative 
incidence of new infections at each preceding age, adjusted for mortality. They assume a 
parametric form for the age specific risk of infection and assume that survival after 
infection with HIV follows a Weibull distribution. The model is fitted to the data using 
maximum likelihood methods. Their "constant prevalence method" is essentially the same 
but they do not parameterise the age specific risk of infection. The latter method is less 
tightly constrained than the former but gives substantially wider confidence limits. 
Under the assumption of stable endemic conditions, reasonable estimates of age-specific 
and cumulative incidence were obtained when applied to data collected from antenatal 
clinic attendees in Kampala, Uganda, between 1989 and 1990, while estimates of HIV 
incidence were sensitive to assumptions regarding the length of the survival period. 
Demographic models 
The main purpose of demographic models is to develop population projections in an 
attempt to answer questions about the demographic impact of HIV. Projections are usually 
based on current knowledge about population size and age structure, rates of birth, death 
and migration, and assumptions about how quickly these rates will change. Two such 
examples are described below: 
UNAIDS/WHO methods 
UNAIDS and WHO, with the guidance and recommendations of an external group of 
scientists and researchers (the UNAIDS Reference Group on Estimates, Modelling and 
Projections) have developed a set of methods and assumptions to model epidemic trends, 
to determine annual estimates of HIV prevalence in countries, and to make demographic 
projections of the epidemic.450 For countries with generalized epidemics in which HTV is 
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firmly established in the general population, the Estimation and Projection Package (EPP) 
has been designed as a tool to construct national and sub-national (e.g., urban and rural, or 
provincial) epidemic curves, an essential step in the estimation of levels and trends in the 
epidemic and its impact. 557 
For each defined sub-epidemic, the EPP fits a simple epidemic model to a full set of HTV 
surveillance data points collected from sentinel surveillance sites over time. This produces 
an estimate of the time trend of adult HP/ prevalence for each sub-epidemic, which are 
then combined (using population estimates assigned to the different sub-populations) to 
produce national prevalence estimates and trends. The EPP model incorporates population 
change over time and fits curves to epidemics by varying four parameters (shown in Figure 
8.1): 557 the rate of growth of the epidemic (r); the start year of the epidemic (to); the 
fraction of the population considered to be at risk of infection at the start of the epidemic 
(/b); and a behavioural response parameter which determines the final epidemic prevalence 
(0). It further provides the user with the ability to apply prevalence adjustments to 
surveillance data, or to calibrate the curve using, for example, more representative data 
from national population based surveys. 
<& <& 
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Figure 8.1 Parameters in the EPP model that are varied to produce the best 
fitting epidemic curve 557 
Once epidemic curves are produced in EPP, they are then incorporated into the 
SPECTRUM Projection Package, developed by the Futures Group, to generate estimates of 
national prevalence, incidence and mortality by sex and age groups.451 The Spectrum 
module for HIV/AIDS projections uses the HTV prevalence curve produced in EPP 
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together with assumptions about the epidemiology of HIV, including the ratio of female to 
male prevalence, distribution of infection by age, the survival distribution (assumed to be a 
Weibull function), and the effect of HIV on fertility, to calculate HIV prevalence, 
incidence and mortality by age and sex. It also calculates the number of child infections 
occurring through infections from the mother, child deaths, and the number of orphans as a 
results of AIDS.451 
The SPECTRUM projection package carries out the various calculations as follows: 
i) The number of adults of age (a) and sex (s) that are infected with HIV in any year 
is calculated as 
HrVast = adult population^ x adult prevalencea.Sit 
ii) The number of new infections is calculated as the total number of infections 
expected in year t minus the number of infections surviving from the previous 
year, where the number of infected people that survive from one year to the next is 
the number of infected in the previous year minus deaths from AIDS or other 
causes during the previous year, i.e., 
New HIV infectionsa.s.t = HIVas.t - (HIVa_i.s.t.i - AIDS deathsa.i.s,t-i - non-AIDS death-s^isn) 
iii) The number of AIDS deaths is calculated as a function of the number of new 
infections in previous years and the rate of progression from infection to death: 
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The Actuarial Society of South Africa (ASSA) has developed an age structured AIDS 
model which has been widely used in South Africa to investigate the demographic impact 
of HrV/AEDS in the different provinces, and from which prevalence, incidence and 
mortality estimates have been derived.279'461'558 The ASSA AIDS and Demographic 
projection model is a cohort component projection model*5 which projects the demographic 
In a cohort-component model initial populations for countries or regions are grouped into cohorts defined 
by age and sex, and the projections proceeds by updating the population for each age-and sex-specific group 
according to assumptions about components of population change, such as fertility, mortality and migration. 
Each cohort survives to the next age group according to assumed age-specific mortality rates. Each cohort is 
treated as a homogenous group and average probabilities of birth, death and migration are used. 
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impact of the heterosexual HIV epidemic and has its origins in the Doyle-Metropolitan 
model, first described by Doyle and Millar in 1990 for use in life insurance, health and 
pension applications.375 The model is concerned only with heterosexual and mother-to-
child transmission and it allows for the effect of prevention and treatment programs.559 The 
model is calibrated using the Department of Health's antenatal clinic prevalence data and 
mortality data from the Department of Home Affairs and is adjusted for under-reporting. 
The model splits the population into subgroups depending on risk factors associated with 
the mechanism of transmission of HIV, including age, behaviour group (high risk such as 
commercial sex workers, those who are significantly exposed to HIV through sexually 
transmitted infections or through engaging in risky behaviour, and those who are not 
significantly exposed to HIV), race and geography (provinces).461 The model gives a good 
fit to the antenatal clinic survey data, allows one to make separate assumptions about men 
and women, model population groups separately, and to limit trends in mortality and 
fertility rates over time, limits in-migration, assumes that the HIV survival curve follows a 
Weibull distribution, allows for a bimodal distribution of paediatric HIV survival, and 
disaggregates a 'contagion matrix' in the model into more measurable and controllable 
parameters of heterosexual behaviour. 
Laboratory methods 
Laboratory methods have been developed for determining incidence through detecting and 
distinguishing recent HIV infections from long term infections. A variety of approaches 
and assays have been described in the literature. While some methods use the measurement 
of HIV p24 antigen or HIV RNA in the absence of HIV antibodies560"563 (i.e., before 
antibody seroconversion) to indicate that an infection has been acquired recently, other 
approaches are based on qualitative and quantitative differences in the evolution of HIV 
antibodies following sero-conversion. An example is the use of a sensitive/less-sensitive 
serological algorithm to determine antibody levels and to infer the likelihood that an 
infection was recently acquired (standardized testing algorithm for recent HIV-1 
seroconversion, or STARHS). To overcome some of the limitations of the sensitive/less-
sensitive assays, which include variability in the window period and subtype-dependent 
performance, the BED-EIA was recently developed to detect HIV infection by measuring 
the increase in HIV immunoglobulin G (IgG) as a proportion of the total IgG following 
seroconversion.5 4 These four types of assays (p24 antigen, HIV RNA, STARHS, and 
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BED-EIA) are the most advanced in terms of calibration, validation and application for 
measuring incident HIV-1 infections, and will be described in more detail below, while 
other methods have been proposed or are under development.5 
p24 antigen and HIV-1 RNA 
In 1995 Brookmeyer and Quinn560 described the use of p24 antigen to determine HIV 
incidence in a cross-sectional study in which 1900 people were tested for HIV in India.566 
The approach is based on testing HIV negative individuals for HIV-1 antigen (p24) to 
identify individuals in the window period which corresponds to the time between exposure 
to HIV and appearance of detectable HIV antibodies. Detection of p24 antigen, prior to 
development of specific HIV antibodies indicates recent infection. The prevalence of p24 
antigen together with the mean duration of the p24 antigen period (i.e., the time between 
the appearance of the p24 antigen and the appearance of HIV antibodies) can be obtained 
from a cross-sectional survey and under the assumption that the epidemic has reached a 
steady state, incidence can be obtained from the relation 
p ~ Ixfi 
or I ~ p I ju 
where I is the current HIV incidence rate, /u is the mean duration of the p24 antigen-
positive pre-seroconversion period and p is the proportion of HIV seronegative individuals 
with p24 antigens. A confidence interval for the incidence rate can be calculated under the 
assumption that the number of individuals who are in the p24 antigen-positive pre-
seroconversion period follows a Poisson distribution with expectation n-I-ju, where n is the 
total number of individuals in the cross-sectional survey who tested negative for HIV 
antibodies and who were tested for p24 antigen. 
The main source of uncertainty in this method is the estimation of the duration of the p24 
antigen period, and large samples are required to obtain reliable estimates. The duration 
has been reported to be short, of the order of 1-2 weeks to about 1 month, which makes it 
difficult to capture enough people in this phase to obtain incidence estimates with 
reasonable confidence.566 
The above concept has been extended to the more sensitive detection of HIV-1 RNA in 
antibody negative individuals with early infection, using specimen pooling and HIV RNA 
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reverse transcriptase-polymerase chain reaction (RT-PCR) tests.563 HIV Nucleic acid-
based testing has been widely used for blood bank screening in the United States.563'5 5 
"Detuned" ELISA 
The Standardized Testing Algorithm for Recent HIV Sero-conversion (STARHS) is based 
on a sensitive/less-sensitive enzyme-linked immunosorbent assay (ELISA). Generally, 
blood samples are tested for HIV using a standard ELISA. Those samples that test positive 
in the standard assay are re-tested, usually in triplicate, using a less-sensitive (LS) ELISA 
to discriminate between recent and old seroconverters. Samples that are positive on the 
standard sensitive ELISA and with standardized optical density below a certain prescribed 
cut-off value, are classified as recent infections.567'568 After STARHS testing, the annual 
incidence (/) can be calculated as: 
. n 365 irvrv 
/ =-, r XlOO 
(m + n) T 
where n is the number of infections classified as recent and m is the number of people who 
are HIV negative on the sensitive ELISA. The window period, T, is the mean number of 
days between the detection of sero-conversion using the two tests. The value of T and the 
appropriate optical density (OD) cut-off for the LS assay depends on the sensitivity of the 
LS assay and on the HIV-1 subtypes that are prevalent in the tested population. A window 
period of about 200 days for an OD cutoff of 0.45 has been recommended for HIV 
subtype C infection by the CDC. Chapter 10 reports on the use of the STARHS method 
and compare this method to a mathematical model developed to estimate incidence from 
age-prevalence data. 
BED-Enzyme Immunoassay 
The IgG-Capture BED-EIA was developed in the CDC laboratories in the USA to detect 
recent HIV seroconversion.564'569'570 The BED-EIA indirectly measures the increasing 
proportion of HIV-IgG in a given blood specimen with respect to total IgG to determine 
the time that has elapsed since HIV infection. To overcome the problem of subtype-
dependent performance (one of the limitations of the sensitive less-sensitive assays), the 
BED-EIA was designed by using a branched gp41 peptide with sequences derived from 
multiple subtypes (B, E and D) to achieve similar performances with different subtypes. 
The assay has been shown to be stable with minimal variation between runs of the assay." 
The method has been applied to specimens from several cross-sectional studies to estimate 
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incidence, including populations from Uganda, Zimbabwe and Ethiopia, an injecting drug 
user population from Bangkok571 and stored surveillance specimens from Cambodia 
(unpublished). Results from these countries were reported at a UN AIDS Reference Group 
meeting in December 2005 and indicated that the BED assay requires further validation 
and calibration before recommending it for routine testing.4 
Discussion 
A recent paper by Shelton et al., ~ assessing trends in prevalence of HIV infection 
worldwide, emphasized the importance of estimating incidence but saw no easy way of 
doing this. Given the time lag between incidence and prevalence they conclude that 
"assessing prevention activities on the basis of prevalence is a perilous undertaking -
literally 'behind the curve'." They further describe incidence as the gold standard for 
assessing prevention efforts. However, incidence is difficult to measure directly because 
of the logistical and ethical considerations when following people until sero-conversion 
and as a result, several methods have been developed to estimate incidence indirectly, 
some of which are described in this chapter. 
Many of the existing mathematical models described in the literature ignore certain key 
epidemiological parameters, such as variables related to the primary route of transmission. 
A further limitation of many of the models is the assumption that the disease incidence and 
population composition remain constant over time. Many of the dynamical models 
described in the literature are therefore limited to stable epidemic conditions. Methods of 
back-calculation require good AIDS data and in countries such as South Africa where 
reporting of AIDS cases is voluntary, data are usually too patchy and incomplete to be of 
use.573 
While statistical and mathematical models can be used to estimate population estimates of 
incidence they cannot be used to identify those individuals who have recently sero-
converted. The advantage of laboratory methods for determining incidence is that it can be 
used to determine whether or not a specific individual infection has been acquired recently. 
Several laboratory methods based on either HIV antigen, RNA or HIV antibodies have 
been developed and some are still being tested. Limitations of the laboratory techniques 
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are mainly associated with poorly defined cut-offs and window periods for different viral 
subtypes. 
Statistical and mathematical models are extremely important for estimating HIV incidence 
but because of assumptions regarding key parameters that cannot always be determined 
directly from raw data, there is always a degree of uncertainty around the estimates, and 
they should therefore be interpreted cautiously. However, Shelton et al.51 point out that 
because the history of HIV is well understood, changing assumptions are unlikely to 
change overall pattens. 
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CHAPTER 9 Developing dynamical models to estimate HIV 
incidence using time trends and age-specific prevalence data in 
South Africa 
"Sensibly used, mathematical models are no more, and no less, than tools 
for thinking about things in a precise way" 
Roy Anderson and Robert May, 1991435 
Introduction 
Many of the models described in the literature to estimate HIV incidence ignore certain 
key epidemiological parameters such as variables related to the primary route of 
transmission, which in South Africa is via sexual activity. Many assume that the incidence 
and population composition remain constant over time. To overcome some of these 
limitations, and for specific application to the South African HIV epidemic an extended 
dynamical model has been developed for estimating HIV incidence rates in epidemic 
situations from data on age-specific prevalence and changes in the overall prevalence over 
time. The model allows for changing force of infection, age-dependence of the risk of 
infection and differential mortality. It uses maximum likelihood methods to obtain age-
specific incidence rates while error estimates are obtained using a Monte Carlo procedure. 
To illustrate the model, the method is applied to data collected from women attending 
antenatal clinics in the rural district of Hlabisa in KwaZulu-Natal. 
It is often the case, however, that age-specific prevalence data are not available, as in the 
case of the national antenatal clinic surveillance data reported by province. In the absence 
of such age-specific prevalence data, another model was developed to estimate incidence 
using only the trends in the prevalence of infection over time. In this chapter it is applied to 
time trend data from Hlabisa and in Chapter 11 it is applied to data from national antenatal 
clinic surveillance to obtain provincial estimates of HIV incidence. 
The study population 
Modelling HIV incidence rates is illustrated here using seroprevalence data on 590 women, 
age 15 to 49 years, who attended antenatal clinics in Hlabisa between December 2000 and 
February 2001. Hlabisa has a well developed clinical service and provides antenatal care 
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through the local hospital, village clinics and mobile clinics to about 95% of pregnant 
women in the district.574 Between 1992 and 2002, anonymous HIV seroprevalence surveys 
were conducted annually among women attending antenatal clinics in the area. The 
antenatal prevalence, which mirrors the results for the whole province, increased from 
4.2% in 1992 to 38.2% in 2001 (Table 9.1) and a logistic regression gave a good fit to the 
data with an intrinsic doubling time in the early stages of the epidemic of 15 months, as 
shown in Figure 9.1. The observed age-specific prevalence rates for 2001, which are used 
for illustrating the dynamical models are shown in Table 9.2 and Figure 9.2. 
Table 9.1 Prevalence of HIV infection among antenatal clinic attendees, aged 15-
49inHlabisa; 1992-2001 
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Figure 9.1 Prevalence of HIV among women attending antenatal clinics in 
Hlabisa fitted to a logistic curve. The doubling time at the beginning of the 
epidemic was 15 months and the asymptotic prevalence 39.2% 
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Table 9.2 The number of women in Hlabisa who were tested for HIV 
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Figure 9.2 The age-specific prevalence of HIV infection fitted to the model 
described here. Error bars are 95% binomial confidence limits. 
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Model 1. Modelling the age-specific prevalence 
The simplest way to estimate the age-specific incidence from age-specific prevalence data 
would be to assume that for newly infected young people, among whom the AIDS related 
mortality is still low, the slope of the prevalence curve gives an estimate of the incidence. 
This clearly does not apply in the older age groups and we can improve the estimate by 
making two corrections. The slope of the age-prevalence curve is the prevalence at age a at 
time t minus the prevalence at age a - 1 at time t - 1. To obtain the incidence, the 
prevalence at any age a - 1 must be reduced by the amount by which the prevalence has 
increased and by the proportion of people who have died due to AIDS related diseases in 
the last year. The incidence at age a at time t, I{a,t) is then 
l{a,t) = P{a,t)-P{a-U)^Z^-^U 9.1 
where P(a,t) is the age-specific prevalence at age a at time t, P(t) is the average adult 
prevalence at time t, and ju is the AIDS related mortality per year. To get the incidence per 
susceptible person in the population the estimate given by Equation 9.1 must be divided by 
1- P(a), the proportion who are susceptible at age a. To determine the age-specific 
incidence Equation 9.1 could then be applied to the age specific prevalence given in Table 
9.2. However, while this approach would give reasonable estimates of the age-specific 
incidence it assumes that the survivorship function of those with HIV infection is 
exponential and it does not allow for the fact that infections in those of age a will have 
been acquired over several of the preceding years. 
A more general model was therefore developed that allows one to relate P(a,t), the 
prevalence of infection among women of age a at time t, to the incidence.33 Details are 
given in Appendix 9.1 where it is shown that the prevalence in people of age a at time t is 
P(a,t)= C M 9.2 
c(a,t) + s(a,t) 
where c{a,t), the proportion of infected people, and s(a,t), the proportion of susceptible 
people of age a at time t, are given by 
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-j7(a,?)dfl 
s{a,t) = e ° 9.3 
c(a,f)=Je" /(5,0e rf5 9-4 
0 
In these equations f(a,t) is the incidence of infection among those of age a at time t and 
ju(a,a)is the AIDS related mortality of someone at age a who was infected at age a . 
Equation 9.3 gives the probability that a person who has reached age a remains uninfected. 
In Equation 9.4 the last term under the first integral sign gives the probability that a person 
remains uninfected at age a , the last but one term gives the probability that they became 
infected at age a , and the first term gives the probability that they then survived from age 
a to their present age a. These events are summed over all possible ages at which the 
infection could have occurred. In Appendix 9.1 it is shown that this result does not depend 
on the background mortality rate. 
The procedure is then to parameterise j{a,f) and ju(a,a), and use Equations 9.2 to 9.4 to 
get the best fit to the data and hence the best fit values of f(a,i), the age specific incidence 
at time t. Because a parametric model is used the parameters can be varied in order to 
determine confidence bands and intervals for any derived functions or estimates. 
Parameterising the model 
In order to parameterise the age incidence function f(a,i), it is assumed that the age and 
time dependence can be separated so that 
f(a,t) = R(a)P(t) 9.5 
where R(a), the relative risk of infection with age is constant over time, and P(t), the 
average adult prevalence is independent of age. If data were available on age matching of 
partners, on how sexual activity varies with age and so on, more sophisticated expressions 
could be used forj{a,t). 
In order to parameterise the age-risk function, which will be proportional to the age 
incidence under this model, a function is needed that approximately matches that of age-
specific prevalence (Figure 9.2) and fertility (Chapter 6, Figure 6.1), i.e., a function that is 
zero, or very small, before the age of onset of sexual activity, increase rapidly as sexual 
activity increases and then decreases among older people. The log-normal function, 
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with off-set a0, mean m, standard deviation cand normalised to N, has these properties. 
It is also necessary to parameterise P(t) which describes the change in overall prevalence 
with time. The available data were obtained from antenatal clinic surveys carried out over 
the past ten years. In the early years of the epidemic the prevalence of HIV infection 
increased exponentially140 and a logistic function of time gave a statistically good fit to the 
overall prevalence. However, by 2000 it was clear that the epidemic was approaching a 
plateau and a logistic function with a variable asymptote was used to fit the overall 
prevalence data, as shown in Figure 9.1. Finally, the best form for the mortality as a 
function of time since infection, ju(a,a), had to be decided on. The UN AIDS Reference 
Group on Estimates, Modelling and Projections, based on data from the CASCADE 
collaboration575 and mortality data from Uganda576'577,Thailand578'579 and Haiti,580has been 
recommending the use of a Weibull survival distribution with a median survival time of 9 
years for modelling AIDS deaths in developing countries in the absence of treatment.450 
The CASCADE collaboration575 (providing an extensive analysis of time from HIV-1 
seroconversion to AIDS and death in Europe, North America and Australia) showed that a 
Weibull survivorship gives a very good fit to available mortality data, and that survival 
declines linearly with age at infection, while it does not depend on gender or mode of 
transmission. For people infected with HIV at 10 years of age the median survival is 14.6 
years, while for people infected at 60 years of age it is 6.2 years.581 For all ages the shape 
parameter is close to 2.28. In this model the survival time was scaled to a median of 9 
years at age 30, which thereafter declines linearly with age. 
Fitting the data and estimating errors 
A visual basic programme in an Excel spreadsheet was written to carry out the fitting 
procedure, as follows: The model given by Equations 9.2 to 9.4 is fitted to the data taking 
as inputs the age-specific prevalence of HIV, the fitted values of the prevalence over time 
and the survivorship, as described above. The parameters N, m, a, and a0 are then varied to 
obtain the maximum likelihood fit to the age-specific prevalence of HIV using binomial 
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error estimates.520 The model gave a good fit to the data as shown in Figure 9.2. Using the 
parameter values to calculate f(a,t) gives the age-specific incidence shown in Figure 9.3. 
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Figure 9.3 The age-specific incidence of HIV infection. Red line: incidence per 
susceptible; blue line: incidence per person alive at a given age both obtained using 
the model described in this chapter. 
To determine confidence limits for estimates of the age-specific and mean incidence the 
Clayton and Hills method582 was followed. They defined the 'supported range' for a set of 
parameter estimates as being the range of parameter values, p ,for which the deviance 
D = -21n Lip) 
I(p). 
exceeds a predetermined critical value, and where p is the set of parameter values that 
maximise the likelihood, L. Since D asymptotically follows a £ distribution with n 
degrees of freedom where n is the number of variable parameters in the model, setting the 
critical value for the supported range to Xn (0.05) gave an approximate 95% confidence 
interval. To determine the corresponding confidence limits for the derived curve, the 
parameters p were varied over the parameter space to determine the family of curves 
corresponding to the supported range of the parameters. While the parameter space could 
be explored over a regular grid, a more efficient approach was to use a Monte Carlo 
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method. The maximum likelihood fit enabled the calculation of a covariance matrix of the 
coefficients.17 Normally distributed random numbers were then generated from the 
multivariate distribution specified by the covariance matrix. For each set of parameters the 
deviance was calculated and tested to see if it falls within the supported range. 
Having generated a sufficient number of runs for which the deviance fell within the 
supported range, typically about 1,000, the maximum and minimum values of the 
incidence at each age and of the overall incidence were determined for these runs. These 
extreme values then gave the estimated 95% confidence intervals for the curve and limits 
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Figure 9.4 The annual age-specific incidence per susceptible with 95% confidence 
intervals. 
Model 2. Estimating incidence using only time trends in prevalence 
In the absence of age-specific prevalence data, incidence can be estimated using only the 
time trends in the prevalence of infection, i.e. from data such as those presented in Figure 
9.1. If there were no deaths then the incidence would be given directly by the slope of the 




Assuming a Weibull survivorship, W(t), the probability that people die a certain number of 
years after they are infected can be calculated by 
Since deaths will lead to a decline in prevalence it is necessary to add to the estimate of 
incidence the decline in deaths due to all previous incident infections so that 
l(f) = /0(f)+ f P(t)M(t-t)dt 
J—oo 
However, when time trends in prevalence among women attending ante-natal clinics are 
used to estimate the incidence in such women a correction must be made for the fact that 
the sample of women represents a narrow range of ages. For example, the age distribution 
of pregnant women in South Africa from the antenatal clinic survey in 2001 is shown in 
Figure 9.5 below. These data can be approximated reasonably well by assuming that 
women enter the sample at age 16 years and leave at a constant rate of p = 7% per year. 
At any given time, therefore, infected women are leaving the sample (and being replaced 
by 16 year old women, none of whom are infected) at a rate p per year so that it is 
necessary to correct the incidence by this amount and a better approximation is 
I2(t) = Il(,t) + pP(t) 
This gives the incidence per person in the sample. To obtain the incidence per susceptible 
person the above equation is divided by the proportion of the population that are 
susceptible, which gives the equation 
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Figure 9.5 Number of women attending antenatal clinics in South Africa in 
2001. The fitted curve is a log-normal function off-set by 12.7 years, with a 
mean at 23.4 years and a standard deviation of 0.691. A least squares fit was 
applied to the data up to the age of 40 years. Errors are 95% Poisson confidence 
limits (Data source: Antenatal clinic data, Department of Health) 
Results 
Model 1 
A dynamical model using age-specific prevalence which allows for all past infections, 
changes in prevalence over time, and a Weibull survivorship probability for those infected 
with HIV, gave the results shown in Figures 9.3 and 9.4. The best estimate of the average 
annual incidence per susceptible in the Hlabisa ANC population aged 15-49 in 2001, 
standardised to a uniform age distribution, was 7.1% (5.5%-9.3% per year). Standardizing 
this result to the observed population distribution the average incidence per person was 
8.1% (5.6%-11.3%), and standardizing to the age distribution of women attending 
antenatal clinics the average incidence per person was 9.9% (7.3%-13.1%). The annual 
incidence of infection per susceptible increased from 5.5% (2.9%-8.4%) at age 15 years to 
12.3% (9.4%-15.91%) at age 21 years and declined to 2.0% (0.5%-5.6%) at age 50 years. 
Incidence by 5-year age groups are shown in Table 9.3. 
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Table 9.3 Estimated HIV incidence by age for women in Hlabisa in 2001 
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When applied to the Hlabisa time trend data shown in Figure 9.1, the HIV incidence using 
method 2 was 9.6%, which is very close to the incidence estimate of 9.9% using method 1 
(standardized to the age distribution of the ANC population), confirming the extremely 
high incidence rates in this rural community in KwaZulu-Natal. Age-specific incidence 
rates cannot be obtained using method 2 because of the lack of age-prevalence data. 
Discussion 
In the absence of cohort studies to measure incidence directly, several methods have been 
developed for indirect estimation of incidence, some of which are described in Chapter 8. 
In this chapter, two new dynamical models are described that have been developed for 
specific application to the epidemic in South African which, at the time of developing the 
model, was still showing an increase in the levels of infection. The first model estimates 
incidence from age-specific prevalence data and changes in the overall prevalence over 
time. It allows for changing force of infection, age-dependence of the risk of infection, and 
an AIDS related mortality function that is both time and age dependent. 
The second model was developed to estimate incidence from data on time trends in the 
prevalence of infection. This model is particularly useful for application to data sets where 
prevalence data are available over time, but age-specific data are not available, as 
sometimes the case for ANC data (e.g., national ANC surveillance data are reported by age 
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and by province, but provincial data are not provided by age). 
The two dynamical models were developed and tested using data from antenatal clinics in 
Hlabisa, KwaZulu-Natal, and show extraordinarily high incidence rates among women in 
this rural area. There is considerable debate as to the extent to which antenatal clinic data 
under or over estimate the prevalence among all adult women. Since the antenatal clinic 
data include only women who are pregnant, and hence sexually active, the ANC 
surveillance may overestimate the population prevalence among younger women. At the 
same time, it may underestimate prevalence among older women, in whom HIV and other 
sexually transmitted infection could cause infertility. If this is indeed so the incidence 
estimates are likely to be too high for the younger women and too low for the older 
women. There is evidence from sub-Saharan African countries that HIV surveillance 
among women attending antenatal clinics provides a good approximation of the magnitude 
of the infection in the general population.531 However, prevalence data from Hlabisa in 
2000 to 2002 indicated that ANC prevalence might be overestimating estimates in the 
general population (Chapter 7), although this needs further investigation. 
The two methods described here give estimates of overall HIV incidence among women in 
Hlabisa in 2001 that are very close; an average standardized estimate of 9.9% using the 
first model and an estimate of 9.6% using the second model. This gives us confidence in 
using both models as a way of estimating incidence indirectly. 
Probably the most important limitation of the first model is the assumption of 
homogeneous mixing which allows us to separate the risk of infection into a term that 
depends only on age and a term that depends only on the overall population prevalence at a 
given time. Anderson and May435 point out that heterogeneity in degrees of sexual activity 
tends to result in fewer infections. To obtain the same prevalence with heterogeneous 
mixing should therefore require higher incidences so that these estimates are more likely to 
be under estimates rather than over estimates. 
The use of a log-normal age-risk function seems reasonable as it matches both the age-
specific prevalence function and the age specific fertility. However, other functions will 
produce different estimates of incidence and it is important to consider the biases that may 
arise from the use of the log-normal distribution. If the age-risk function is either 
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monotonically increasing or constant with age, then the age-prevalence must be 
monotonically increasing so that the data exclude functions of this form. A normal 
distribution declines too rapidly at older ages and extends too far at younger ages. An off-
set Weibull583 distribution function, which like the log-normal is exponentially skewed to 
the right, also gives a good fit to the data but the difference between the estimated age-
specific incidence for this model and for the log-normal model is less than 20% of the 
random errors, as estimated by the confidence inervals in Figure 9.4, so that the differences 
in the two functional forms change the estimates of incidence by considerably less than 
the uncertainty due to the random errors. With sufficiently precise data one could use the 
procedure outlined here to determine the form of the age-risk function. Direct 
measurements of the relative risk of infection as a function of age would also make it 
possible to define the age-risk function independently but the purpose of the procedure 
outlined here is to determine the age-specific incidence without having to do extensive 
cohort studies. Where such data are available it would nevertheless be interesting to 
investigate the functional form of the age-risk function which could then be used in 
analyses such as this. This analysis also shows the importance of collecting prevalence data 
for very young people. Since the prevalence at a given age depends on the cumulative risk 
up to that age, it is important to be able to determine the risk-function precisely for all 
younger ages. 
In the absence of any good cohort data on survival time from HIV infection to death in 
South Africa, it seems reasonable to assume a Weibull survivorship function with median 
survival time of nine years (i.e., in the absence of treatment) in the model. This assumption 
is consistent with the UNAIDS Reference Group on Estimates, Modelling and Projections 
recommendation450 which is based on data and findings from three major cohort studies on 
adult survival in Thailand,578'579 Uganda577 and Haiti,580 and data from pre-ART era cohort 
studies in industrialized countries, including the CASCADE collaboration.575 Few studies 
have been done in South Africa to assess the average survival time of adults after infection 
with HTV, with the exception of some studies in clinical settings to assess survival of 
patients from a certain clinical stage (e.g., onset of AIDS, or CD4 cell count below a 
certain level) after presenting to a clinic, showing that survival in untreated cohorts was 
similar to that of cohorts in the USA.584'585 
It would clearly be desirable to obtain direct measures of incidence from cohort studies. To 
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obtain the same statistical precision as in this study (i.e. approximately 10% ± 2%, overall) 
from a cohort study would require approximately 1,600 HIV-negative people who would 
then be followed up for at least one year. In the absence of direct measures of incidence 
the next best approach may be to use laboratory methods which are further explored in 
Chapter 10. If it is assumed that a method such as this gives the number of people who 
have sero-converted in the last three months this would require a sample of about 6,400 
people to obtain the same precision. Clearly, the approach suggested here is very attractive 
but, being an indirect measure, does rely on assumptions about the form of the age-risk 
function. Where direct measures of incidence have been made it would be very interesting 
to compare them with the results obtained using the method described here. 
In summary, the analyses illustrated in this chapter provide useful measures of the 
incidence of infection which is a key aspect of the transmission dynamics of HIV infection. 
When applied to the Hlabisa data set, the procedures provide plausible estimates of age-
specific incidence rates, which are essential for the planning of future studies in this area. 
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Appendix 9.1 Age-specific prevalence in terms of age-specific incidence 
Let the probability, per unit time, that a susceptible person of age a becomes infected at 
time t bef{a,t). Then, if the background mortality is S(a,t), the proportion of people who 
are born susceptible and survive to age a at time t among those who are not infected with 
HIV, 
-}{f{a,t)+S{a))da 
s{a,t) = e ° Al 
The proportion of cases who are infected at age a to a + da at time 7 to 7 + d7 and then 
survive to age a at time t, 
c{a,T)da = e - f i ( ^Ma.5 )^ / ( 5 r ) e - j 0
s ( / ( a , -M*^ A 2 
where ju(a,a) is the excess mortality due to HIV infection of someone who was infected 
at age a and is now of age a. In Equation A2, the last term is the probability of surviving 
and remaining uninfected up to age a , the last but one term is the probability of being 
infected at age a , and the first term is the probability of surviving with HIV from age a to 
age a. The probability that a person is alive and infected at age a is obtained by integrating 
Equation A2 over all ages up to a so that 
/ \ -\n8{a)da f -\~u(a,a)da r/„ ~\ -L f[a,i)da ,_ c{a,t) = e Jo w Je Jfl f{a,t}Q J° da A3 
0 
When using Equations Al and A3 to determine the prevalence of infection the terms 
containing the background mortality S(a) cancel giving Equations 2 to 4 in the text. To 
estimate the incidence requires parameterised expressions forf(a,t) and fi{a,a), so that 
the parameters can be varied to get the maximum likelihood fit to the age-specific 
prevalence as discussed in the text. 
CHAPTER 10 Measuring the incidence of HIV in KwaZulu-
Natal using a standardized testing algorithm for recent HIV 
sero-conversion (STARHS) 
"Equations are more important to me, because politics is for the present, but an 
equation is something for eternity." 
Albert Einstein586 
Introduction 
Cross-sectional measurements of HIV prevalence are carried out routinely and form the 
basis of epidemic forecasting models and impact assessments. Much more powerful 
analyses can, however, be done using measurements of age-specific incidence, as they 
provide information on the current rates of infection rather than the rates averaged over 
some time period. Reliable age-specific incidence data can make it possible to forecast the 
course of the epidemic with greater confidence, identify particular risk groups and assess 
the impact of interventions. As pointed out in previous chapters, incidence is best 
measured in cohort studies but these are expensive and time consuming, and raise many 
ethical problems. Several alternative, indirect, methods have been developed to estimate 
the incidence of HIV, including statistical and mathematical models as described in 
Chapters 8 and 9, and the use of novel laboratory techniques. The laboratory techniques 
include a variety of approaches that commonly rely on the properties of early HIV 
antibodies after seroconversion.570 The sensitive/less-sensitive testing strategy (the 
"detuned" assay) was first developed by Janssens et al.567 to provide a simple laboratory 
tool to detect recent seroconversion in a cross-sectional population. They observed that 
recently developed HIV tests could detect antibodies sooner than the older tests and 
created a test that is deliberately less sensitive so that the two tests would detect 
seroconversion at different times. The "Standardized Testing Algorithm for Recent HIV 
Seroconversion" (STARHS),420'567'568'587 based on differential antibody titres in recent 
versus long-term infections, is the topic of this chapter. 
In Chapter 9 it is shown that temporal or age-specific changes in HIV prevalence can be 
used to estimate the incidence of HIV infection. Such estimates generally depend on 
assumptions regarding the parametric form of the age-specific risk of infection, the 
survivorship as a function of the time since sero-conversion, and the overall change in 
prevalence with time. Furthermore, these methods give population estimates of incidence 
and cannot be used to identify those individuals who have recently sero-converted. The 
advantage of laboratory methods for determining incidence, such as the STARHS method, 
is that it can be used to determine whether or not a specific individual infection has been 
acquired recently. The ability of the sensitive/less-sensitive testing strategy to differentiate 
persons with early infections from those with later infection is essential, not only to 
provide timely estimates of incidence in cross-sectional studies, or for the study of 
population dynamics and for guiding HIV prevention programs, but also for clinical care. 
Once antiretroviral therapy becomes widely available identification of individuals with 
early infection will become increasingly important, both to improve opportunities for 
providing early therapy and to prevent opportunistic infections. 
The first aim of this chapter is to estimate the incidence of HIV infection among women 
attending antenatal clinics in rural KwaZulu-Natal using STARHS, which relies on the rise 
in HIV antibody levels over several months after infection so that those who have recently 
sero-converted have low antibody titres. The second aim is to compare the STARHS 
estimates to estimates of HIV incidence independently obtained from age-specific 
prevalence using the mathematical model described in Chapter 9. 
Methods 
Study population 
The data for this study were collected in 1999 in the Hlabisa district of northern KwaZulu-
Natal as part of the MRC research in this area. Antenatal care in Hlabisa is provided by the 
local district hospital, ten community clinics and two mobile clinics where about 95% of 
pregnant women in the district receive antenatal care. Blood samples were taken from a 
random sample of 2,623 women, aged 15 to 49 years, attending antenatal clinics and tested 
anonymously for HIV-1 prevalence and incidence. 
Laboratory methods 
Serum samples were initially stored at 4°C and were frozen at -20°C within 48 hours. 
Frozen samples were shipped on dry ice to the Viral and Rickettsial Disease Laboratory, 
Department of Health Services, California for the independent assessment of early 
infection using the STARHS. Following HIV testing using a standard ELISA, the 
STAHRS was applied using two HIV-1 ELISAs approved by the Food and Drug 
Administration (FDA). To make the ELISAs less-sensitive and so discriminate between 
recent and old sero-converters, the first ELISA (3A11, Abbott Laboratories, Abbott Park, 
111) was modified by a) increasing the initial sample dilution from 1:400 to 1:20,000; b) 
reducing the sample incubation time from 60 minutes to 30 minutes; and c) reducing the 
conjugate incubation time from 120 minutes to 30 minutes. The second ELISA 
(Vironostikaa HFV-l Microelisa, Organon Teknika, Raleigh, NC) was modified by a) 
increasing the sample dilution from 1:76 to 1:20,000; b) reducing the sample incubation 
from 100 minutes to 30 minutes while retaining the kit-specified conjugate incubation time 
of 30 minutes. Both assays were supplemented with HIV-1 LS-EIA calibrator plasma 
(CAL), low positive control (LPC), high positive control (HPC), and a 
proficiency/calibration panel made up of five specimens with pre-determined antibody 
levels, obtained from the Centers for Disease Control, Atlanta GA (CDC). Controls were 
run in triplicate and the standardized optical density (SOD) was calculated as SOD = 
(sample OD - average negative control OD)/(average CAL OD). Samples that were 
positive in the standard sensitive assay and had an SOD below 1.5 in the less-sensitive 
(LS) assay were re-tested in triplicate using the LS assay. The average SOD was then 
calculated as (average sample OD - average negative control OD)/(average CAL OD). 
Samples with an average SOD below the prescribed cut-off, 0.45 for subtype C, were 
classified as recent infections. 
Comparison between the Abbott and Vironostikaa ELISA 
The study was started using the FDA approved Abbott ELISA. However, halfway through 
the study this assay was removed from the market because of an FDA ruling against 
Abbott and the Vironostikaa assay was used instead. A subset of the samples (n = 240) 
were re-tested with both assays to establish the comparability of the results. Using a cut-
off of 0.45 for classification of recent sero-converters, the two assays agreed on 95.4% 
(95% CI: 92.7 - 98.1%) of the total sample. Compared to the Abbott assay the 
Vironostikaa assay had a sensitivity of 98% (95% CI: 96.2 - 99.8%) and a specificity of 




There is a time after infection with HIV that antibodies to the virus are not detected in a 
person. The appearance of detectable antibodies is called "sero-conversion". The time from 
sero-conversion on the sensitive test to sero-conversion on the less sensitive test defines 
the "window period".588 Sero-conversion on the less-sensitive test means that the standard 
optical density (OD) measured by the test rises above a pre-specified cut-off. The window 
period varies from person to person, but the mean can be adjusted by varying the OD cut-
off. If a specimen from an HIV-infected person tests positive on a sensitive test and 
negative (below the OD cut-off) on a less-sensitive test, one can conclude that the person 
was infected within a known time window. 
After STAHRS testing the annual incidence, /, is calculated as: 
where n is the number of infections classified as recent (i.e., n people reacted to the 
sensitive but not to the less-sensitive ELISA) and m is the number of people who are HIV 
negative on the sensitive ELISA.567 The window period, T, is the estimated mean number 
of days that would elapse between the detection of sero-conversion using the sensitive and 
the less-sensitive tests. The value of T depends on the sensitivity of the detuned test and 
the initial detuned ELISA was designed to give a value of 200 days using the cut-off 
recommended for HIV subtype C by the CDC. For the STARHS estimates of incidence, 
95% confidence limits were calculated assuming binomial errors. 
Mathematical model 
The mathematical model described in Chapter 9 was used to estimate age-specific 
incidence from measurements of age-specific prevalence and changes in overall prevalence 
with time in an epidemic situation. To validate STARHS, the mathematical model was 
used, completely independently, to estimate the incidence of infection from prevalence 
data for the same blood samples. 
Briefly, the model uses maximum likelihood methods to obtain age-specific incidence rates 
while error estimates are obtained using a Monte Carlo procedure. A simplifying, but not 
essential, assumption is that the risk of acquiring infection is determined by the product of 
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the force of infection, which is proportional to the overall prevalence at any time, and an 
age-risk function, which is determined by the likelihood that people will engage in high 
risk sex as a function of age, i.e. 
f(a,t) = R(a)P{t) 
where R(a) is the relative risk of infection with age, and P(t) is the average adult 
prevalence independent of age. 
The age-risk function is assumed to be zero below a certain age because most data sets for 
South Africa show that the prevalence of infection among girls younger than 15 years is 
either zero or is very low. The prevalence of infection among girls older than 15 years 
increases rapidly, reaches a peak between the ages of 22 and 25 years, and then decreases 
with age. An off-set log-normal function (Chapter 9, Equation 9.6) has this general form 
and was therefore chosen to parameterize the age-risk function. 
The function P(t) describes the overall prevalence with time, which is available from the 
antenatal clinic surveillance data in Hlabisa from 1990 onward (shown in Chapter 9, Figure 
9.1). In the early years of the epidemic the prevalence of HIV infection increased 
exponentially and a logistic function of time gave a statistically good fit to the overall 
prevalence. However, by 2000 it was clear that the epidemic growth rate was slowing and 
a logistic function with a variable asymptote has been used to fit the overall prevalence 
data. 
A Weibull survivorship function was used to describe the median survival of people 
infected with HIV. As described in Chapter 9, survival declines linearly with age at 
infection. In the model we assumed a shape parameter for all ages of 2.28, and a median 
survival time of 9 years. 
Results 
Data from which incidence rates were estimated are given in Table 10.1. Both methods, 
the STARHS and the mathematical model, were used completely independently, to 
estimate the age-specific incidence of HIV infection among women attending antenatal 
clinics in Hlabisa. The age-specific prevalence of HIV infection, P(a,t), fitted to the model 
is shown in Figure 10.1 and shows that the prevalence of HIV infection increases rapidly 
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between the ages of 15 and 20 years, peaks among women aged 24 years and declines 
among older women. The log-normal function provided a good fit to the data. The average 
ANC prevalence in Hlabisa for 1999 was 34.2% (95% CI: 32.0 - 36.5%). 
Table 10.1 Women attending antenatal clinics in Hlabisa who were tested for HIV 
infection in 1999. The number of HIV negatives, recent infections, and definite 
positives by age, followed by the HIV prevalence (%). 
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Figure 10.1 Age prevalence of HIV-1 infection among women attending 
antenatal clinics in Hlabisa in 1999. The curve was fitted to the data in one 
year age groups but the data are plotted in five yearly groups for clarity. 
Error bars are 95% confidence limits. 
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Using the model described above the annual age-specific incidence per susceptible with 
95% confidence bands are shown in Table 10.2 and plotted in Figure 10.2. The STARHS 
estimates using the initial window period of 200 days provided age-specific estimates of 
incidence of the same shape, but 60% higher than the estimates obtained from the model. 
When scaled down accordingly, i.e., suggesting a window period of 320 days, the 
STARHS estimates of incidence (Table 10.2 and shown as dots in Figure 10.2) are similar 
up to the age of 40 years. Although the scaled estimates of incidence are similar to the 
model estimates, the STARHS method shows some uncertainty about the window period 
to be used for subtype C samples of HIV. 
The estimates disagree significantly only in the estimate of incidence among 40 to 45 year 
old women. The prevalence curve suggests an upward trend after the age of 40 years but 
this is not statistically significant and the sample size is small. Furthermore, the STARHS 
provides an estimate of the incidence of infection among people aged 40 to 45 years that is 
almost as high as the prevalence (18.7% vs. 20.7%, respectively) in this group, suggesting 
that the STARHS estimate may be too high. 
Table 10.2 Annual age-specific incidence of HIV infection estimated using STARHS 
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Figure 10.2 The annual age-specific incidence per susceptible. Heavy line: 
estimated from age-prevalence data; light lines: 95% confidence intervals. 
Dots: estimated from STARHS with 95% binomial confidence limits. 
Discussion 
The epidemic in South Africa has been among the fastest growing epidemics in the world 
and reliable incidence estimates are needed to understand the dynamics of the epidemic. 
Samples taken from women attending antenatal clinics in Hlabisa, rural KwaZulu-Natal, 
in 1999 provide the first estimates of HIV incidence using the STARHS in a South African 
population where subtype C is the dominant strain. The validity of the estimates is 
confirmed by comparing the STARHS results with incidence estimates based on modeling 
age-specific prevalence data. The annual incidence of infection, as estimated by the 
mathematical model, increases rapidly with age and reaches 15% in 22 year old women; 
the overall incidence of infection among women aged 15 to 49 years, standardized to the 
age distribution of women attending ANC in Hlabisa is 11.4% (95% CI: 9.9 - 13.0%). 
The incidence rates reported here, which average 11.4% for 15-49 year old women and 
peak at 14.9% are much higher than rates reported in other comparable populations in 
Africa. A study of pregnant and post-partum women in Malawi found an annual incidence 
of 6.0% among women less than 20 years old with lower rates in older women.589 Among 
women enrolled at delivery in a hospital in Kigali, Rwanda the annual incidence of HIV 
infection decreased linearly from 7.6% during the first six months post-partum to 2.5% 
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during the last six months of the three year follow up. In a study of concordant and 
discordant couples in Uganda the annual incidence of infection was 0.82% for men and 
0.87% for women when both partners were initially sero-negative but was 8.7% for men 
and 9.2% for women if the partner was already HIV-positive.591 In a study conducted 
among male factory workers in Harare, Zimbabwe, the annual incidence of HIV infection 
was 3.0%.592 In a cohort study of men in Bujumbura, Burundi, the annual incidence varied 
between 1.5% and 2.3% depending on the ages of the men.55 
The extraordinarily high incidence rate of HIV infection gives cause for alarm. While 
young women below 30 years of age are experiencing the highest incidence rates, the 
incidence rates in women from 30 to 40 years are still between 5% and 10%. As will be 
shown in Chapter 11, the incidence rates reported here for 1999 were close to the peak 
rates for this epidemic, but it is essential that incidence rates are measured annually in 
order to monitor the epidemic trends. 
The measured incidence in this South African population is very high but confirmed by 
two independent methods of estimation. The two methods agree for all but the oldest age 
group. The higher estimate of incidence among women aged 40 to 44 years using 
STARHS rather than the prevalence based model could indicate that the incidence is 
genuinely high among older women or that the STARHS tends to overestimate the 
incidence in older women. The overestimation in the older women could be related to a 
weaker immune system which in turn could affect the window period of the STARHS. The 
data however, are not sufficiently precise to resolve this issue, particularly for the oldest 
age group, and more extensive studies are needed. 
The application of sensitive/less-sensitive assays to detect incident infections, following 
the initial report by Janssens et a/.,567 demonstrates that simple modifications in the assay 
protocol of commercial ELIS As can be used to detect recent HIV sero-conversion. Several 
laboratories in the United States have used versions of the less-sensitive ELISA to detect 
recent infections.564 However, several reports indicated that there are limitations to this 
approach,564'570 the most important of which include the significant variability of the 
window period and the dependence of the test on the particular subtype of HIV. Two 
studies using the 3All-less sensitive and Vironostika-less-sensitive ELISA showed 
significant differences in the window period in subtypes B or E infected individuals from 
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Thailand. ' The longer window period (270 to 350 days) in persons infected with 
subtype E were attributed to the use of subtype B derived antigens in the assays, indicating 
that other divergent HIV-1 subtypes from Africa and Asia are also likely to be different. 
This necessitated a change in seroconversion duration and the cut-off values to make it 
more applicable to areas of the world with multiple subtypes. The STARHS technique used 
in our analysis was designed to give a value of 200 days using the cut-off recommended 
for subtype C by the CDC. However, to make the estimates comparable to the model 
estimates, the window period had to be adjusted to 320 days, confirming the variability of 
the window period for different populations. 
As a result of the limitations of the STARHS, in particular in relation to the poorly defined 
cut-offs and window periods in the circulating HIV subtypes, new tests have been 
developed, including those that detect recent HIV infection by indirectly measuring the 
increasing HIV IgG as a proportion of the total IgG following seroconversion, called the 
IgG-capture BED-EIA.569'570'594 It is claimed that the format of the assay, which includes a 
multi-subtype derived antigen, allows reasonably high consistency and similar window 
periods in different subtypes. However, despite reasonable performance characteristics, 
results reported from several countries at a recent UNAIDS Reference Group meeting 
(Athens 2005) indicated that it is still an assay with limited applicability which requires 
further validation and calibration.476 
Measurements of incidence should be carried out among other groups in South Africa to 
determine the current rate of new infections, to provide the basis for the design of effective 
interventions and to monitor the impact of such interventions as and when they are 
implemented. While cohort studies should be encouraged they are expensive, time 
consuming, difficult to carry out logistically and raise ethical problems. Laboratory 
techniques such as the sensitive/less-sensitive algorithm, the BED-EIA assay, p24 antigen 
and the HIV RNA assays, when properly applied, have the potential to provide estimates 
of incidence from existing programmes that conduct studies of HIV prevalence, but further 
research should be carried out to ensure the reliability and accuracy of these methods of 
measuring incidence across different settings and different viral subtypes. Laboratory 
techniques have the important advantage that they can be used to determine which 
individuals have recently sero-converted595'596 while the estimates obtained by modeling 
age-specific prevalence data can only give a population estimate of the age incidence. 
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Because of the presence of divergent HIV subtypes and the need to monitor the impact of 
interventions, it is important to estimate incidence using a method that is robust, performs 
similarly in different subtypes and is widely applicable. 
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CHAPTER 11 HIV incidence rates in South Africa 
"The desire to understand the world and the desire to reform it are the two great 
engines of progress." 
Bertrand Russell, 1919597 
Introduction 
To fully understand temporal changes in the epidemic of HIV we need to know how 
incidence and mortality have changed over time. While incidence is difficult to measure 
directly for logistical and ethical reasons, mortality is difficult to measure directly because 
of the stigma associated with AIDS. Prevalence provides a measure of incidence and 
mortality averaged over the previous 5 to 10 years so that it is much more difficult to 
interpret immediate changes in the dynamics of the epidemic using prevalence than it is 
using incidence. Ideally, incidence rates should therefore be used to measure recent 
changes in the HIV epidemic. 
Available data suggest that the HIV epidemic in South Africa is reaching stability: 
incidence is falling, prevalence appears to be levelling off, while mortality is still rising. 
Unlike estimates of the prevalence of HIV in South Africa that are available from annual 
national antenatal clinic surveillance, sentinel site surveillance, and studies among specific 
risk groups, few estimates of incidence are available. Very few cohort studies have been 
performed in South Africa because of the cost, logistics and the ethical considerations of 
following negative individuals until they seroconvert. More recently, a number of Phase 
III HIV prevention trials have been initiated with HIV infection as the endpoint and it is 
likely that more incidence data will become available in the near future. To date however, 
the only directly measured incidence data available are those collected from the UNAIDS 
sponsored Col-1492 Phase III microbicide trial among sex workers in KwaZulu-Natal.28 
As described in the previous three chapters, several indirect methods, many of which 
utilize cross-sectional age-prevalence data, have been developed to estimate the incidence 
of HIV infection. These include back-calculation methods, statistical models, 
mathematical models, and several laboratory techniques. 
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Although statistical and mathematical models are extremely important for understanding 
the dynamics of the HIV epidemic, model estimates should be interpreted with care 
because there is always a degree of uncertainty around the estimates. The estimates depend 
both on the structure of the model and assumptions regarding the key parameters which 
cannot necessarily be determined directly from the raw data. 
In this chapter the incidence rates obtained directly from the one cohort study conducted in 
South Africa among sex workers in KwaZulu-Natal are described. The two models that 
were developed and described in Chapter 9 are then applied to estimate incidence in 
several populations in South Africa for which cross-sectional prevalence data are available. 
These populations include the national antenatal clinic attendees (15-49 year old women), 
the rural community (male and female) of Hlabisa, and the urban community (male and 
female) in Carletonville, Gauteng. These populations are described in more detail in 
Chapter 4. 
Incidence rates estimated directly from the UNAIDS sponsored phase III 
Col-1492 microbicide trial 
A cohort of female sex workers operating at truck-stops along the national road linking 
Durban to Johannesburg was established in 1996, in preparation for a Phase III multi-
centre microbicide (Col-1492) trial.478 The mean age of 477 sex workers who were 
screened for possible participation in the trial was 25.1 years (range 15 - 48) with an 
average education of six years (range 0-16). The mean number of years as a sex worker 
was 2.5 years, ranging from one month to 31 years. On average they had four partners per 
day, and only 20% of women indicated that they used condoms more than 50% of the time. 
Baseline data on these 477 sex workers revealed a high HIV prevalence rate (51.3%; 95% 
CI: 46.7 - 55.8%). 
A cohort of 198 HIV negative sex workers were then followed up as part of the 
microbicide trial for a period of about three years between 1996 and 1998 and represents 
the only data set in South Africa providing direct estimates of incidence from longitudinal 
data. The overall incidence rate per annum in this cohort study of women of mean age 25 
years (range 15-48 years) was 18.2% (13.0%-23.0%), ranging from 16.8% in 1996/1997 
to 20.0% in 1999 (Table ll.l).282'598 This high incidence was not surprising given the 
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sexual risk, in terms of number of clients, low condom use and high incidence of other 
STIs, in particular HSV-2, that this cohort was exposed to.281 
Table 11.1 HIV incidence rate in a cohort of sex workers participating in the Col-1492 
microbicide trial in KwaZulu-Natal 
Person-months of HIV incidence rate (%) per year 
Year Number HIV+ follow-up (95% CI) 
1996/1997 14 996 
1998 25 1644 
1999 13 780 
1996-1999 52 3420 
Estimating incidence rates indirectly 
The following section presents incidence rates estimated indirectly using dynamical 
models developed and described in Chapter 9. Here the models are applied to data 
collected from the National and Hlabisa antenatal clinic surveys and the Carletonville 
community-based surveys using data on the age-specific prevalence of infection and time-
trends in the average prevalence of infection to estimate age-specific incidence. Monte 
Carlo methods were used to estimate confidence limits for the projections. 
Incidence rates estimated for South Africa 
National and provincial estimates of incidence rates among antenatal clinic attendees for 
the period 1991 to 2005 are given in Table 11.2 and projected forward to 2010 in Figure 
11.1. Incidence rates for the national ANC population peaked at 6.6% per year in 1997 
while rates vary substantially between provinces, reflecting the differences in the spread of 
HIV between provinces. Incidence rates in most provinces peaked between 1996 and 1999, 
except in the Western Province where it peaked in 2000. As with the prevalence data, the 
highest incidence rates occurred in KwaZulu-Natal, reaching a peak in 1997 at 9.9% per 
year, while the lowest occurred in the Western Cape reaching a peak in 2000 at 2.9% per 
year. Both national and provincial incidence data suggest that the HIV epidemic in South 
Africa might be approaching a steady state and the forward projection indicate that the 
incidence among all pregnant women attending antenatal clinics in South Africa will 
remain at around 5.8% in the next five years. 





The model-based estimate for the adult population (aged 15-49 years) of the same social 
class as the women attending antenatal clinics, is 3.8%. Further adjustment through 
application of the correction factor as calculated in Appendix 5.1, yields an incidence 
estimate for the general adult population (aged 15-49 years) in South Africa of 2.4%. 
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Figure 11.1 Estimates of incidence (percentage) from 1985 to 2010, by 
province, for women attending antenatal clinics in South Africa. 
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Incidence rates estimated for rural KwaZulu-Natal 
Model estimates based on data collected annually from antenatal clinic attendees in the 
district of Hlabisa between 1992 and 2001, where the HIV prevalence rose from 4.2% in 
1992 to 14.0% in 1995 and 36.1% in 2001, show a peak incidence of 10.3% in 1997 
(Figure 11.2). As shown in Chapter 5 for HIV prevalence data, the estimated incidence 
rates for Hlabisa district are similar to those for the province of KwaZulu-Natal. 
Estimates of annual incidence rates for Hlabisa using the two different models described in 
Chapter 9, are presented in Table 11.3. Model 1 was fitted to antenatal clinic data 
collected from 1997 to 2001 and estimates were derived from age-specific prevalence and 
changes in overall prevalence with time. Estimates of incidence were standardized using 
the age distribution of the Hlabisa female population attending antenatal clinics. The 
method described by Podgor and Leske in Chapter 8 was applied to estimate incidence in 
1993 and 1995 because of the unavailability of age-specific data for these two years. 
Model 2 uses time trends in prevalence. The two sets of estimates are similar and both 
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Figure 11.2 Temporal trends in prevalence and annual incidence among 


















The age-specific estimates of incidence for women attending antenatal clinics in Hlabisa 
from 1997 to 2001, using Model 1 in Chapter 9 with a Weibull survival distribution 
function, are presented in Table 11.4 and Figure 11.3, together with the corresponding 
prevalence data for this period. While age-specific estimates did not show dramatic 
changes between 1997 and 1999, estimates for 2001 were slightly lower. Similar to 
prevalence data, incidence peaked in the 20-24 year age groups at 13.1% in 1997, 14.6% in 
1998, 14.6% in 1999, and 12.1% in 2001. 
Table 11.3 Prevalence and estimated annual incidence of HIV infection among 
antenatal clinic attendees aged 15-49 years in Hlabisa, 1992 - 2001, using two 
different models. Model 1 uses age-specific prevalence and changes in overall 
prevalence with time, while Model 2 uses time trends in prevalence only. 

















Prevalence of HIV (95% CI) 
4.2% ( 3.0- 5.7) 






















Table 11.4 Prevalence and annual incidence with 95% confidence intervals for women 
attending antenatal clinic in Hlabisa, by age 1997-2001 


































































































Figure 11.3 Age-specific estimates of HIV incidence.per year for women attending 
antenatal clinics in Hlabisa in 1997, 1998, 1999 and 2001. 
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Estimated incidence rates by gender and age for an urban community in Gauteng 
Using Model 1 in Chapter 9 with a WeibuU survival distribution function, incidence rates 
were estimated from age-prevalence data collected from an urban mining community in 
Carletonville in 1998." The overall incidence for men aged 15-49 years was 9.6% 
(assuming a flat age distribution) compared to 13.5% for women in the same age range. 
Age specific incidence rates for men and women are provided in Figure 11.4 and Table 
11.5, and show a dramatic peak incidence of 22.8% among women aged 24 years and of 
16.4% among men aged 30 years old. It is of interest to note that the incidence rate among 
young women in this community in 1998 was higher than that reported for the truck-stop 
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Figure 11.4 Age-specific incidence per year for women and men in the general 
population in Carletonville in 1998. 
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Discussion 
South Africa has experienced one of the fastest growing HIV epidemics in the world and in 
2002 more than 25% of women attending public antenatal clinics were infected with HIV. 
In order to understand the dynamics of HIV infection we need to know more about the 
current burden of disease, the rate of new infections and the rate of deaths, for which 
reliable estimates of prevalence and incidence are required. In this chapter, incidence rates 
were estimated indirectly from HIV prevalence data using dynamical models developed 
specifically for South Africa. 
The annual incidence rate for women attending antenatal clinics in South Africa in 2005 
was estimated to be 5.8%, ranging from 2.5% in the Western Cape to 9.3% in KwaZulu-
Natal. National ANC indicence peaked at 6.6% in 1997. Extrapolating the ANC estimates 
to the general population, adjusting for racial differences and differences in prevalence 
between pregnant women and the general population, the annual incidence rate for the 
adult (men and women aged 15-49 years) population in South Africa in 2005 is estimated 
to be 2.4%. This is in agreement with the incidence estimate obtained from the Actuarial 
Society of South Africa (ASSA) model of 2.1% per year (Dorrington, personal 
communication). 
The incidence estimates from two communities in South Africa demonstrate 
extraordinarily high levels of HIV infection in South Africa. The extremely high 
incidences among young men and women in both Carletonville and Hlabisa are a reflection 
of the very rapid rise in HIV prevalence after the onset of sexual activity. In Carletonville, 
HIV prevalence among young women in 1998 went up from 5% in 15-year olds to 56% in 
25 year olds. Taking into account that many of the infections in this age group will be new 
infections, the high incidence estimates presented here are likely to be a true reflection of 
the rate at which young people acquire new infections. It should further be pointed out that 
Carletonville is a special case because it is a mining community with many male migrant 
workers working on the mines and living in single sex hostels, and hence the spread of 
HIV among young people is probably much higher than in other settings. 
Age-specific incidence curves, similar to age-prevalence curves, show peak incidences 
among young people with a decline among older age groups. Young women aged 20 to 24 
years are at highest risk of being infected with HIV, while infection rates among men peak 
at a later age (30-39 years). The shapes of the age-specific incidence curves are similar for 
urban and rural populations. 
Data in South Africa suggest that the epidemic is starting to level off. Incidence estimated 
among national antenatal clinic attendees peaked in 1997 at 6.6% per year. The slight 
decrease in incidence after 1997/1998 probably reflects the natural course of the epidemic 
as it reaches a steady state. If there is no change in behaviour in the coming years, the 
epidemic curve is likely to stay steady. However, should the HIV transmission rate fall 
significantly as a result of natural behaviour change or effective interventions, this will first 
be seen in falling incidence, as incidence rates respond to change more quickly than does 
prevalence. Prevalence reflects the average incidence and mortality over the past 5 to 10 
years, and a change in the epidemic will take a longer time period to manifest in estimates 
of prevalence. 
The models described here and in previous chapters can be used to obtain good fits to the 
prevalence of infection and reliable estimates of the incidence of infection. However, in 
order to explore the biological and social factors that influence the course of the epidemic 
or to investigate the likely impact of different interventions, dynamic models based firmly 
on the knowledge of the natural history of the epidemic will be needed. 
CHAPTER 12 The impact of anti-retroviral therapy on HIV 
incidence and AIDS related mortality in South Africa 
"It is our duty as children of the same God and citizens of the same planet to pool 
our energies and banish the scourge of ADOS from the headlines of our newspapers 
to the chapters of our history books once and for all" 
William J Clinton599 
Introduction 
While the benefits of providing combination antiretroviral therapy for the management of 
HIV disease are well established in developed countries (having resulted in a reduction in 
HlV-related deaths from 17 to 5 per 100,000 people in the United States of America600), 
access to ARV drugs in Africa has been limited. Of an estimated four million people who 
were in need of ARV treatment at the end of 2002, only about 1% were receiving 
treatment.60 However, since the United Nations (UN) Member States made a declaration 
of commitment on HIV/AIDS at the 2001 Special Session of the UN General Assembly,601 
the global response to HIV/AIDS has grown significantly. The Global Fund to Fight AIDS, 
Tuberculosis and Malaria was established to provide low- and middle-income countries 
with additional funding for AIDS, TB and malaria; the World Bank provides large-scale 
grants through its multi-country AIDS Program; and the Government of the United States 
of America has set up the Presidents Emergency Fund for AIDS Relief (PEPFAR) which 
aims to provide treatment to 2 million HIV-infected people with anti-retroviral drugs by 
2010. u" The prices of first-line antiretrovirals have in the last few years been reduced 
substantially as a result of civil society advocacy, special pricing by pharmaceutical 
companies for low-income countries, increased generic competition and local production. 
Building on these developments the World Health Organization, together with UNAIDS 
and other partners, launched the "3 by 5" initiative in 2002 to mobilize support and expand 
access to antiretroviral treatment.10'538'600 At the end of 2005, world leaders had committed 
themselves to "developing and implementing a package for HIV prevention, treatment and 
care with the aim of coming as close as possible to the goal of universal access to treatment 
by 2010 for all those who need it".14 
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With the introduction of cheap antiretroviral drugs, widespread treatment of HIV infected 
people, even in resource-limited settings, has become possible. In November 2003, the 
National Department of Health in South Africa announced an operational plan to provide 
comprehensive care, management and treatment for HIV and AIDS in the public health 
sector in South Africa.34 The operational plan includes: a) strengthening prevention; b) 
providing prophylaxis and treatment for opportunistic infections and improving nutrition; 
and c) providing appropriate treatment for AIDS related conditions, including combination 
antiretroviral therapy for patients with CD4 cell counts less than 200 cells/jil. The plan 
assumes that 10% of about 5 million people infected with HIV are currently in need of 
antiretroviral therapy (ART). Between 2004 and 2008 the cumulative number in need of 
starting therapy is estimated to be around 1.9 million. The plan consider three scenarios, 
assuming 20% ART coverage, assuming 50% ART coverage and assuming 100% ART 
coverage, in which between 200,000 and 1.2 million people would be receiving treatment 
bytheendof2008.34 
In light of these ambitious plans, it is important to explore the likelihood that targets will 
be met. Mathematical models can be used to explore the potential impact of various 
treatment strategies and to guide policy on the design of treatment programmes. In this 
chapter a simulation model is developed to explore the impact of ARV drugs on AIDS 
related mortality and also on HIV incidence, through the impact that the reduced viral load 
of people taking ARV drugs will have on transmission. The predictions of this model in the 
absence of treatment are firstly compared to those of previously published models and then 
the consequences of providing ARV drugs at different levels of coverage and starting at 
different levels of CD4 cell count are explored. 
Methods 
Epidemic models 
Several attempts to model the course of the epidemic in South Africa have been published, 
including the ASSA model,24'558 the UNAIDS EPP model,557 and the Spectrum model 
developed by the Futures Group (also used as part of the UNAIDS package to estimate the 
demographic impact of HP/).451 An extension of the model described in Chapter 9 to 
estimate incidence from time trends in the prevalence data and to estimate the impact of 
antiretroviral treatment is decribed in this chapter, here referred to as the ART Impact 
Model (AM). 
The above models (ASSA, EPP and Spectrum) have been described in more detail in 
chapter 8. Briefly, the ASSA AIDS and demographic model is a cohort component-
projection model designed to investigate the demographic impact of HIV in South 
Africa.558 The model is fitted to the national antenatal clinic prevalence data and to 
mortality data from the Department of Home Affairs. The population is separated into 
men and women, age groups, behavioural groups (high risk, including commercial sex 
workers; medium risk, including those with high rates of sexually transmitted infections 
and those who engage in risky behaviour; low risk, including those who are not 
significantly exposed), ethnic groups, and geographically by province. The model makes 
assumptions about mortality and fertility rates over time and about migration, which is 
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important in the South African context. 
The EPP model is used by UNAIDS to make estimates and projections of HrV prevalence 
for each country in the world and is, of necessity, a simpler and more restricted model.557 
Four parameters are varied to obtain the best fitting epidemic curve to time series of HIV 
prevalence data. The first parameter determines the rate of spread of the epidemic, the 
second determines the proportion of the population considered to be at risk of infection and 
hence the peak prevalence, the third the behavioural response of the population and hence 
the long term epidemic trend, and the fourth parameter determines the timing of the 
epidemic. 
The Spectrum model is a demographic model and uses the prevalence curves developed 
in EPP together with a set of demographic and epidemiological assumptions, including the 
relative risk of infection for women relative to men, effects of HIV on fertility, mother-to-
child transmission of HIV, survival time from infection to death, age patterns of 
prevalence, and effects and coverage levels of ARV, to produce age and sex-specific 
estimates of incidence, prevalence and mortality for adults and children (available at 
http://www.futuresgroup.com). The EPP and Spectrum models have been used in many 
countries in sub-Saharan Africa, including South Africa, to project future trends in 
HIV/AIDS.4'374 
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The basis for the AIM model is described in Chapter 9 and uses data on the time-trends in 
the average prevalence of infection together with assumptions about the form and 
survivorship function for people infected with HIV to project HIV incidence and mortality. 
Extending this model to include the impact of antiretroviral therapy is the focus of this 
chapter. 
Data and model assumptions 
Prevalence of infection 
The most important set of data on trends of HIV infection in South Africa is from the 
Department of Health's annual HIV surveillance programme based on anonymous, 
unlinked, cross-sectional surveys of pregnant women attending antenatal clinics in the 
public health sector (described in more detail in Chapter 4).~ ' ' ' Data on national and 
provincial HIV prevalence have been available annually since 1990 and most models on 
the course of the epidemic in South Africa rely primarily on these data. 
In 2002 and 2005, national population-based HIV surveys were conducted in South Africa 
by the Nelson Mandela Foundation and the HSRC.4 9'470 Complex, multi-stage sampling 
strategies were used to select individuals of whom about 10,000 in both surveys provided 
samples (saliva in 2002 and blood in 2005) to be tested for HIV, including males and 
females of all races, aged two years and older, from all nine provinces, including urban and 
rural areas. The data set has subsequently been used in some modeling exercises to adjust 
estimates of the HIV epidemic obtained from ANC surveillance.374 
Life expectancy 
Models which attempt to derive estimates of incidence or mortality from prevalence data 
all depend critically on estimates of the survival probability as a function of time for 
people infected with HIV. The UNAIDS Reference Group on Estimates, Modelling and 
Projections, using data from the CASCADE collaboration and mortality data from 
cohort studies in Uganda603, Thailand579 and Haiti580 recommend the use of a Weibull 
survival function with a median survival time after infection with HIV of 9 years for 
developing countries. ' Williams et al, drawing on data from several cohort studies 
of survival and AIDS mortality, show that under optimal conditions the median life 
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expectancy, standardized to an age at seroconversion of 27 years, is 9 ± 1 years for those 
who receive no treatment, 10+1 years if AIDS related opportunistic infections are treated 
effectively, 11 + 1 years if ARV mono-therapy is also provided, 12 ± 1 years with dual 
therapy, and 18 ± 2 years with triple therapy, when initiated at an average CD4 cell count 
of about 350/ul. If combination therapy is provided at a CD4 count of 350/ul or more, it is 
therefore anticipated that life expectancy can be extended by an additional 9 years. Little 
data are available on the estimated increase in life expectancy if ART is started at 200 
cells/(j,l, although the authors of the Government of South Africa's plan for comprehensive 
HIV care, management and treatment anticipate that this could add an additional 4 years to 
the life expectancy of HIV-positive people.268 Under this scenario, it is further estimated 
that with an ART coverage of 20%, close to a million additional years of life in South 
Africa would be saved relative to the baseline scenario of not providing ART by 2010, 
with coverage of 50% an additional 2.3 million life years could be saved, and with 100% 
coverage an additional 5 million years of life relative to the non-ARV scenario over the 
period to 2010.268 
Initiation of therapy 
The prognosis for HIV infected patients who are starting ART is strongly related to the 
CD4 cell count at baseline.34 While it has been shown that antiretroviral therapy initiated in 
patients with CD4 cell counts below 200/ul is associated with higher mortality as 
compared to those who start therapy at higher CD4 cell counts, the precise count at which 
to initiate therapy remains unclear.605'606 Some recommendations are that therapy should 
start when the CD4 cell count falls below 350 cells/ul and it is argued that above this level 
the risk of 3-year clinical progression is low so that concerns about impact of antiretroviral 
regimens on quality of life, risk of serious adverse drug effects, and limitations on future 
treatment options generally outweigh the benefits of durable viral suppression.607 The 
recommendation from the International AIDS Society-USA panel is that physicians and 
patients should weigh risks and benefits of starting antiretroviral therapy for CD4 counts in 
the range between 200 and 350/u.l and above, and should make individualized informed 
decisions. Although the increased awareness of the activity and toxicity of antiretroviral 
therapy has shifted the initiation of therapy to a later time in the course of HIV disease, the 
International AIDS Society-USA panel recognizes that the availability of new drugs has 
broadened options for therapy initiation. 07 In 2003 the World Health Organization issued 
guidelines for the treatment of HIV-infected people in resource-limited settings 
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recommending combination antiretroviral therapy for people with AIDS (WHO clinical 
stage IV) regardless of CD4; WHO clinical stage IE and CD4 less than 350/ul; or CD4 
below 200/u.l regardless of clinical stage. 
Infectivity 
While there are many studies on the impact of ART on survival, the effect of ART on 
infectivity is less certain. ART is clearly associated with a decrease in the HIV-RNA viral 
load. With effective therapy it is estimated that viral load will be reduced by more than 
90% within 8 weeks of treatment.607 Successful suppression of viral replication is 
associated with viral loads below the reliable level of detection, i.e. less than about 50-200 
copies/ml within the first 24 weeks. 
The aim of combination ART is complete suppression of HIV replication. However, it is 
generally accepted that ART does not durably suppress HIV replication in 20-50% of 
treatment naive patients and in up to 50-70% of treatment experienced patients. There is 
evidence to suggest that continuing viral replication in the presence of therapy leads to 
drug resistance and viral rebound,609 and new infections through transmission of drug 
resistant strains to individuals who have never been exposed to therapy are increasingly 
being reported, raising serious public health concerns.608 Factors known to be associated 
with virological failure and the selection of drug-resistant variants include: sequential 
introduction of drugs (i.e., adding drugs to a patients treatment therapy as new drugs 
become available), inadequate drug potency, pre-existing resistance, non-adherence, poor 
drug absorption, drug interactions, altered intracellular metabolism of drugs, advanced 
disease stage, low baseline CD4 cell count, and high baseline plasma HIV-1 RNA 
concentrations.609 The proportion of patients infected with drug-resistant HIV-1 in the 
USA has increased from less than 5% before 1991 to 10-22% in 1998-2000, although the 
trend may not be similar in other countries.609,610 Despite publications on the rate of 
primary resistance, it is difficult to draw general conclusions, in particular for Africa, 
where ART access to date has been limited. 
A study of viral load as a function of adherence to therapy suggested that viral load 
declines by a factor of 10 for every 30% increase in adherence,611 but with great variation. 
Hence, as adherence increases from zero to 100% the HIV-RNA viral load can fall by a 
178 
factor of 1000. In another study, Paterson and colleagues612 suggested that the percentage 
of people with incomplete viral suppression increases from 22% at 95% adherence to 82% 
at less than 70% adherence. Gray et al. in 2001 estimated that the unadjusted 
probability of transmission of HIV per sex act is 0.0011 (95% CI: 0.0008-0.0015). At 
viral loads greater than 38500/ml the probability of transmission per sex act is 0.0023, 
while at viral loads less than 1700/ml the probability per sex act is 0.0001 (p = 0.002).613 
We can therefore assume that with effective suppression of viral load through ART, an 
individual will make little contribution to transmission of HIV. However, in order to obtain 
effective suppression of viral load, high levels of adherence of people taking antiretroviral 
drugs have to be achieved. 
Modelling the impact ofARVs 
The AIM model described here is used to explore the impact of ART on survival. It is first 
noted that if there were no deaths then the incidence of infection (as described in Chapter 
9) would be given directly by the slope of prevalence curve so that 
w-™ dt 12.1 
If the probability that a person survives for t years is W{t) then the probability per unit time 
that a person dies t years after being infected is 
M(,)=M£) n.2 
dt 
Since deaths will reduce prevalence the decline in deaths due to all previous incident 
infections need to be added to the estimate of incidence 
Il(t) = I0(t)+f^P(t)M(t-t)dt = I0(t) + P{t)®M(t)\i 12.3 
In Chapter 9 and 11, incidence rates were estimated using data on the prevalence of 
infection among women attending antenatal clinics. These estimates included a correction 
for the fact that the sample of women represents a narrow range of ages. In this chapter, it 
is assumed that the prevalence of HIV in pregnant women is a reasonable representation of 
the overall prevalence in men and women (i.e., from the same social class as women 
attending ANC), and this further correction is not applied to the incidence. 
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Finally, to obtain the incidence per susceptible person we divide by the proportion of the 
population that are susceptible to get 
72(f) = / 1 ( f ) / [ l -P(f ) ] 12.4 
Having estimated the incidence we then replace the Weibull survivorship with a Markov 
process with five stages. The model is illustrated and described in Figure 12.1. The rates at 
which susceptible people become infected is given by the incidence calculated from 
Equation 12.4, and the rates at which people move from one stage to the next, after being 
infected, are 0.44/year, for the first four stages. They die in the last stage at a rate of 
2.0/year. If we assume that people spend equal times in the four classes, then the mean 
survival in the first four stages is 2.3 years and in the last stage 0.5 years.c 
The numbers are chosen so that the survival in the last stage corresponds to the survival of 
people with late-stage AIDS and the survival in the first four stages is chosen to give the 
best fit to the assumed Weibull survival. The overall survival is then not significantly 
different using the Weibull or the Markov Model. The reason for this approach is that it is 
possible to intervene at any one of the four intermediate stages and to examine the impact 
on the epidemic. 
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Figure 12.1 Model of HIV progression. People are born and enter into the susceptible 
class at a rate /?; they become infected at a rate 7]() and of those who become infected 
a proportion 7IQ are put on anti-retroviral treatment (Al) while the rest remain infected 
but not on treatment (II). The people in these two classes then progress to the next 
class at rates 77] and ct\ and of those that progress from the infected but untreated 
stage (II) a proportion JC\ are put on anti-retroviral treatment. The median residence 
time in stage i is \lr]\ or \lo\ for untreated and treated people, respectively. 
c If CD4 counts start at about 800/ul and fall linearly to about 200 after 9 years then we should have people 
spending about 150/(800-200)x9 years = 2.3years in stages 1, 2, 3 and 4 
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Having fixed the rates at which people progress from one stage to the next without ART 
(;z- = 0 for all i) the parameters Oj are then chosen to match what is known about survival 
on ART. Finally the model is run with different values of the parameters n\ corresponding 
to starting treatment at different CD4 cell counts. Setting 7ZQ > 0 would correspond to 
giving that proportion of the population preventive therapy or alternatively reducing 
incidence by that proportion; setting ;ZJ > 0 would correspond to putting that proportion of 
the people onto ART when their CD4 counts were about 500/|il; 350/jj.l or 200/|il, 
respectively. 
Results 
Changes in prevalence, incidence and mortality without ARVs 
Four sets of models (ASSA24, HSRC374, UNAIDS4, and the AIM model described here) 
have been used to project changes in the prevalence, incidence and mortality in the absence 
of widespread coverage with ART. Results from the AIM model are newly generated using 
the model described here, while results from the other models were taken from published 
reports. The model referred to as HSRC374 used the EPP and Spectrum models applied to 
antenatal clinic data but adjusted the prevalence according to the national population based 
survey conducted by the HSRC469(an adjustment factor set to the ANC prevalence/HSRC 
prevalence= 0.63 was used).374 The UNAIDS estimates4 were based on the application of 
EPP and Spectrum models to antenatal clinic data and prevalence was adjusted down by 
about 20% to account for the relative attendance rates at antenatal clinics. Estimates from 
the ASSA and AIM models were based on antenatal clinic prevalence data, also adjusted 
for potential difference in prevalence between the ANC population and the general 
population. For the AIM model, a female to male ratio of HTV prevalence of 1.7 was 
assumed, as calculated in Chapter 6. Results for 2003 are summarized in Table 12.1. 
Assuming a total adult (age 15-49 year) population of 24 million (UN Population Division 
estimates),465 the models suggest that between 4 and 5 million adults were living with HIV 
at the end of 2003 and that adult (15-49 year) prevalence was about 20%. The HSRC 
estimates374 for prevalence and number of people infected with HrV were lower than the 
other models because the estimates were adjusted according to the national household 
survey conducted in 2002 that produced a lower adult prevalence (15.6% in 2002) than the 
ANC estimate of 24.8% 2001. The HSRC and UNAIDS estimates of the number of AIDS 
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deaths in 2003 were similar at about 370,000, but slightly higher than the ASSA estimate 
of 311,000. The incidence for adults varied between 1.7% (HSRC), 1.9% (ASSA) and 
2.3% (AIM). Both the AIM and HSRC models suggest that incidence peaked among 
adults (men and women) between 1996 and 1997 at a rate of just over 4% per year, and in 
the absence of treatment mortality is estimated to peak in 2008-2009 when about 500,000 
people per year will die from AIDS. 
Using the AIM model we estimated and projected the prevalence, incidence and mortality 
in each of the nine provinces in South Africa and in Figure 12.2 we show the results for 
KwaZulu-Natal (the province with the highest prevalence), the Western Cape (the province 
with the lowest prevalence) and for the country as a whole. Estimates for the other seven 
provinces (not shown here) all fall between the two provinces with the highest and the 
lowest burden. In the absence of successful interventions or significant behaviour change, 
the prevalence is expected to remain at the same level as the asymptotic prevalence for the 
foreseeable future. However, it is likely that as people experience the consequences of HIV 
directly in their own lives there might be some change in behaviour and it is also possible 
that effective prevention interventions may be implemented. 
As seen in Figure 12.2, the incidence for adults (men and women) in most of the provinces 
peaked between 1995 and 1997. The decrease in incidence after 1995-1997 probably 
reflects the natural course of the epidemic as it reaches a steady state. In the absence of 
interventions, and if there is no change in behaviour in the coming years, the incidence is 
likely to remain steady, at around 2.8% for the national adult population, 3.8% in 
KwaZulu-Natal, and 1 % in the Western Cape. In the event of no effective intervention, 
mortality is expected to peak among the national adult population in 2008 at about 2.8%, 
among the population in KwaZulu-Natal in 2008 at about 3.9%, and in the Western Cape 
in 2009 at around 1.0%, and will remain steady thereafter. 
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Table 12.1 Comparison of HIV estimates between different models in the absence of 
ART. The estimates are for the year 2003-2004 except for the peak incidence and 
mortality where the expected year is given. Total refers to the total population of the 
country. For 'Adults' and 'Women' the age group is indicated in column 1. 
Adults (age 15-49 years) 
living with HIV (millions) 
HIV prevalence (%) 
(adults 15-49 years) 
HIV incidence (%) 
(adults 15-49 years) 
Mortality due to ADDS (k) 
(adults and children) 
Peak incidence 
(year and %) 
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Figure 12.2 HIV prevalence, incidence and mortality in the worst 
and least affected provinces, and in the country as a whole. 
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Changes in prevalence, incidence and mortality with ARVs 
Here the impact of providing ART on the prevalence and incidence of HIV and the 
mortality due to HIV/AIDS under different scenarios is considered. Firstly, the impact of 
putting 50% or 100% of the population on ART when their CD4 cell count falls to 200/u.l 
or below, as proposed in the South African governments plan, is considered.268 Secondly, 
the impact of putting 100% of the population on ART but starting at CD4 cell counts of 
350/[il is considered. Throughout, the assumptions are made that of those people who are 
offered ART 80% are able to take them and comply fully, and that the interventions are 
introduced in 2005 and reach close to full coverage by 2010. 
The results of these simulations are shown in Figure 12.3 and Table 12.2. In the absence of 
effective prevention measures or treatment programmes South Africa can expect about 5.1 
million deaths and 4.9 million new infections in the ten year period between 2005 and 
2014, and double that number in the next twenty years (Figure 12.3a). If 50% of the 
population are started on ART at 200 CD4+ cells/(il in the next ten years (Figure 12.3b) 
there will be a short term improvement but this will soon be lost. About 500 thousand 
cumulative deaths and about 80 thousand new infections will be averted in the next 10 
years and in 2015 about 560 thousand people will be receiving ART. The situation is much 
better if the proportion of the population being offered ART is increased to 100% (Figure 
12.3c). In this case about one million cumulative deaths and about 150 thousand 
cumulative new infections will be averted; and in 2015 about 1.1 million people will be 
receiving ART. Starting therapy even earlier, at 350/jil (Figure 12.3d), will substantially 
reduce mortality, and about 1.5 million cumulative deaths can be averted, but there will be 
relatively little impact on the number of new cases averted which will increase to just over 
150 thousand and the number of people who would be receiving treatment in 2015 will 
increase to 2.3 million. It is clear from Figure 12.3 and Table 12.2 that providing ART 
can reduce mortality quite substantially but the impact on incidence is much less, and 
mainly seen over the longer term. 
The results from the above analysis show that ART will work in preventing deaths in the 
short term, particularly when given at a CD4 cell count of about 350/u.l rather than at 
200/uI. The main effect will be on mortality. However, even in the more optimistic 
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scenario, about 3.6 million AIDS related deaths will occur in the next ten years and about 
7.7 million in the next twenty. 
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Figure 12.3 Fitted and projected prevalence, incidence and mortality (assuming 
80% coverage of ART), for the following scenarios : a) No intervention; b) 50% 
with CD4 count<200 receive ART by 2010; c) 100% with CD4<200 receive ART 
by 2010; d) 100% with CD4 count < 350 receive ART by 2010. Prevalence among 
women attending antenatal clinics is indicated by the dots. 
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Table 12.2 The first part of the table gives the cumulative number of deaths and number of 
new cases (millions) that will arise over a ten year (2005 to 2014) and twenty year (2005 to 
2024) period, as well as the number of people that will be on treatment at the end of these 
time periods. All figures are in millions. Four scenarios are considered; No ART; 50% of 
people are offered ART at a CD4 cell count of 200/|il or lower; 100% offered ART at 
CD4<200; and 100% offered ART at CD4<350/ul. The second part of the table gives the 
number of deaths and new infections averted (in millions) during the 10 and 20 year time 




























































Cross-sectional data on HIV prevalence in South Africa is widely available, the most 
extensive are those from the annual surveillance which was set up by the National 
Department of Health in 1990 to monitor the prevalence of HIV infection in pregnant 
women attending public antenatal clinics.23 Data on HIV prevalence collected from the 
national antenatal surveys have been widely used, not only to obtain estimates of the 
current burden of HIV infection in South Africa (prevalence, incidence and mortality), but 
also to model the future course of the epidemic. In this chapter estimates of prevalence, 
incidence, and mortality in the absence of antiretroviral treatment from four different 
models, including the ASSA24, HSRC374, UNAIDS4 models, and the model developed and 
described here (AIM model), are firstly reported on. Differences in prevalence, incidence 
and mortality estimates from the models summarized in this chapter can be ascribed to 
differences in model input parameters and the structures of the models. 
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While prevalence and incidence appear to be leveling off, the next stage of the epidemic 
has been reached, with a steady increase in mortality rates. The AIM model estimates for 
2003 show overall mortality rates of 2.3% among adults in South Africa, ranging from 
3.1% in KwaZulu-Natal and 0.7% in the Western Cape. In the absence of effective 
interventions, these rates will continue to rise to a level of around 2.8% among the national 
population in 2008. Model estimates show that the epidemic is reaching equilibrium, with 
mortality estimates approaching the same level as incidence. In the absence of any 
effective future interventions or substantial changes in behaviour, it can be anticipated that 
these epidemic trends will remain at around the same levels in the foreseeable future, i.e. 
incidence and mortality will remain at about 2.8% per year. 
In November 2003, the South African Government approved an operational plan for 
comprehensive HIV/AIDS care, management and treatment in the public health sector in 
South Africa,268 with implications for future epidemic trends. In this plan, it was 
envisaged that there will be at least one service point in every health district across the 
country within one year and one service point in every local municipality within five years. 
These service points will give citizens access to comprehensive HIV/AIDS care and 
treatment, and will be integrated with intensified prevention and awareness campaigns. 
While prevention remains the cornerstone of the governments strategy, it is anticipated that 
approximately 50,000 new cases will start ART in 2003/2004, and that more than 1.4 
million cases will be on ART by the end of 2009.268 The provision of ART is expected to 
have a significant impact on mortality as well as on the transmission of HIV (i.e. 
incidence). 
According to the Minister of Health, ART had been provided to 19,500 patients in over 
103 sites nationally as at the end of October 2004.614 Although the progress in 
implementation of the operational plan was initially slower than anticipated, there is a clear 
trend toward rapid scaling up of treatment availability and the number of people receiving 
ART at the end of 2005 (in both the private and public sector) had increased to around 
200,000 (Department of Health, personal communication). 
The simple differential equations model described in this chapter was developed to assess 
the impact of successful provision of ART on future HIV epidemic trends (prevalence, 
incidence and mortality). The model is based on past and existing trends of HIV 
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prevalence as observed through the surveillance of pregnant women attending antenatal 
clinics in the public health sector in South Africa. 
Several assumptions were made in structuring the model. It was firstly assumed that in the 
absence of successful intervention, the median survival time for infected individuals, 
following a Weibull distribution, is approximately 9 years, depending on age. However, 
with the introduction of antiretroviral therapy we can expect an increase in survival, 
depending on the baseline CD4 cell count. For ART initiated at a CD4 cell count of 200/u.l, 
life expectancy is expected to increase by an additional 3-4 years.268 The additional 
increase in life expectancy when ART is provided at a baseline CD4 count of 350/(0,1, is 
expected to be about 9 years (i.e., total average survival after infection of about 18 years), 
depending on age.581 Provision of ART to an infected individual earlier in the disease 
progression, i.e., at a CD4 cell count higher than 350/(11, may prolong life even further, but 
is generally not recommended in the developing world and must be weighed against the 
risk of toxicity, adverse events, problems with adherence and subsequent development of 
drug resistance. 
Secondly, it was assumed that successful provision of ART is associated with suppression 
of viral load and therefore does not contribute to transmission of HIV, i.e. associated with a 
reduction in incidence. Virologically effective therapy should reduce viral load 
substantially within the first 2 - 8 weeks and for the majority of patients should decrease 
below detectable levels (<50 - 200 RNA copies/ml of plasma) by 16-24 weeks.615 A study 
in Cape Town, conducted among an HIV positive cohort attending a public sector hospital 
and receiving ART through phase III studies, showed successful viral suppression in 
66.1% of those patients who reached 48 weeks of therapy.616 Predictors of virologic 
failure (i.e. >400 HIV RNA copies/ml) in this study included baseline viral load, three 
times daily dosing, incomplete adherence, age and dual nucleoside therapy. Among those 
who were >95% adherent at 48 weeks, 73.4% had a viral load of <400 copies /ml, 
compared with 61.0% of those whose adherence was <95% (p = 0.018).616 In another 
study to assess the feasibility of implementing ART programs in Africa, 28 articles 
involving 14 African countries were reviewed and showed that a median of 73% of 
patients achieved undetectable viral loads by the end of the study period.617 Further, even if 
viral load in all patients may not be reduced to undetectable levels, estimates by Gray et 
a/.,618 suggest that the transmission probability is reduced with a reduction in viral load and 
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that for viral loads below 1700/ml the transmission probability is almost negligible 
(probability per sex act is 0.0001). 
In order to achieve successful reduction in viral load, good adherence is required. In the 
model described in this chapter it is assumed that coverage, which here is a function of 
ART coverage, adherence and effective management, is 80% among infected individuals 
meeting the criterion for receiving ART. A study conducted among 289 patients attending 
a public sector hospital and receiving ART through phase III trials in South Africa,619 
showed adherence levels of the cohort of 93.5% and was hence not regarded as a 
significant barrier to successful antiretroviral therapy. In the study, ART was provided 
free and socio-economic status had no impact on adherence. The high level of adherence 
in the South African study was similar to the high levels of adherence found among 58 
treatment-nai've patients receiving ART in Senegal (88% adherence),620 and adherence 
levels of 95% or more for the majority of studies reporting on adherence levels in a review 
of 10 studies that documented ART use in Africa.617 Given the South African 
governments commitment to provide free ART to all those in need of therapy by the year 
2009, and the high level of adherence found in studies across Southern Africa, the 
assumption of 80% coverage in this model is reasonable, but can easily be changed once 
more data have become available. 
While the government's treatment plan is aimed at providing antiretroviral therapy to those 
individuals with AIDS defining illness or with a CD4 cell count < 200/ul, the model 
described here predicts that provision of ART at this level will have a slight impact on 
mortality, but little effect is expected on incidence because treatment at this late stage will 
have a limited impact of transmission of the virus. If everyone with CD4< 200 is put on 
ART by 2010, we can expect a 10% decrease in mortality from 2.5% to about 2.25% in 
2010 and a decrease in incidence of about 5% (from 2.5% to 2.38%). We can then expect 
an increase in prevalence over the next few years, to a level of about 30% in 2010. Under 
this scenario we can expect that about 1.1 million people will be receiving ART by 2015 
and that about one million cumulative deaths and about 150 thousand cumulative new 
infections will be averted during the ten year period between 2005 and 2014. A more 
dramatic effect on mortality, incidence and prevalence is expected with provision of 
antriretrovirals earlier on in the progression of disease, i.e. at a higher CD4 cell count. If 
provided at a CD4 cell count of 350/(0.1, mortality is expected to decrease to a level of 1.8% 
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in 2010 (as compared to 2.25% when provided at a CD4 count of 200/ixl), averting 1.5 
million deaths, while incidence is expected to decrease to a level of 2.35% (from 2.5%). 
An even greater impact may be expected if ART is provided at CD4 cell counts higher than 
350/u.l, but provision of ART in this early stage of the disease is generally not 
recommended because antiretroviral regimens are very complex, have serious side effects 
linked to the activity and toxicity of current drugs, and pose difficulty with adherence, all 
of which have serious potential consequences such as the development of viral 
resistance.615 At the same time, it has been shown that patients with early-stage HIV 
disease, lower viral loads and/or higher baseline CD4 cell counts have better virological 
response to therapy than later-stage disease.609 Patient education and involvement in 
therapeutic decisions are critical and while treatment should be offered to all patients with 
symptoms of AIDS defining illness, recommendations for offering antiretroviral therapy to 
asymptomatic patients will require analysis of real and potential risks and benefits. 615 
However, although the optimal time to initiate therapy remains imprecisely defined, it is 
recognized that the availability of new drugs constantly broaden options for therapy 
initiation and management of treatment failure. 
Although the assumptions of the mathematical model in this chapter are based on the best 
available data, it is recognized that the model could be further improved as more accurate 
and reliable data become available. Good monitoring and evaluation of the massive task of 
providing ART to those meeting the eligibility criteria in South Africa will therefore be 
essential. Evaluation of the impact of ART will be essential, as will be the monitoring of 
circulating HTV-strains, survival rates, changes in CD4 cell count and HIV RNA viral load, 
adherence rates, side effects on ART, and assessing drug resistance and the effect thereof 
on future therapy options, all of which will also be required for future planning. 
Furthermore, while the continued annual surveillance of the antenatal clinic population for 
estimation of prevalence will be essential for monitoring the epidemic in the general 
population, the estimation of the annual incidence is going to be equally important for 
assessing the effect of ART on HIV transmission. Incidence is the best measure of impact 
because it shows the immediate impact of ART on the population and responds to change 
much quicker than prevalence (prevalence reflects the average incidence over the past 5 to 
10 years, and a change in the epidemic will take a longer time period to manifest in 
estimates of prevalence). 
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In a review of the epidemiological impact of antriretroviral therapy predicted by 
mathematical models, Baggaley and colleagues suggest that HIV transmission models 
should incorporate a realistic progression through stages of infection in order to 
realistically capture the timing of treatment initiation. Although it was suggested that 
further elaboration of models should include variables such as sexual behaviour and 
evolution of drug resistance, modeling exercises are dependent on the availability of 
setting specific surveillance and behavioural data, hence the importance of collection of 
such data in areas where large scale ART use is introduced. 
Of the few studies in Africa to model the impact of antiretroviral therapy on HIV, Gray 
and colleagues "" showed, using a stochastic simulation model, that ART could reduce but 
not interrupt transmission in Uganda and that the effective Ro will remain above 1. It will 
therefore have minimal impact on the number of HIV-infected people and the number 
requiring treatment will increase substantially over time. 
Of concern in African countries is that a small percentage of HIV infected individuals are 
believed to know their HIV status, and for the immediate future, most individuals may start 
receiving care only when they develop life-threatening, AIDS defining illnesses.605At an 
infectious disease institute in Uganda, the mean CD4 cell count at the start of ART was 63 
cells/u.1.605 Starting treatment at this stage is unlikely to have a significant effect and many 
studies have shown that full immune reconstitution and survival rates are reduced if ART 
is started among patients with severe CD4 cell depletion.623 
While Southern Africa has been the most severely affected region in the word, and several 
countries have reported prevalences exceeding 25%, the epidemic in eastern Africa appears 
to be declining,624 showing that success is possible, even in the absence of ART. In Uganda 
there is evidence of a rapid reduction in the prevalence of HIV among women attending 
antenatal clinics. A cohort including the total adult population of a cluster of 15 
neighbouring villages in a rural part of Masaka district in south-west Uganda has been 
followed since 1989. " The cohort was exposed to national health education messages. 
Seroprevalence among adults of all ages fell from 7.8% in 1989/1990 to 6.4% in 
1998/1999, while incidence fell from 8.0 to 5.2 per 1000 person years during the same 
period. ~ The results demonstrated that an early, consistent and multisectoral control 
192 
strategy can reduce both the prevalence and incidence of HIV infection, " giving hope to 
AIDS control programmes elsewhere in Africa. 
In 1996, Brazil became the first developing country to provide unrestricted, cost-free 
access to antiretroviral therapy to AIDS patients through its public health care system628 
with adherence rates between 41% and 69%.629'630 Despite systemic deficiencies and 
individual obstacles, the introduction of ART was associated with a reduction in total 
mortality in Brazil between 1996 and 1999 of about 50%631'632 (although it is recognized 
that it may not be exclusively ART-related) and a reduction in hospitalization rates from an 
average of 1.65 admissions per patient per year in 1996 to 0.28 per patient per year in 
2001, with 358,000 hospitalizations being prevented.632 
Given the political and multisectoral commitment, both of the above countries have shown 
that HIV can be successfully managed: Uganda using prevention techniques, and Brazil 
through the provision of universal access to ART. A comprehensive approach including 
both treatment and prevention will have an even bigger impact on the epidemic. These 
results give hope to millions of South Africans infected with HIV, entering a critical new 
phase of strong commitment from politicians and health professionals, community 
mobilization, more funding and scaling up of treatment and prevention programmes. 
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Chapter 13 Conclusions 
"In the face of the grave threat posed by HIV/AIDS, we have to rise above our 
differences and combine our efforts to save our people. History will judge us harshly if 
we fail to do so." 
Nelson Mandela, 2005 
HIV continues to spread throughout the world, and almost every country is affected, 
although in different ways and in different degrees of severity. In 2005, it was estimated 
that around 40 million people were infected with HIV globally and that more than 25 
million have died of AIDS since the beginning of the epidemic.3 Almost 95% of those 
infected with HIV live in developing countries, the majority in sub-Saharan Africa. South 
Africa, with a total population of only 45 million people, currently accounts for almost 
14% of the global number of infections and at 5.5 million has the highest number of people 
living with HIV in the world.4 
In South Africa, HIV prevalence among national antenatal clinic attendees increased 
dramatically over a ten year period from 0.73% in 1990 to 24.5% in 2000. While data in 
2001 suggested that the prevalence might be stabilizing, further increases have been 
observed since then and in 2004 the HIV prevalence among antenatal attendees was 
29.5%.31 While the provision of antiretroviral therapy (ART) to HIV positive people in 
need of treatment is expected to lead to an increase in prevalence, only 19,500 people 
(about 0.4% of the more than 5 million people infected with HIV) were estimated to be 
receiving ART at the end of 2004,614 a figure too small to explain the observed increase in 
prevalence between 2001 and 2004. The increase in HIV prevalence over the last 15 years 
occurred despite a very substantial response by the scientific community, nationally and 
internationally, as shown in Chapter 2 of this thesis. Our knowledge covers all aspects of 
the HIV epidemic, including routes of transmission, trends in prevalence, the efficacy of 
interventions, social and behavioural aspects of the epidemic, HIV related illnesses, the 
association with sexually transmitted diseases and other risk factors, the molecular and 
genetic components of the virus, and the economic impact of HIV. However, relatively 
little research have been done in South Africa to understand the population level dynamics 
of the HIV epidemic. While prevalence data in South Africa have been well studied and 
have provided important information on the trends in the level of infection over time, from 
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which estimates of the total number of people living with HIV and hence resource needs 
can be estimated, prevalence on its own is not enough to understand the dynamics of the 
epidemics. In addition to overall estimates of prevalence, we need to understand how 
patterns of infection vary in space and between groups, and how they are changing with 
time. We also need to know more about the incidence of infection, that is to say the 
number of new infections that occur every year. Incidence provides an immediate measure 
of current infection rates and is therefore more sensitive to the dynamics of disease 
transmission, is more useful for projecting future epidemic trends, and gives more 
immediate measures to assess the impact of interventions. At equilibrium, an epidemic will 
have stable levels of prevalence while the number of new infections will be balanced by an 
equivalent number of deaths. In this thesis, the epidemiology and the dynamics of the HIV 
epidemic are studied in relation to prevalence and incidence, and new ways of estimating 
the incidence of infection indirectly are described. In addition, the impact of the provision 
of antiretroviral drugs on HIV prevalence, incidence and mortality is investigated. 
HIV prevalence estimates obtained from cross-sectional studies in South Africa are widely 
available, as shown in Table 2.1. Some of these sources are described in more detail in 
Chapter 4 and were used in subsequent chapters to analyse prevalence levels in time and 
space and to derive estimates of incidence. In addition to extensive surveys among 
antenatal clinics in South Africa, data from three community surveys made it possible to 
compare the prevalence of infection among men and women and in urban and rural areas. 
Data are also available for certain high risk groups, including sex workers and migrant 
workers in KwaZulu-Natal and Gauteng province. In Chapter 5, data collected over a 
period of fifteen years were analysed to compare different stages of the epidemic, by 
province, gender, geographic area, and risk group (migrant workers and sex workers). 
Before 1987 the epidemic was concentrated mainly among men who have sex with men 
and recipients of blood products but in this thesis we focus on the distinct heterosexual 
epidemic which became established in the late 1980s. Although the prevalence of 
infection is still increasing, the rate of increase has slowed substantially, and the 
prevalence data suggest that the epidemic is starting to level off. Throughout this thesis 
logistic functions were used to describe the epidemic trends over time as described in 
Chapter 3; the three parameters of the logistic curve determine the intrinsic growth rate, 
the level at which the epidemic is likely to level off (the asymptote), and the time at which 
the epidemic reaches half its asymptotic value. In 2005, the logistic curve was also 
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introduced into the UNAIDS method for describing epidemic trends in countries where the 
epidemic is concentrated among high risk groups such as injecting drug users, sex workers, 
or men who have sex with men. 
In order to understand the natural history of the epidemic, and to design, target and 
evaluate interventions, data on the age-specific prevalence of infection among different 
groups of men and women were analysed in Chapter 6 to investigate patterns of infection. 
Differences in the age-specific risk of infection between antenatal clinic attendees, men 
and women in the community and in the workplace, urban and rural areas, migrant workers 
(including truck drivers and mine workers) and sex workers were investigated. It is shown 
that men in South Africa generally have lower levels of infection than women and 
prevalence peaks at an older age among men than among women. Three community 
surveys showed that the female to male ratio of HIV infection in South Africa is about 1.7. 
As the epidemic is maturing, the age at which the prevalence peaks among antenatal clinic 
attendees shifted by 3.5 years from 23 in 1995 to 26.5 years in 2004 while the level of 
peak prevalence during this period increased from 14.2% in 1995 to 37.1% in 2004. Four 
different patterns of infection were identified: among women attending antenatal clinics, 
among women in the general population, among men in the general population, and among 
migrant workers. Unlike data from several countries in sub-Saharan showing that HIV 
prevalence in urban areas is generally higher than in rural areas,634 data from South Africa 
indicate that differences between urban and rural populations are not significantly 
different, so that the age-risk of infection does not appear to depend on whether people live 
in urban or rural areas. This result is likely to be a reflection of the high rates of circular 
migration between urban and rural areas in South Africa. 
Understanding the trends in the HIV epidemic in South Africa depends largely on data 
collected annually from national antenatal clinic attendees in each of the nine provinces by 
the Department of Health. In countries with generalized epidemics, the prevalence among 
ANC attendees has been used as a proxy for the prevalence in the general heterosexual 
population, and several community based studies in Africa have shown that prevalence 
among pregnant women is indeed a good approximation for prevalence among the sexually 
active adult population.531 In the first study to compare antenatal clinic estimates to 
community estimates in South Africa, described in Chapter 7, HIV prevalence among 
women from the general population in Hlabisa (measured through the Vaccine 
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Preparedness Study) was significantly lower (22.2%; 95% CI: 18.8 - 25.6%) than 
prevalence among women attending antenatal clinics in the same area in Hlabisa (38.2%; 
95% CI: 33.4 - 43.6%), and the difference remained significant after standardizing the data 
to the age distribution of women in the general population in Hlabisa. A limitation of this 
study was that more than 60% of the women in the community survey refused to give a 
blood sample to be tested for HIV, and although differences in potential confounding 
variables between those who consented and those who did not cannot explain the lower 
prevalence in the community survey, further studies are needed to investigate the 
relationship between prevalence among women attending antenatal clinics and women and 
men in the general population and to understand the biases that operate in both groups. 
Unlike prevalence data, estimates of incidence are not widely available because incidence 
is much more difficult to measure than prevalence. Measuring incidence directly is 
logistically difficult and raises ethical problems because cohorts of people need to be 
followed up over time to determine if and when they sero-convert to HIV. Incidence has 
been estimated directly from only one cohort study in South Africa (as part of a 
microbicide trial of sex workers in KwaZulu-Natal).282 In Chapter 8, existing indirect 
methods for estimating incidence are reviewed, including statistical models, dynamical and 
demographic models, and laboratory techniques. 
Because of the limitations of applying existing methods (most of which assume stable 
epidemics) to estimate incidence in the South African situation, two new dynamical 
models were developed and are described in Chapter 9 for estimating incidence indirectly 
from HIV prevalence data. In the first, an extended dynamical model was developed to 
estimate HIV incidence rates from data on age-specific prevalence and changes in the 
overall prevalence over time. The model allows for changing force of infection, age-
dependence of the risk of infection and differential mortality. It uses maximum likelihood 
methods to obtain age-specific incidence rates while standard errors are estimated using a 
Monte Carlo procedure. The age incidence function is expressed as a function of the risk 
of infection with age and the change in the average adult prevalence over time. A log-
normal function is used to describe the age-specific risk of infection: the function is very 
small (or zero) before the age of onset of sexual activity, increases rapidly thereafter as 
sexual activity increases, and then decreases more slowly among older people. The change 
in overall adult prevalence over time, for which antenatal clinic data showed an 
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exponential increase in the early years of the epidemic, is best described by a logistic 
function with a variable asymptote. A Weibull survival function with a median survival 
time of 9 years after infection with HIV, as recommended by the UNAIDS Reference 
Group on Modelling, Estimates and Projections,450'604 is used. It is often the case that age-
specific prevalence data are not available, and in the absence of such data, a second model 
was developed to estimate incidence (also described in Chapter 9). This model only uses 
trends in the average adult prevalence of infection over time and the same Weibull 
survivorship function is used to calculate the probably of death within any given number of 
years after infection. Both models were applied to HIV prevalence data obtained from 
antenatal clinic data in Hlabisa and show similar, but extraordinarily high incidence rates 
of up to 10% per year in this population. 
In Chapter 10 incidence was estimated using a laboratory technique designed to identify 
people who have recently sero-converted (Standard Testing Algorithm for Recent HIV 
Sero-conversion), and these estimates were then validated by comparing them with 
incidence estimates obtained independently, for the same population, from the dynamical 
model described in Chapter 9. The technique involves assessing the HIV status of a 
sample using a sensitive ELISA; if positive, it is then tested using a less-sensitive ELISA 
and if negative on this latter ELISA, it can be concluded that the person became infected 
within a certain window of time. The STARHS method confirmed the very high incidence 
rates among the Hlabisa antenatal clinic attendees and highlights the particularly high risk 
of infection in young women aged 20-24 years among whom incidence rates were close to 
15% in 1999. Two limitations of the sensitive-less sensitive ELISA technique are that 
standard optical density cut-offs and window periods are poorly defined and that the test is 
dependent on the particular subtype of HIV. Indeed, in the application of the method in 
this thesis, the window period had to be adjusted to obtain agreement with the model 
estimates; instead of using the cut-off of 200 days as recommended by the Centre for 
Disease Control and Prevention, the window period was adjusted to 320 days, which is 
close to the longer window period of 270 to 350 days found for subtype E infected 
individuals from Thailand.594 New laboratory techniques that can be used to estimate 
incidence rapidly, reliably and accurately are still being developed. One of these detects 
recent HIV infection by measuring the increase in HIV immunoglobulin G (IgG) as a 
proportion of the total IgG following seroconversion. This IgG-capture BED-enzyme 
immunoassay (BED-CEIA) is designed to provide reasonably high consistency and similar 
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window periods for different subtypes and is currently being validated and calibrated 
using data from studies conducted in several countries. 
The two dynamical models used to estimate incidence from prevalence data were applied 
to different prevalence data sets from South Africa, including the national antenatal clinic 
data, data from rural KwaZulu-Natal (Hlabisa) and from an urban community in Gauteng 
(Carletonville). Estimates for the above data sets show very high levels of HIV incidence 
in South Africa, in all nine provinces, although with wide variation, as well as in urban and 
rural settings. As with the age-specific prevalence, the age-specific incidence rises rapidly 
to a peak among young people and then declines more slowly with age in older people. 
Young women aged 20-29 years are at highest risk of becoming infected while incidence 
among men peak at older ages (30-39 years). Shapes of age-specific incidence curves are 
similar for urban and rural populations. The data presented in Chapter 11 further indicate 
that incidence among antenatal clinic attendees in South Africa peaked in 1997 at a level of 
around 6.6%. The drop in incidence immediately after 1997/1998 is probably a reflection 
of the natural course of the epidemic reaching a steady state and in the absence of any 
behaviour change or effective intervention is expected to remain steady. In 2005, incidence 
among antenatal clinic attendees was estimated to be 5.8%, ranging from 2.5% in the 
Western Cape to 9.3% in KwaZulu-Natal. The best estimate of HIV incidence for the 
general population in South Africa in 2005, using the ANC data adjusted for potential bias 
(as described in Appendix 5.1), is 2.4%. Incidence responds to change in the epidemic 
much more quickly than does prevalence, and any change in the transmission rate as a 
result of behaviour change or effective interventions will be reflected in falling incidence 
before it is reflected in falling prevalence. 
In addition to prevalence and incidence, mortality estimates are needed to understand the 
dynamics of the HIV epidemic, for planning the allocation of resources and for identifying 
vulnerable populations. Estimates of the impact of HIV on mortality, however, are not 
widely available and where such estimates have been made they have been a contentious 
issue in South Africa, partly because of the lack of reliable death statistics. An analysis by 
the Medical Research Council of cause-specific death rates for 1996 and 2000-2001 using 
vital registration data shows a substantial rise in mortality in both men and women in the 
age groups most affected by the HIV epidemic, with the increase in mortality 
concentrated among young children, women aged 25-39 years and men aged 30-49 years. 
199 
The age pattern is consistent with the age pattern observed for HIV seroprevalence in 
South Africa, with an age lag. Results have been confirmed by Statistics South Africa and 
a report in February 2005515 (available at http://www.statssa.gov.za) showed an increase 
of 57% in South Africa's mortality rate from 1997 to 2002. The group most affected were 
those in the economically productive ages of 30-34 years, in which the number of deaths 
more than doubled. Estimates of the total burden of disease show that in 2000, HIV/AIDS 
was the leading cause of death in all provinces with the exception of the Western Cape, 
and accounted for 30% of all deaths in South Africa.466 In 2004, it was estimated that HIV 
was responsible for 44% of all deaths in South Africa, and 70% of the deaths in the age 
group 15-49 years.24 
In Chapter 12, comparison of four different models to estimate the demographic impact of 
HIV show that the number of AIDS deaths in 2003 ranged between 300,000 and 400,000. 
Using antenatal clinic data, the model that was developed and described in this chapter 
(referred to as the ART Impact model model, AIM) shows that while prevalence and 
incidence are levelling off, mortality is increasing. The model estimates that annual 
mortality among adults in South Africa in 2003 was 2.3% and without intervention will 
increase to around 2.8% in 2008. As the epidemic reaches equilibrium, mortality estimates 
are approaching the same level as incidence and in the absence of any effective future 
interventions or substantial changes in behaviour, it can be anticipated that these trends 
will remain at around the same level for the foreseeable future. 
The announcement by the South African Government to provide a comprehensive 
treatment and care programme to those in need of treatment has brought hope to many 
South Africans infected with HIV and facing death.268 While prevention remains the 
cornerstone of the government's strategy, they have an ambitious plan to provide ART to 
more than 1.4 million people infected with HIV by the end of 2009. In order to estimate 
the impact of ART on future trends of the epidemic a 4-stage dynamical model was 
developed, making the following assumptions: 1) that survival for infected individuals 
follows a WeibuU distribution with median survival time of 9 years in the absence of 
treatment; 2) that ART is associated with suppression of viral load and that people 
receiving it do not contribute significantly to transmission of HIV; and 3) that coverage 
(allowing for adherence and effective management) is 80% among infected individuals 
who meet the criterion for receiving ART. The model was firstly applied to the scenario 
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currently proposed in the government's strategy, namely that ART will be provided at a 
CD4 cell count below 200/ul; and secondly to assess the impact should ART be provided 
at a higher CD4 cell count (i.e., CD4 <350/ul). The model predicts that if everyone with 
CD4 < 200/ul is put on ART by 2010, mortality should fall by about 10%, from 2.5% to 
about 2.25%, and incidence should fall by about 5%. At the same time, because people 
remain infected when they are on ART, prevalence is expected to increase to about 30% in 
2010 and about 1.12 million people will be receiving ART by 2015. Under this scenario, 
about one million cumulative deaths and about 150 thousand cumulative new infections 
will be averted over a ten year period. If ART is provided earlier on in the progression of 
disease a greater effect on mortality, incidence and prevalence is expected. If people are 
started on ART at a CD4 cell count of 350/ul mortality is expected to decrease from 2.5% 
to 1.8%/year in 2010 (by 28%), incidence to decrease from 2.5% to 2.35% by 2010 (by 
6%), and 1.5 million deaths are estimated to be averted over a ten year period. Under this 
scenario, about 2.3 million people will be receiving ART by 2015. 
The current recommendation by the World Health Organization for countries with limited 
resources is that ART should be provided to those with WHO clinical stage IV disease 
regardless of CD4 cell counts, WHO clinical stage III disease and CD4 less than 350/ul, or 
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CD4 below 200/ul regardless of clinical symptoms. However, the majority of published 
data support initiating ART when the CD4 cell count is below 350/ul (i.e. in the 200-
350/ul range),635 and WHO is currently reviewing its guidelines to determine if the 
universal CD4 threshold for provision of ART should be changed from 200 to 350/ul. 
There is substantial variation in CD4 cell counts of HIV negative as well as HIV positive 
individuals and in a recent study by Williams et al.,636 it has been shown that at a CD4 cell 
count of 200/ul the median life expectancy (in the absence of ART) of HIV-positive people 
in Zambia is 4 years, almost twice that of people in South Africa where it is 2.3 years so 
that the thresholds at which ART should ideally commence may be different in different 
settings. However, further studies and much better data on the factors that determine CD4 
count distribution (in HIV positive and negative individuals), the patterns of decline of 
CD4 over the course of infection, and on the utility of CD4 as a prognostic indicator, 
would help to assess the stage of HIV epidemics in countries, the future demand for ART, 
and would help determine the most effective criteria for initiating ART. 
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A further problem related to the provision of antiretroviral drugs to those in need, on the 
basis of the WHO treatment guidelines,130 is that CD4 cell count tests are often not 
available to help decide which people infected with HIV need treatment at the primary care 
level and eligibility for ART will have to depend on clinical staging by medical personnel. 
In a study conducted at two primary health care settings in South Africa (one in Soweto 
and one in an urban setting in Limpopo province) researchers compared CD4 cell counts 
with clinical staging among 2000 HIV positive adults, the majority of whom were seen and 
attended to by nurses.637 Overall, 24% of patients classified with stage I and 46% with 
stage II disease (who would be regarded as ineligible for ART according to the WHO 
definition) had CD4 cell counts below 200 cells/|il3. Hence, if ART is restricted to WHO 
clinical stages 3 and 4 exclusively, about 70% of patients would not have been given ART. 
One other study in South Africa reported that clinical disease stage is a stronger predictor 
than CD4 cell counts of the risk of both developing AIDS and death. 
The provision of universal access to ART in the public health sector through international 
initiatives such as WHO's 3x5 strategy538 and the South African Government's 
comprehensive plan," ' has given hope to individuals in low income countries. However, 
the roll-out was initially slow, globally10 as well as nationally.614 The goal of the 
comprehensive treatment plan of the government was to provide ART to 50,000 South 
Africans between 2003 and 2004,268 but by the end of 2004, less than 20,000 people had 
received it.614 By the end of 2005 however, greater progress had been made and about 
200,000 people were estimated to be receiving ART through the private and public sector 
in South Africa. Athough WHO had not met its target of providing antiretrovirals to 3 
million people globally (the estimated number on people receiving ART at the end of 2005 
was 1.3million), much had been done to mobilize support and ongoing efforts to provide 
treatment has brought about positive change and has paved the way for greater advances 
towards the ultimate goal of universal access.13 
Given the initial slow roll-out and the critically high and still rising prevalence in South 
Africa, the need to increase and extend prevention efforts is essential. Furthermore, the 
model presented in Chapter 12 shows that while scaling up of ART will have a significant 
impact on mortality, it will have less impact on the number of new infections. This result 
was confirmed by Salomon et al.639 who applied an epidemiological model to sub-Saharan 
Africa and showed that while a treatment-centered strategy will reduce mortality in sub-
Saharan Africa by 9-13% over the next 15 years, it will have little effect on the number of 
new infections. However, a combined response of scaling up treatment and providing 
effective prevention programmes could reduce new infections by up to 55% and mortality 
by 27% by 2020. Combining treatment with prevention efforts will also substantially 
reduce the resources needed for future treatment. 
In developing countries, the delivery of antiretroviral therapy to those in need of treatment 
presents several challenges. Although millions of dollars are provided through 
international donors and local governments, the number of patients targeted for treatment 
are ambitious and African countries will find it difficult to provide the human resources, 
including personnel who can deliver required interventions, infrastructure, and financial 
resources to treat everyone who is in need. With the increased availability of 
antiretroviral drugs, there will be an increased demand for HIV testing, counselling, drugs 
and care. In addition to the increased burden in hospitals, clinics and laboratories 
performing HIV tests, the workload of an already limited number of doctors, nurses, 
dispensers, pharmacists and counsellors will be increased and ways will have to be found 
to organize effective clinical teams for providing HIV care services.605 Major training 
initiatives and the reorganization of health services will be required. To ensure good 
adherence among patients, a strong patient-centred approach was used in a study involving 
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ART in an urban township (Khayelitsha), including a comprehensive counselling 
infrastructure providing for one-on-one individual counselling with trained counsellors, 
and regular support groups. A treatment access non-governmental organization, the 
Treatment Action Campaign, was active in the clinics included in the study and their 
activities contributed to the treatment literacy of patients. Although the study showed that 
ART can be provided in resource limited settings with good patient retention and clinical 
outcomes,641 it will require lots of resources and staff to extend such an infrastructure to all 
areas in South Africa, and in particular to rural areas. It is further anticipated that 
monitoring the efficacy of antiretroviral treatment will be problematical because of the lack 
of available and reliable laboratory facilities to perform viral load and resistance testing.605 
In relation to the development of antiretroviral drugs, much research has been done to find 
ways to introduce new drugs and drug classes, to reduce the costs of treatment, and to 
reduce toxicity and adherence burdens. Although drug regimes are being simplified and the 
number of pills that HIV infected individuals have to take per day has been reduced, 
current therapeutic approaches can still not cure HIV. Currently, 32 new drugs are being 
tested in clinical trials (phase II or III), including nucleoside reverse transcriptase inhibitors 
and new classes of entry inhibitors (e.g. CCR5).9 New approaches, targeted at eliminating 
HIV from latent infections of resting CD4 cells, have provided new hope for a potential 
cure in the future. In a recent study in San Francisco,642 the use of valproic acid on four 
volunteers showed a significant decline of resting cell infection in three of the four 
participants. Although the research is still in its very early stages, the results suggest that 
eradication of established HIV infection might be achieved in a staged approached of 
firstly treating infected individuals with standard ARV drug regimens and for those in 
whom viral replication is suppressed, to then tackle latent viral infection with histone 
deacetylase inhibitors, intensified therapy, or both.642 
Despite a massive effort to promote HIV prevention strategies including school-based 
programmes and peer education, voluntary testing and counseling services, outreach 
programmes for sex workers and their clients, encouraging condom use and reducing the 
number of sexual partners, workplace prevention programmes, media campaigns, and 
diagnosis and treatment of sexually transmitted infections, these interventions have had 
little impact on the epidemic trends of HIV in South Africa. More research is needed to 
establish the reasons for the lack of success to date and to develop methods of prevention 
that will be effective in reducing transmission. Three areas of prevention that could have a 
significance impact on the future course of the epidemic include vaccine development, 
microbicide development, and the impact of male circumcision on HIV, all of which are 
briefly discussed below. 
Since HIV was identified as the cause of AIDS in the early 1980's, more resources have 
been spent on the search for a vaccine against the virus than on any vaccine effort in the 
history of infectious diseases.643 The USA National Institute of Health alone invests about 
$500 million on HIV vaccine research each year, and more than 50 different formulations 
have entered clinical trials.643 Yet, an effective vaccine that could potentially prevent 
millions of new infections is still a long way off, and David Ho, Director of the Aaron 
Diamond AIDS research centre told a symposium on HIV vaccines in 2005 that "we don't 
have a protective vaccine available today, and we don't expect to have a protective vaccine 
available in the foreseeable future." 4 There are several difficulties associated with 
developing an HIV vaccine, of which one of the biggest obstacles is the lack of a correlate 
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of protection. Futhermore, there are many different and diverse strains of the virus, the 
virus is not well controlled by the immune system during natural infection, it often 
manages to develop resistance to antiretroviral drugs and the host's immune response, 
superinfection with more than one strains of the virus occurs, and finally there is no good 
animal model to be used in experiments.644 Because it is difficult to raise neutralising 
antibodies against HIV, research has shifted from envelope-based vaccines designed to 
induce neutralizing antibodies towards ways of promoting cellular immune response (also 
called cellular immunity, consisting mainly of helper T cells (CD4) cells and killer T cells 
(CD8 cells)), specifically targeting and eliminating HIV infected cells. Several vaccines 
being tested aim to stimulate the production of killer T cells, although cellular immunity 
also involve macrophages, cytokines and natural killer cells. 43 Despite these difficulties, 
the search for a successful HIV vaccine continues and new directions will continue to be 
explored. In 2003, the Global HIV Vaccine Enterprise was established by a group of 24 
scientists, including the former director of the National cancer institute, Rick Klausner, and 
Nobel laureates Harold Varmus and David Baltimore.645 The Enterprise was developed as 
an alliance of independent organizations committed to accelerating the development of a 
preventive vaccine for HIV through the implementation of a jointly developed scientific 
plan, mobilization of resources and greater collaboration among vaccine researchers 
worldwide. This led to several new activities having started in 2005, including a new NIH 
centre for HIV/AIDS Vaccine Immunology. However, in the absence of an effective 
vaccine, research must continue to focus on other prevention efforts and providing 
antiretroviral drugs to those in need. 
At the same time, while large amounts of resources are being allocated to vaccine research 
an important aspect of this is the preparation of communities among which vaccine trials 
can be conducted. It is often forgotten that before such trials can be conducted one needs to 
spend several years not only educating communities about vaccine research but also 
collecting baseline data which are essential for the effective planning and execution of 
such trials. While one such study was conducted in Hlabisa, more are needed in South 
Africa. 
Women in Africa have been disproportionately affected by HIV.6 Currently available HIV 
prevention methods are often not feasible for women who live in resource poor settings, 
and they are often not in a position to negotiate condom use with their partners. One 
205 
approach, as an alternative or supplement to condoms, that would empower women to 
protect themselves and their partners, is the use of microbicides. Topical microbicides, that 
can be formulated as gels, creams, films or suppositories, are compounds that can be 
applied inside the vagina or rectum to protect the body's mucosal surfaces against sexually 
transmitted infections including HIV, and unlike male or female condoms, provides a 
way of preventing infection that can easily be controlled by women. There are different 
ways in which microbicides act to prevent genital infections: some microbicides provide a 
physical barrier that keeps HIV and other pathogens from reaching the target cells; others 
act by enhancing the natural vaginal defence mechanisms by maintaining an acidic pH 
level which protects the vagina; others kill or disable pathogens by stripping them of their 
outer covering; and another class acts by preventing the virus from replicating after it has 
entered the cell. 4? Several microbicide products have been tested or are currently being 
evaluated in clinical research studies. In 2005, WHO reported that 23 products are in 
various stages of clinical development.647 Many products, including Acidform, cellulose 
sulphate and tenofovir, are still being tested in Phase I safety and acceptability trials, while 
others are further along in the development pipeline, including Carraguard, BufferGel, 
PRO 2000, Savvy and Cellulose Sulfate, which are being tested in Phase lib or III trials. 
Although some products, such as nonoxynol-9, have been shown to offer no protection 
against sexually transmitted diseases or HP/, evaluation of other potential microbicides 
should continue. Future research and challenges should include product formulation and 
delivery, as well as the development of combination products to inactivate the HIV virus 
and to inhibit STI pathogens simultaneously.648 
Results recently released from the first randomised controlled trial on the effect of male 
circumcision on HrV transmission have produced new hope for prevention of sexually 
transmitted HIV. In the first of three randomized controlled trials conducted in Africa, 
Auvert and colleagues351 showed that male circumcision reduced the transmission of HIV 
from women to men in Orange Farm, South Africa, by 60% (95% CI: 32% -76%). If these 
results, and similar findings in other observational studies,508'509 are confirmed by the two 
other randomised trials currently underway in Kenya and Uganda, they will have profound 
implications for the prevention of HrV. Mathematical models to investigate the impact of 
male circumcision show that, if full coverage of male circumcision can be reached in South 
Africa over the next ten years, up to 144 thousand new infections can be averted each 
year.510 
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Finally, South Africa, in the current stage of the epidemic, has to deal with large numbers 
of new infections, rising morbidity and rising mortality. Life expectancy at birth for men 
dropped from 61.5 years in 1994 to 49 years in 2004, and is expected to fall to about 40 
years in 2010 if the epidemic is not dealt with effectively in the next few years.24 More 
than 1000 people are currently dying from AIDS in South Africa every day,4 and in 2004, 
there were about 1 million orphaned childen with the number expected to increase in 
coming years. In addition to the loss of human life, the epidemic has enormous 
implications for the economy of the country, partly because the epidemic targets the young 
economically active population in South Africa. Not only does AIDS cause loss of labour, 
but is also causing an increase in labour costs and threatens the competitiveness of the 
South African industry.252 HIV infection among the workforce is associated with increased 
cost related to sick leave, productivity loss, retirement, death, disability and medical 
benefits. In a study in six corporations in South Africa and Botswana between 1999 and 
2002, it was found that the annual cost of AIDS to these companies ranged from 0.4% to 
about 6% of the wage bill.251 In addition, HIV/AIDS is placing a heavy burden on health 
care services in the country. Already in 2000, more than 50% of patients admitted to a 
tertiary hospital in KwaZulu-Natal were infected with HIV, of whom more than 80% had 
AIDS. Similarly, among children submitted to a paediatric ward in the same hospital 
over a four week period in 1998, 62.5% were infected with HIV.419 And as the epidemic is 
maturing, more and more people will be needing care and support, not only clinical , but 
also psychological and palliative care, 4 and there will be an increased expectation for 
communities and families to provide this care at home. 
South Africa is facing a catastrophe and much will have to be done to bring the HIV 
epidemic under control. In addition to rapidly scaling up antiretroviral therapy for those in 
need, comprehensive prevention packages to reduce new HIV infections need to be put in 
place urgently; prevention of mother-to-child programmes must be scaled up to reduce 
transmission of HIV to newborn babies; care services need to be strengthened to ensure the 
provision of prophylaxis and treatment of opportunistic infections and anti-retroviral 
treatment; social services for families who are affected by AIDS deaths need to be 
strengthened; programmes and social services to take care of orphans have to be 
established; social stigma associated with HIV/AIDS needs to be addressed so that more 
people can speak out about causes of illness and deaths, as Nelson Mandela did in speaking 
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about the death of his son due to AIDS in 2005; and most of all, political commitment is 
needed at all levels, not only to ensure that interventions are effectively implemented 
without any barriers, but also to acknowledge the scale of the problem and the need to 
increase the response to the epidemic. Finally, to track the future course of the epidemic 
and the impact of interventions, better understanding of the dynamics of the epidemic is 
still needed. This thesis is an attempt to understand the epidemiology of the epidemic in 
South Africa and to describe ways to measure it, including the development of models to 
obtain essential information. More analysis of this kind will be needed if we want to 
monitor future trends and evaluate the impact of interventions. In particular, the roll-out of 
antiretroviral drugs will have to be carefully monitored and evaluated in relation to 
adherence to treatment, adverse events, morbidity and mortality. Using dynamical models 
and the appropriate epidemiologic measures, we can assess whether interventions work or 
not, identify problems early, predict future trends and resource needs, identify those groups 
most at risk and most in need of treatment, care and support. Understanding the 
epidemiology of HIV, in turn, will help us find ways to deal with the epidemic. The fight 
against HIV and AIDS will only be won over the years, or even decades, ahead, but to 
ensure that we finally win this battle, we need to mobilize the best possible science in 
support of those people and communities affected by the epidemic. 
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